{"PMC7445710": [["Pathophysiologische Grundlagen des klinischen ErscheinungsbildsMit Auftreten des neuartigen \u201esevere acute respiratory syndrome corona virus 2\u201c (SARS-CoV-2) hat sich eine neue Krankheitsentit\u00e4t entwickelt, die durch das Vorliegen einer Pneumonie und Erkrankung anderer Organsysteme bis hin zum Multiorganversagen gekennzeichnet ist [1].", [["respiratory syndrome", "DISEASE", 106, 126], ["Pathophysiologische Grundlagen des klinischen ErscheinungsbildsMit Auftreten des neuartigen \u201esevere acute respiratory syndrome corona virus 2\u201c (SARS-CoV-2) hat sich eine neue Krankheitsentit\u00e4t entwickelt, die durch das Vorliegen einer Pneumonie und Erkrankung anderer Organsysteme bis hin zum Multiorganversagen gekennzeichnet", "SPECIES", 0, 326], ["Pathophysiologische", "TEST", 0, 19], ["Grundlagen des", "TREATMENT", 20, 34], ["acute respiratory syndrome", "PROBLEM", 100, 126], ["corona virus", "PROBLEM", 127, 139], ["SARS", "TEST", 144, 148], ["CoV", "TEST", 149, 152], ["Pneumonie", "TEST", 235, 244], ["Erkrankung", "TEST", 249, 259], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126]]], ["Ausl\u00f6ser ist ein einstr\u00e4ngiges RNA-Coronavirus, das sein nat\u00fcrliches Reservoir in Flederm\u00e4usen hat, aber als Zwischenwirt auch Schuppentiere nutzt [2].", [["Ausl\u00f6ser ist ein einstr\u00e4ngiges RNA", "PROBLEM", 0, 34], ["Coronavirus", "PROBLEM", 35, 46]]], ["Das Virus dringt \u00fcber nasale und bronchiale Epithelzellen, wo es an Angiotensin-konvertierendes-Enzym-2-Rezeptoren (ACE-2) bindet, in den K\u00f6rper ein.", [["Angiotensin", "CHEMICAL", 68, 79], ["Enzym-2-Rezeptoren", "SIMPLE_CHEMICAL", 96, 114], ["ACE-2) bindet", "SIMPLE_CHEMICAL", 116, 129], ["Virus dringt \u00fcber nasale und bronchiale Epithelzellen, wo es an Angiotensin-konvertierendes-Enzym-2-Rezeptoren", "SPECIES", 4, 114], ["Das Virus", "TEST", 0, 9], ["an Angiotensin", "TREATMENT", 65, 79], ["Enzym", "TREATMENT", 96, 101], ["Rezeptoren (ACE-2) bindet", "TREATMENT", 104, 129]]], ["Im weiteren Verlauf der Infektion werden neben den epithelialen Zellen auch Endothelzellen infiziert; es resultiert eine Endothelialitis [3] und als eine Folge der Entz\u00fcndungsreaktion neben einer Vasoplegie eine Infiltration des alveol\u00e4ren Raums mit Makrophagen und neutrophilen Granulozyten.", [["Im weiteren Verlauf der Infektion werden neben den epithelialen Zellen auch Endothelzellen infiziert; es resultiert eine Endothelialitis [3] und als eine Folge der Entz\u00fcndungsreaktion neben einer Vasoplegie eine Infiltration des alveol\u00e4ren Raums mit Makrophagen und neutrophilen Granulozyten", "SPECIES", 0, 291], ["Im weiteren Verlauf der Infektion", "TREATMENT", 0, 33], ["Endothelzellen infiziert", "TREATMENT", 76, 100], ["Vasoplegie eine Infiltration des", "TREATMENT", 196, 228], ["mit Makrophagen", "TREATMENT", 246, 261], ["neutrophilen Granulozyten", "TREATMENT", 266, 291]]], ["Weil auch die endotheliale Barriere gest\u00f6rt ist, entwickeln sich interstitielle und alveol\u00e4re \u00d6deme und Gewebsvermehrungen, was einerseits die St\u00f6rung des Gasaustauschs und andererseits die Milchglastr\u00fcbungen in der radiologischen Diagnostik erkl\u00e4rt.Pathophysiologische Grundlagen des klinischen ErscheinungsbildsDie COVID-19-Pneumonie wird auf Grund des klinischen Bildes, der CT-Befunde und des Ansprechens auf die therapeutischen Ma\u00dfnahmen zur Atemunterst\u00fctzung in einen L(\u201elow\u201c)- und einen H(\u201ehigh\u201c)-Typ unterschieden [4].", [["Pathophysiologische Grundlagen des klinischen ErscheinungsbildsDie COVID-19-Pneumonie wird auf Grund des klinischen Bildes, der CT-Befunde und des Ansprechens auf die therapeutischen Ma\u00dfnahmen zur Atemunterst\u00fctzung in einen L(\u201elow\u201c)- und einen H(\u201ehigh\u201c)-Typ unterschieden", "SPECIES", 250, 521], ["Pathophysiologische", "TEST", 250, 269], ["COVID", "TEST", 317, 322], ["Pneumonie", "TREATMENT", 326, 335], ["der CT", "TEST", 374, 380]]], ["Welcher Typ vorliegt, ist dabei abh\u00e4ngig von verschiedenen Faktoren:dem Schweregrad der Infektion, der durch die Immunantwort des Patienten, die physiologische Reserve und Komorbidit\u00e4ten bestimmt wird,der ventilatorischen Reaktion auf die Hypoxie,der Dauer zwischen Symptombeginn und Vorstellung im Krankenhaus.Pathophysiologische Grundlagen des klinischen ErscheinungsbildsZu Beginn der Erkrankung zeigt sich ein L\u2011Typ.", [["Welcher Typ vorliegt, ist dabei abh\u00e4ngig von verschiedenen Faktoren:dem Schweregrad der Infektion, der durch die Immunantwort des Patienten, die physiologische Reserve und Komorbidit\u00e4ten bestimmt wird,der ventilatorischen Reaktion auf die Hypoxie,der Dauer zwischen Symptombeginn und Vorstellung im Krankenhaus", "SPECIES", 0, 310], ["Pathophysiologische Grundlagen des klinischen ErscheinungsbildsZu Beginn der Erkrankung zeigt sich ein L\u2011Typ", "SPECIES", 311, 419], ["Pathophysiologische Grundlagen des", "TREATMENT", 311, 345]]], ["Dieser zeichnet sich aus durch:\u201elow\u201c (niedrige) Elastance (d. h. hohe Compliance der Lunge),\u201elow\u201c (niedriges) Ventilations/Perfusions-Mismatch (VA/Q),\u201elow\u201c (niedriges) Lungengewicht (in der CT vor allem Korrelation mit subpleuralen Milchglastr\u00fcbungen),\u201elow\u201c (niedriges) Rekrutierungspotenzial (wenige nichtbel\u00fcftete Lungenareale).Pathophysiologische Grundlagen des klinischen ErscheinungsbildsBeim L\u2011Typ f\u00fchrt die Virusinfektion zu einem m\u00e4\u00dfigen lokalen interstitiellen \u00d6dem.", [["Dieser zeichnet sich aus durch:\u201elow\u201c (niedrige) Elastance (d. h. hohe Compliance der Lunge", "SPECIES", 0, 90], ["\u201elow\u201c (niedriges)", "TREATMENT", 92, 109], ["Mismatch (VA/Q)", "TREATMENT", 134, 149], ["\u201elow\u201c (niedriges)", "TREATMENT", 150, 167], ["mit subpleuralen Milchglastr\u00fcbungen", "TREATMENT", 215, 250], ["\u201elow\u201c (niedriges)", "TREATMENT", 252, 269]]], ["Die Hypox\u00e4mie wird durch eine entz\u00fcndungsbedingte Vasoplegie und ein erh\u00f6htes Shuntvolumen bedingt, wobei die Lungenmechanik wenig gest\u00f6rt ist.", [["Die Hypox\u00e4mie wird durch eine entz\u00fcndungsbedingte Vasoplegie und ein erh\u00f6htes Shuntvolumen bedingt, wobei die Lungenmechanik wenig gest\u00f6rt", "SPECIES", 0, 138], ["Die", "PROBLEM", 0, 3]]], ["Obwohl die Kriterien f\u00fcr ein akutes Lungenversagen (\u201eacute respiratory distress syndrome\u201c, ARDS) erf\u00fcllt sind, unterscheidet sich die Therapie der respiratorischen Insuffizienz von der des klassischen ARDS mit bilateralen, konsolidierenden Infiltraten und einer Hypox\u00e4mie.", [["respiratory distress syndrome", "DISEASE", 59, 88], ["ARDS", "DISEASE", 91, 95], ["ARDS", "DISEASE", 201, 205], ["Obwohl die Kriterien f\u00fcr ein akutes Lungenversagen (\u201eacute respiratory distress syndrome\u201c, ARDS) erf\u00fcllt sind, unterscheidet sich die Therapie der respiratorischen Insuffizienz von der des klassischen ARDS mit bilateralen, konsolidierenden Infiltraten und einer Hypox\u00e4mie", "SPECIES", 0, 271], ["\u201eacute respiratory distress syndrome", "PROBLEM", 52, 88], ["ARDS", "PROBLEM", 91, 95], ["ARDS mit bilateralen", "PROBLEM", 201, 221], ["respiratory distress", "OBSERVATION", 59, 79]]], ["Die Erkrankung kann in diesem Stadium ausheilen oder in einen Typ H \u00fcbergehen.Pathophysiologische Grundlagen des klinischen ErscheinungsbildsDer H\u2011Typ entspricht dem klassischen ARDS und zeichnet sich durch folgende Kriterien aus:\u201ehigh\u201c (hohe) Elastance (niedrige Compliance der Lunge),\u201ehigh\u201c (hoher) Rechts-Links-Shunt mit hohem Ventilations/Perfusions Mismatch,\u201ehigh\u201c (hohes) Lungengewicht,\u201ehigh\u201c (hohe) Rekrutierbarkeit.Pathophysiologische Grundlagen des klinischen ErscheinungsbildsBei sehr schweren COVID-19-Verl\u00e4ufen entwickelt sich eine ausgepr\u00e4gte systemische Entz\u00fcndungsreaktion, die mit einer massiven Zytokinaussch\u00fcttung einhergeht und u. a. eine disseminierte intravasale Gerinnung mit Verbrauch von pro- und antikoagulatorischen Gerinnungsfaktoren hervorruft [5, 6].", [["ARDS", "DISEASE", 178, 182], ["Pathophysiologische Grundlagen des klinischen ErscheinungsbildsBei sehr schweren COVID-19-Verl\u00e4ufen entwickelt sich eine ausgepr\u00e4gte systemische Entz\u00fcndungsreaktion, die mit einer massiven Zytokinaussch\u00fcttung einhergeht und u. a. eine disseminierte intravasale Gerinnung mit Verbrauch von pro- und antikoagulatorischen Gerinnungsfaktoren hervorruft", "SPECIES", 423, 771], ["Die", "PROBLEM", 0, 3], ["Pathophysiologische Grundlagen des", "TREATMENT", 78, 112], ["ARDS", "PROBLEM", 178, 182], ["Elastance (niedrige Compliance der Lunge)", "TREATMENT", 244, 285], ["Rechts", "TEST", 301, 307], ["Shunt mit hohem Ventilations", "TREATMENT", 314, 342], ["Pathophysiologische", "TEST", 423, 442], ["COVID", "TEST", 504, 509], ["Perfusions Mismatch", "OBSERVATION", 343, 362]]], ["Gef\u00fcrchtet sind bei schwer erkrankten COVID-19-Patienten thrombotische Komplikationen, die tiefe Beinvenenthrombosen, Lungenembolien, aber auch Schlaganf\u00e4lle, Myokardinfarkte und Extremit\u00e4tenarterienverschl\u00fcsse [7].", [["Gef\u00fcrchtet sind bei schwer erkrankten COVID-19-Patienten thrombotische Komplikationen", "SPECIES", 0, 85], ["Gef\u00fcrchtet", "TEST", 0, 10], ["COVID", "TEST", 38, 43], ["Patienten thrombotische Komplikationen", "TREATMENT", 47, 85], ["Lungenembolien", "TREATMENT", 118, 132]]], ["Da ACE-2-Rezeptoren auch ausgepr\u00e4gt im Gehirn exprimiert werden, scheint auch eine direkte neuronale Infektion m\u00f6glich und k\u00f6nnte einen Teil der beobachteten Enzephalitiden erkl\u00e4ren.", [["Da ACE", "TREATMENT", 0, 6], ["Rezeptoren auch ausgepr\u00e4gt", "TREATMENT", 9, 35]]], ["Auch das bei COVID-19-Patienten h\u00e4ufig zu beobachtende Nierenversagen kann durch die systemische Entz\u00fcndung, die disseminierte intravasale Gerinnung, den Schockzustand mit Hypoxie, aber auch durch eine direkte Infektion tubul\u00e4rer Zellen verursacht sein [8].Pathophysiologische Grundlagen des klinischen ErscheinungsbildsTypischerweise verl\u00e4uft die SARS-CoV\u20112 in aufeinanderfolgenden Phasen, die das klinische Bild und in der Folge das klinische Vorgehen bestimmen.", [["SARS-CoV\u20112", "DISEASE", 348, 358], ["COVID", "TEST", 13, 18], ["aber auch durch eine direkte", "TREATMENT", 181, 209], ["Pathophysiologische Grundlagen des", "TREATMENT", 257, 291]]], ["1 dargestellt.Infektiosit\u00e4t von COVID-19-PatientenDie \u00dcbertragung des Virus erfolgt \u00fcber Tr\u00f6pfcheninfektion aus Aerosolen der Atemwege; die Infektiosit\u00e4t ist am h\u00f6chsten zum Zeitpunkt des Auftretens von Krankheitssymptomen.", [["Infektiosit\u00e4t von COVID-19-PatientenDie \u00dcbertragung des Virus erfolgt \u00fcber Tr\u00f6pfcheninfektion aus Aerosolen der Atemwege; die Infektiosit\u00e4t ist am h\u00f6chsten zum Zeitpunkt des Auftretens von Krankheitssymptomen", "SPECIES", 14, 222], ["Infektiosit\u00e4t von COVID", "TEST", 14, 37], ["Die \u00dcbertragung des Virus", "TREATMENT", 50, 75]]], ["In epidemiologischen Studien konnte gezeigt werden, dass Infektionen durch Indexpatienten 5 Tage nach Symptombeginn selten sind [12].Klinische Pr\u00e4sentation und VerlaufDie allermeisten Patienten entwickeln klinische Symptome einer SARS-CoV-2-Infektion sp\u00e4testens 12 Tage nach Inokulation des Erregers, meist bereits nach 5 Tagen [13].", [["Klinische Pr\u00e4sentation und VerlaufDie allermeisten Patienten entwickeln klinische Symptome einer SARS-CoV-2-Infektion sp\u00e4testens 12 Tage nach Inokulation des Erregers, meist bereits nach 5 Tagen", "SPECIES", 133, 327], ["Klinische", "TEST", 133, 142], ["CoV", "TEST", 235, 238], ["Infektion sp\u00e4testens", "TREATMENT", 241, 261]]], ["Pr\u00e4diktiv f\u00fcr einen komplizierten Krankheitsverlauf sind Komorbidit\u00e4ten.", [["Pr\u00e4diktiv", "TREATMENT", 0, 9], ["Komorbidit\u00e4ten", "TREATMENT", 57, 71]]], ["In einer gro\u00dfen deutschen Studie lag in 56 % der F\u00e4lle eine arterielle Hypertonie, in 28 % ein Diabetes mellitus, in 27 % eine kardiale Arrhythmie, in 23 % eine Niereninsuffizienz, in 20 % eine Herzinsuffizienz und in 14 % eine chronische Lungenerkrankung vor [14].Klinische Pr\u00e4sentation und VerlaufDie h\u00e4ufigsten Symptome einer SARS-CoV-2-Infektion sind:Fieber (bis zu 90 %),trockener Husten (60\u201386 %),Luftnot in Ruhe oder bei Belastung (53\u201380 %),gastrointestinale Symptome wie \u00dcbelkeit, Erbrechen, Durchfall (15\u201339 %),Myalgie (15\u201344 %),Geruchs- und Geschmacksst\u00f6rung (64\u201380 %).Klinische Pr\u00e4sentation und VerlaufAls Ver\u00e4nderungen der Laborwerte werden eine Lymphopenie und eine leichte Thrombozytopenie im Blutbild beschrieben.", [["Diabetes mellitus", "DISEASE", 95, 112], ["Klinische Pr\u00e4sentation und VerlaufDie h\u00e4ufigsten Symptome einer SARS-CoV-2-Infektion sind:Fieber (bis zu 90", "SPECIES", 265, 372], ["Ruhe oder bei Belastung", "SPECIES", 414, 437], ["Klinische Pr\u00e4sentation und VerlaufAls Ver\u00e4nderungen der Laborwerte werden eine Lymphopenie und eine leichte Thrombozytopenie im Blutbild beschrieben", "SPECIES", 579, 727], ["lag", "TEST", 33, 36], ["Hypertonie", "TEST", 71, 81], ["Diabetes mellitus", "PROBLEM", 95, 112], ["Klinische", "TEST", 265, 274], ["Pr\u00e4sentation", "TEST", 275, 287], ["VerlaufDie", "TEST", 292, 302], ["Symptome", "TEST", 314, 322], ["SARS", "TEST", 329, 333], ["CoV", "TEST", 334, 337], ["Fieber (bis zu", "TREATMENT", 355, 369], ["Myalgie", "TEST", 520, 527], ["Klinische Pr\u00e4sentation", "TREATMENT", 579, 601]]], ["H\u00e4ufig findet sich auch eine Erh\u00f6hung der Laktatdehydrogenase (LDH), der Transaminasen sowie des C\u2011reaktiven Proteins (CRP) und Ver\u00e4nderungen der Gerinnung im Sinne einer aktivierten Koagulation (D-Dimere erh\u00f6ht, partielle Thromboplastinzeit [PTT] verl\u00e4ngert).", [["Ver\u00e4nderungen der Gerinnung im Sinne einer aktivierten Koagulation (D-Dimere erh\u00f6ht, partielle Thromboplastinzeit [PTT] verl\u00e4ngert", "SPECIES", 128, 258], ["der Laktatdehydrogenase (LDH)", "TEST", 38, 67], ["der Transaminasen", "TEST", 69, 86], ["Proteins", "TEST", 109, 117], ["CRP", "TEST", 119, 122], ["Ver\u00e4nderungen", "TEST", 128, 141], ["Gerinnung", "TEST", 146, 155], ["aktivierten", "TEST", 171, 182], ["Koagulation", "TEST", 183, 194], ["D", "TEST", 196, 197], ["erh\u00f6ht", "TEST", 205, 211]]], ["Ist das Herz im Krankheitsprozess beteiligt, werden erh\u00f6hte Biomarker (Troponin und NT-Pro-BNP [B-Typ-natriuretische Peptide]) beobachtet.", [["Biomarker", "TEST", 60, 69], ["Troponin", "TEST", 71, 79], ["NT", "TEST", 84, 86], ["Pro", "TEST", 87, 90], ["BNP", "TEST", 91, 94], ["B-Typ-natriuretische Peptide", "TREATMENT", 96, 124], ["beobachtet", "TREATMENT", 127, 137]]], ["Alle diese Laborwertver\u00e4nderungen sind unspezifisch [16].Klinische Pr\u00e4sentation und VerlaufCOVID-19 ist eine systemische Infektion, die letztlich jedes Organ betreffen kann.", [["Klinische Pr\u00e4sentation und VerlaufCOVID-19 ist eine systemische Infektion, die letztlich jedes Organ betreffen kann", "SPECIES", 57, 172], ["Klinische Pr\u00e4sentation", "TREATMENT", 57, 79], ["VerlaufCOVID", "TEST", 84, 96], ["ist eine systemische Infektion", "TREATMENT", 100, 130]]], ["So wurden kardiale Manifestationen mit Myokarditis, Kardiomyopathie, Herzrhythmusst\u00f6rungen und Kreislaufversagen beschrieben [20].", [["mit Myokarditis", "PROBLEM", 35, 50], ["Kardiomyopathie", "PROBLEM", 52, 67], ["Herzrhythmusst\u00f6rungen", "TEST", 69, 90]]], ["Bei schwer Erkrankten treten auch zerebrovaskul\u00e4re Manifestationen und in bis zu 8 % der Patienten auch Enzephalitiden auf [17, 18].", [["Bei schwer Erkrankten treten auch zerebrovaskul\u00e4re Manifestationen und in bis zu 8 % der Patienten auch Enzephalitiden auf", "SPECIES", 0, 122]]], ["Ven\u00f6se oder auch arterielle thrombembolische Komplikationen erleiden 10\u201325 % der mit COVID-19 hospitalisierten Patienten; bei den intensivmedizinisch behandelten Patienten sind diese noch h\u00e4ufiger [19, 20].Klinische Pr\u00e4sentation und VerlaufEine intensivmedizinische Behandlung ist bei ca.", [["Ven\u00f6se oder auch arterielle thrombembolische Komplikationen erleiden 10\u201325 % der mit COVID-19 hospitalisierten Patienten; bei den intensivmedizinisch behandelten Patienten sind diese noch h\u00e4ufiger", "SPECIES", 0, 196], ["Ven\u00f6se oder auch arterielle thrombembolische", "TREATMENT", 0, 44], ["Komplikationen erleiden", "TREATMENT", 45, 68], ["Klinische Pr\u00e4sentation", "TREATMENT", 206, 228]]], ["17\u201335 % der COVID-19-Patienten erforderlich, meist aufgrund eines hypoxischen Lungenversagens.", [["COVID", "TEST", 12, 17]]], ["Ein 2\u2011Organ-Versagen (Beatmungs- und Dialysepflichtigkeit) ging mit einer Mortalit\u00e4t von 73 % einher [14].", [["Ein 2\u2011", "CHEMICAL", 0, 6], ["Organ-Versagen (Beatmungs- und Dialysepflichtigkeit)", "TREATMENT", 6, 58]]], ["Eine Leberbeteiligung mit erh\u00f6hten Leberwerten wurde in einer anderen Studie in 19 % der F\u00e4lle beschrieben.Screening auf die M\u00f6glichkeit einer SARS-CoV-2-Infektion ::: Notfallmedizinisches Vorgehen in der COVID-19-PandemieIn der Pandemie stellt sich bei jedem Patienten, der sich in einem Notfallzentrum des Krankenhauses vorstellt, die Frage, ob eine SARS-CoV-2-Infektion vorliegt und diese die beobachteten Krankheitserscheinungen erkl\u00e4ren kann [21].", [["Notfallmedizinisches Vorgehen in der COVID-19-PandemieIn der Pandemie stellt sich bei jedem Patienten, der sich in einem Notfallzentrum des Krankenhauses vorstellt, die Frage, ob eine SARS-CoV-2-Infektion vorliegt und diese die beobachteten Krankheitserscheinungen erkl\u00e4ren kann", "SPECIES", 168, 446], ["ob eine SARS", "TEST", 344, 356], ["CoV", "TEST", 357, 360], ["Infektion", "PROBLEM", 363, 372]]], ["Es ist wichtig, infektionsgef\u00e4hrdende COVID-19-Patienten sofort zu identifizieren.", [["Es ist wichtig, infektionsgef\u00e4hrdende COVID-19-Patienten sofort zu identifizieren", "SPECIES", 0, 81], ["COVID", "TEST", 38, 43]]], ["Das bedeutet, dass die Patienten bereits vor Betreten des eigentlichen Krankenhausbereichs auf Symptome hin befragt werden m\u00fcssen, die auf eine Infektion hinweisen sowie nach einem Aufenthalt in einem Gebiet mit hohem Infektionsrisiko.", [["Das bedeutet, dass die Patienten bereits vor Betreten des eigentlichen Krankenhausbereichs auf Symptome hin befragt werden m\u00fcssen, die auf eine Infektion hinweisen sowie nach einem Aufenthalt in einem Gebiet mit hohem Infektionsrisiko", "SPECIES", 0, 234], ["Betreten des", "TREATMENT", 45, 57]]], ["Hierzu hat das Robert Koch-Institut (RKI) eine Orientierungshilfe f\u00fcr \u00c4rzt*innen entworfen, die an die Bedingungen der jeweiligen H\u00e4user angepasst werden muss [22].", [["Hierzu hat das Robert Koch-Institut (RKI) eine Orientierungshilfe f\u00fcr \u00c4rzt*innen entworfen", "SPECIES", 0, 90]]], ["Als Beispiel ist in Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 20, 23], ["Abb", "PROTEIN", 20, 23], ["Abb", "OBSERVATION", 20, 23]]], ["1 das Vorgehen in der M\u00fcnchen Klinik dargestellt.Screening auf die M\u00f6glichkeit einer SARS-CoV-2-Infektion ::: Notfallmedizinisches Vorgehen in der COVID-19-PandemieAuf diesem Triagebogen werden prim\u00e4r schwerste Infektionen anhand des Q\u2011SOFA-Scores identifiziert und die weiteren relevanten Informationen in Themenbl\u00f6cken (Block 1: Respiratorische Symptome, Block 2: Allgemeine Infektsymptome, Block 3: Infektionsrisiko durch m\u00f6gliche Exposition) abgefragt.", [["Notfallmedizinisches Vorgehen in der COVID-19-PandemieAuf diesem Triagebogen werden prim\u00e4r schwerste Infektionen anhand des Q\u2011SOFA-Scores identifiziert und die weiteren relevanten", "SPECIES", 110, 289], ["Notfallmedizinisches", "TEST", 110, 130], ["COVID", "TEST", 147, 152], ["Triagebogen", "TEST", 175, 186]]], ["Sollten sich Infektsymptome oder Risikokonstellationen herausstellen, werden die Patienten in dem separierten Abkl\u00e4rungsbereich des Notfallzentrums durch pflegerisches und \u00e4rztliches Personal behandelt, die komplett mit pers\u00f6nlicher Schutzausr\u00fcstung ausgestattet sind.Schockraumversorgung in der Corona-Pandemie ::: Notfallmedizinisches Vorgehen in der COVID-19-PandemieAlle Patienten, die im Schockraum behandelt werden, m\u00fcssen potenziell als infekti\u00f6s gelten, und es werden spezifische Schutzma\u00dfnahmen erforderlich.", [["dem separierten Abkl\u00e4rungsbereich des Notfallzentrums durch pflegerisches und \u00e4rztliches Personal behandelt, die komplett mit pers\u00f6nlicher Schutzausr\u00fcstung ausgestattet sind", "SPECIES", 94, 267]]], ["Diesbez\u00fcglich haben die Vereinigungen f\u00fcr Wiederbelebung f\u00fcr die COVID-19-Pandemie Empfehlungen herausgegeben.", [["Diesbez\u00fcglich haben die Vereinigungen f\u00fcr Wiederbelebung f\u00fcr die COVID-19-Pandemie Empfehlungen herausgegeben", "SPECIES", 0, 109], ["COVID", "TEST", 65, 70]]], ["Alle Mitglieder des Schockraumteams m\u00fcssen komplette pers\u00f6nliche Schutzausr\u00fcstung tragen, die Ma\u00dfnahmen an den Atemwegen sind von darin Ge\u00fcbten durchzuf\u00fchren und das Team sollte auf die absolut notwendige Personalst\u00e4rke reduziert werden [23].Notfallmedizinische Diagnoseschritte in der Corona-Pandemie ::: Notfallmedizinisches Vorgehen in der COVID-19-PandemieNach der Erstevaluation muss bei allen COVID-19-Verdachtsf\u00e4llen die Diagnose gesichert werden.", [["Alle Mitglieder des Schockraumteams m\u00fcssen komplette pers\u00f6nliche Schutzausr\u00fcstung tragen, die Ma\u00dfnahmen an den Atemwegen sind von darin Ge\u00fcbten durchzuf\u00fchren und das Team sollte auf die absolut notwendige Personalst\u00e4rke reduziert werden", "SPECIES", 0, 236], ["Notfallmedizinisches Vorgehen in der COVID-19-PandemieNach der Erstevaluation muss bei allen COVID-19-Verdachtsf\u00e4llen die Diagnose gesichert werden", "SPECIES", 306, 453], ["Alle Mitglieder des", "TREATMENT", 0, 19]]], ["Dazu wird Atemwegssekret gewonnen und mittels Polymerase-Kettenreaktion (PCR) untersucht.", [["Dazu wird Atemwegssekret gewonnen und mittels Polymerase-Kettenreaktion", "SPECIES", 0, 71], ["Polymerase", "TEST", 46, 56]]], ["Die Sensitivit\u00e4t dieser Test h\u00e4ngt von dem gewonnenen Material, der richtigen Technik der Gewinnung und dem Zeitpunkt der Infektion ab.", [["h\u00e4ngt von dem gewonnenen Material, der richtigen Technik der Gewinnung und dem Zeitpunkt der Infektion ab", "SPECIES", 29, 134]]], ["So hat eine Studie berichtet, dass die Rate richtig-positiver Tests 4 Tage nach der Infektion 33 %, zum Zeitpunkt des Auftretens von Symptomen 62 % und 3 Tage nach Symptombeginn 80 % betr\u00e4gt [24\u201326].", [["zum Zeitpunkt des Auftretens von Symptomen 62 % und 3 Tage nach Symptombeginn 80 % betr\u00e4gt", "SPECIES", 100, 190], ["Rate", "TEST", 39, 43], ["richtig", "TEST", 44, 51], ["Tests", "TEST", 62, 67], ["Infektion", "TEST", 84, 93], ["zum Zeitpunkt des", "TREATMENT", 100, 117]]], ["In Notfallzentren k\u00f6nnen Schnelltests als PCR durchgef\u00fchrt werden, die nach 30\u201345 min ein Ergebnis liefern.", [["Notfallzentren k\u00f6nnen Schnelltests", "TREATMENT", 3, 37]]], ["Weil diese Patienten aber oft so schwer krank sind, dass sie einer intensivmedizinischen Behandlung oder zumindest einer \u00dcberwachung bed\u00fcrfen und gerade in diesen Bereichen eine Infektionsgef\u00e4hrdung f\u00fcr andere Patienten und das Personal vermieden werden muss, ist es wichtig, bei diesen Patienten neben der PCR zus\u00e4tzliche Diagnostik hinzuzuziehen.", [["Bereichen eine Infektionsgef\u00e4hrdung f\u00fcr andere Patienten und das Personal vermieden werden muss, ist es wichtig, bei diesen Patienten neben der PCR zus\u00e4tzliche Diagnostik hinzuzuziehen", "SPECIES", 163, 347], ["Diagnostik hinzuzuziehen", "TREATMENT", 323, 347]]], ["Auf diese Weise kann die diagnostische Sicherheit betr\u00e4chtlich erh\u00f6ht werden.Notfallmedizinische Diagnoseschritte in der Corona-Pandemie ::: Notfallmedizinisches Vorgehen in der COVID-19-PandemieWeitere Aufgabe der Notfallzentrums ist die Evaluation der Patienten bez\u00fcglich m\u00f6glicher Differenzialdiagnosen, denn auch das Vorliegen einer positiven SARS-CoV-2-PCR schlie\u00dft andere Krankheiten, z.", [["Notfallmedizinisches Vorgehen in der COVID-19-PandemieWeitere Aufgabe der Notfallzentrums ist die Evaluation der Patienten bez\u00fcglich m\u00f6glicher Differenzialdiagnosen, denn auch das Vorliegen einer positiven SARS-CoV-2-PCR schlie\u00dft andere", "SPECIES", 141, 377], ["SARS", "TEST", 347, 351], ["CoV", "TEST", 352, 355], ["PCR", "TEST", 358, 361]]], ["B. als Ursache einer Dyspnoe, nicht aus.", [["B. als Ursache einer", "SPECIES", 0, 20]]], ["Zudem m\u00fcssen Komorbidit\u00e4ten erfasst und dokumentiert werden.", [["Zudem", "TREATMENT", 0, 5], ["Komorbidit\u00e4ten erfasst", "TREATMENT", 13, 35]]], ["Besonders wichtig ist die Erfassung einer Hyperglyk\u00e4mie, einer kardialen Beteiligung, einer An\u00e4mie, die die Gewebehypoxie verschlechtert, sowie einer eingeschr\u00e4nkten Nierenfunktion und neurologischer Begleitsymptome.Notfallmedizinische Diagnoseschritte in der Corona-Pandemie ::: Notfallmedizinisches Vorgehen in der COVID-19-PandemieAm Ende des Evaluationsprozesses steht die Entscheidung, wo die Weiterversorgung am besten erfolgen sollte.", [["Notfallmedizinisches Vorgehen in der COVID-19-PandemieAm Ende des Evaluationsprozesses steht die Entscheidung, wo die Weiterversorgung am besten erfolgen sollte", "SPECIES", 280, 440]]], ["Die Entscheidung, ob ein \u00dcberwachungsbett oder ein Intensivbett ben\u00f6tigt wird, h\u00e4ngt von dem Ausma\u00df der respiratorischen Insuffizienz und der Funktionseinschr\u00e4nkung anderer Organe, dem Therapieziel im Hinblick auf die Gesamtprognose und nicht zuletzt vom Patientenwunsch ab.", [["Die Entscheidung, ob ein \u00dcberwachungsbett oder ein Intensivbett ben\u00f6tigt wird, h\u00e4ngt von dem Ausma\u00df der respiratorischen Insuffizienz und der Funktionseinschr\u00e4nkung anderer Organe, dem Therapieziel im Hinblick auf die Gesamtprognose und nicht zuletzt vom Patientenwunsch ab", "SPECIES", 0, 273], ["ob", "ANATOMY", 18, 20]]], ["Liegen ein Therapiewunsch und ein realistisches Therapieziel vor, dann sind folgende Kriterien f\u00fcr die Unterst\u00fctzung der Aufnahmeentscheidung von COVID-19-Patienten auf die Intensivstation empfohlen [27]:Hypox\u00e4mie (SpO2 <90 % unter 2\u20134 l Sauerstoff/min bei nicht vorbestehender Therapie),Dyspnoe mit einer Atemfrequenz >25\u201330/min,systolischer Blutdruck <100 mm Hg oder einem erh\u00f6hten Laktatwert.Therapie des hypox\u00e4mischen Lungenversagens bei COVID-19-Pneumonie Typ\u00a0L und Typ\u00a0H ::: Intensivmedizinisches Vorgehen bei COVID-19-PatientenDa die \u00fcberwiegende Mehrheit der Patienten mit einer schweren COVID-19-Pneumonie die Berlin-Kriterien eines ARDS erf\u00fcllten [28], empfahl die Surviving Sepsis Campaign zu Beginn der Corona-Pandemie eine Beatmungstherapie analog zu Patienten mit einem ARDS anderer Genese [29].", [["ARDS", "DISEASE", 642, 646], ["Sepsis", "DISEASE", 685, 691], ["ARDS", "DISEASE", 784, 788], ["Liegen ein Therapiewunsch und ein realistisches Therapieziel vor, dann sind folgende Kriterien f\u00fcr die Unterst\u00fctzung der Aufnahmeentscheidung von COVID-19-Patienten auf die Intensivstation empfohlen [27]:Hypox\u00e4mie (SpO2 <90 % unter 2\u20134 l Sauerstoff/min bei nicht vorbestehender Therapie),Dyspnoe mit einer Atemfrequenz >25\u201330/min", "SPECIES", 0, 329], ["Therapie des hypox\u00e4mischen Lungenversagens bei COVID-19-Pneumonie Typ\u00a0L und Typ\u00a0H", "SPECIES", 395, 476], ["Intensivmedizinisches Vorgehen bei COVID-19-PatientenDa die \u00fcberwiegende Mehrheit der Patienten mit einer schweren COVID-19-Pneumonie die Berlin-Kriterien eines ARDS erf\u00fcllten [28], empfahl die Surviving Sepsis Campaign zu Beginn der Corona-Pandemie eine Beatmungstherapie analog zu Patienten mit einem ARDS anderer Genese", "SPECIES", 481, 803], ["Hypox\u00e4mie", "TEST", 204, 213], ["SpO2", "TEST", 215, 219], ["Atemfrequenz", "TEST", 306, 318], ["systolischer", "TEST", 330, 342], ["Therapie", "TEST", 395, 403], ["COVID", "TEST", 442, 447], ["Intensivmedizinisches", "TEST", 481, 502], ["COVID", "TEST", 516, 521], ["COVID", "TEST", 596, 601], ["Kriterien eines ARDS erf\u00fcllten", "TREATMENT", 626, 656], ["Sepsis", "PROBLEM", 685, 691]]], ["Weiterhin zeigte sich, dass beatmungspflichtige Patienten initial nicht von einem hohen PEEP (\u201epositive end-expiratory pressure\u201c) profitierten und die Compliance der Lunge noch erstaunlich hoch war.", [["PEEP", "TREATMENT", 88, 92], ["\u201epositive end-expiratory pressure\u201c", "TREATMENT", 94, 128]]], ["Dadurch unterscheidet sich das ARDS bei einer COVID-19-Pneumonie teilweise deutlich von einem ARDS anderer Genese.", [["ARDS", "DISEASE", 94, 98], ["Dadurch unterscheidet sich das ARDS bei einer COVID-19-Pneumonie teilweise deutlich von einem ARDS anderer Genese", "SPECIES", 0, 113], ["ARDS", "TEST", 31, 35], ["COVID", "TEST", 46, 51], ["Pneumonie", "PROBLEM", 55, 64], ["ARDS", "PROBLEM", 94, 98]]], ["Dies f\u00fchrte zu einer differenzierten Therapiestrategie des ARDS nach dem bereits erw\u00e4hnten Modell von Gattinoni et al. [4].Therapie der hypox\u00e4mischen respiratorischen InsuffizienzBei Vorliegen eines L\u2011Typs stehen zur Therapie der oxygenatorischen respiratorischen Insuffizienz die Sauerstoffapplikation mittels Nasenbrille, Venturi-Maske (mit oder ohne Reservoir) sowie die High-flow-Sauerstofftherapie (HFOT) zur Verf\u00fcgung.", [["Therapie der hypox\u00e4mischen respiratorischen InsuffizienzBei Vorliegen eines L\u2011Typs stehen zur Therapie der oxygenatorischen respiratorischen Insuffizienz die Sauerstoffapplikation mittels Nasenbrille, Venturi-Maske (mit oder ohne Reservoir) sowie die High-flow-Sauerstofftherapie (HFOT) zur Verf\u00fcgung", "SPECIES", 123, 423], ["Therapie der hypox\u00e4mischen respiratorischen InsuffizienzBei Vorliegen eines L\u2011Typs", "TREATMENT", 123, 205], ["respiratorischen Insuffizienz", "TREATMENT", 247, 276], ["Sauerstoffapplikation mittels Nasenbrille", "TREATMENT", 281, 322], ["Venturi-Maske (mit oder ohne Reservoir", "TREATMENT", 324, 362]]], ["Bei deutlicher Progredienz der respiratorischen Insuffizienz unter dieser Therapie, sollte der Einsatz einer CPAP-Therapie (\u201econtinuous positive airway pressure\u201c), einer nichtinvasiven Beatmung (NIV) oder der invasiven Beatmung gepr\u00fcft werden.", [["CPAP", "TREATMENT", 109, 113], ["Therapie", "TREATMENT", 114, 122], ["\u201econtinuous positive airway pressure\u201c", "TREATMENT", 124, 161], ["einer nichtinvasiven Beatmung", "TREATMENT", 164, 193]]], ["Als Zielwerte der Therapie wird ein SpO2 \u226590 % bzw. ein paO2 >55 mm Hg empfohlen [27].", [["Hg", "CHEMICAL", 68, 70], ["SpO2", "TEST", 36, 40], ["ein paO2", "TEST", 52, 60]]], ["W\u00e4hrend die Sauerstoffzufuhr mittels Nasenbrille und Venturi-Maske Therapieoptionen f\u00fcr die Normalstationen sind, sollten HFOT und NIV nur unter strengem Monitoring und unter Intubationsbereitschaft auf der Intensivstation angewandt werden.High-flow-Sauerstofftherapie (HFOT)Bei der HFOT wird mit Sauerstoff angereicherte Luft (FiO2 bis 100 %) mit einem hohen Fluss (bis 70 l/min) durch eine Nasenkan\u00fcle verabreicht.", [["FiO2 bis", "CHEMICAL", 328, 336], ["W\u00e4hrend die Sauerstoffzufuhr mittels Nasenbrille und Venturi-Maske Therapieoptionen f\u00fcr die Normalstationen sind, sollten HFOT und NIV nur unter strengem Monitoring und unter Intubationsbereitschaft auf der Intensivstation angewandt werden", "SPECIES", 0, 239], ["Bei der HFOT wird mit Sauerstoff angereicherte Luft (FiO2 bis 100 %) mit einem hohen Fluss (bis 70 l/min) durch eine Nasenkan\u00fcle verabreicht", "SPECIES", 275, 415], ["High-flow-Sauerstofftherapie (HFOT)", "TREATMENT", 240, 275], ["Luft (FiO2 bis", "TREATMENT", 322, 336], ["mit einem hohen Fluss (bis", "TREATMENT", 344, 370], ["durch eine Nasenkan\u00fcle verabreicht", "TREATMENT", 381, 415]]], ["Dadurch kommt es neben der Oxygenierung zu einer CO2-Auswaschung und der Erzeugung eines geringf\u00fcgigen PEEP.", [["Dadurch kommt es neben der Oxygenierung zu einer CO2-Auswaschung und der Erzeugung eines geringf\u00fcgigen", "SPECIES", 0, 102], ["PEEP", "TREATMENT", 103, 107]]], ["Bei mildem oder moderatem ARDS (paO2/FiO2 100\u2013300 mm Hg) kann ein Therapieversuch mit HFOT durchgef\u00fchrt werden [27, 30].", [["ARDS", "DISEASE", 26, 30], ["Hg", "CHEMICAL", 53, 55], ["ARDS", "PROBLEM", 26, 30], ["paO2", "TEST", 32, 36], ["FiO2", "TEST", 37, 41], ["ARDS", "OBSERVATION", 26, 30]]], ["Bei der HFOT sollten die Patienten einen Mund-Nasen-Schutz \u00fcber der Nasenkan\u00fcle tragen, um die Aerosolbildung zu reduzieren [31].", [["Bei der HFOT sollten die Patienten einen Mund-Nasen-Schutz \u00fcber der Nasenkan\u00fcle tragen, um die Aerosolbildung zu reduzieren", "SPECIES", 0, 123]]], ["Allerdings wird dies patientenseitig h\u00e4ufig nicht toleriert.Nichtinvasive Beatmung (NIV)Bei leichtem ARDS sowie im Vordergrund stehender hyperkapnischer respiratorischer Insuffizienz (chronisch-obstruktive Lungenerkrankung [COPD], neuromuskul\u00e4re Erkrankungen etc.) ist ein Therapieversuch mit CPAP oder NIV gerechtfertigt.", [["COPD", "DISEASE", 224, 228], ["Bei leichtem ARDS sowie im Vordergrund stehender hyperkapnischer respiratorischer Insuffizienz (chronisch-obstruktive Lungenerkrankung [COPD], neuromuskul\u00e4re Erkrankungen etc.) ist ein Therapieversuch mit CPAP oder NIV gerechtfertigt", "SPECIES", 88, 321], ["Nichtinvasive Beatmung", "TREATMENT", 60, 82], ["NIV", "TEST", 84, 87], ["ARDS", "PROBLEM", 101, 105], ["stehender", "TEST", 127, 136], ["hyperkapnischer", "TEST", 137, 152], ["respiratorischer", "TEST", 153, 169], ["Insuffizienz", "TEST", 170, 182], ["obstruktive Lungenerkrankung", "PROBLEM", 194, 222], ["COPD]", "PROBLEM", 224, 229], ["neuromuskul\u00e4re Erkrankungen", "TREATMENT", 231, 258], ["ist ein Therapieversuch mit CPAP", "TREATMENT", 265, 297], ["NIV gerechtfertigt", "TREATMENT", 303, 321]]], ["Dabei ist auf einen guten Sitz der Maske zu achten, um zum einen eine erh\u00f6hte Aerosolexposition und des Weiteren einen PEEP-Verlust und ein daraus folgendes Derecruitment mit Atelektasenbildung zu vermeiden Dabei kommen \u201enon-vented\u201c (leckagefreie) Mund-Nasen-Masken, Gesichtsmasken und Beatmungshelme zur Anwendung.", [["Dabei ist auf einen guten Sitz der Maske zu achten, um zum einen eine erh\u00f6hte Aerosolexposition und des Weiteren einen PEEP-Verlust und ein daraus folgendes Derecruitment mit Atelektasenbildung zu vermeiden Dabei kommen \u201enon-vented\u201c (leckagefreie) Mund-Nasen-Masken, Gesichtsmasken und Beatmungshelme zur Anwendung", "SPECIES", 0, 314], ["Dabei ist auf einen guten Sitz", "TREATMENT", 0, 30], ["PEEP", "TREATMENT", 119, 123], ["Verlust und ein daraus", "TREATMENT", 124, 146]]], ["Der Therapieerfolg muss engmaschig \u00fcberwacht werden, damit es bei einem Therapieversagen nicht zu einer verz\u00f6gerten Intubation und damit Prognoseverschlechterung kommt [32].", [["Der Therapieerfolg muss engmaschig \u00fcberwacht werden, damit es bei einem Therapieversagen nicht zu einer verz\u00f6gerten Intubation und damit Prognoseverschlechterung kommt", "SPECIES", 0, 167], ["Intubation", "TREATMENT", 116, 126]]], ["In unserem Patientenkollektiv mussten ca.", [["mussten ca", "OBSERVATION", 30, 40]]], ["50 % der mit NIV therapierten Patienten im Verlauf invasiv beatmet werden, u. a. auch aufgrund unzureichender Toleranz der Beatmungsmaske \u00fcber einen l\u00e4ngeren Zeitraum.Aerosolbildung bei atemunterst\u00fctzenden VerfahrenSowohl bei der Low-flow und High-flow-Sauerstoffapplikation als auch bei der NIV kann es zu einer erh\u00f6hten Aerosolbildung mit potenzieller Viruskontamination kommen.", [["Aerosolbildung bei atemunterst\u00fctzenden VerfahrenSowohl bei der Low-flow und High-flow-Sauerstoffapplikation als auch bei der NIV kann es zu einer erh\u00f6hten Aerosolbildung mit potenzieller Viruskontamination kommen", "SPECIES", 167, 379], ["der mit NIV therapierten", "TREATMENT", 5, 29], ["Aerosolbildung", "TEST", 167, 181], ["Sauerstoffapplikation als auch bei der NIV", "TREATMENT", 253, 295]]], ["Dabei kommt es jedoch zu keiner erh\u00f6hten Belastung bei einem Abstand von mehr als einem Meter [33].", [["Dabei kommt es jedoch zu keiner erh\u00f6hten Belastung bei einem Abstand von mehr als einem Meter [33", "SPECIES", 0, 97]]], ["Unter Verwendung der pers\u00f6nlichen Schutzausr\u00fcstung (Augenschutz, Handschuhe, Kittel und mindestens FFP 2-Maske) k\u00f6nnen diese Therapieformen ohne erh\u00f6htes Infektionsrisiko angewandt werden.Invasive BeatmungBei schwerer therapierefrakt\u00e4rer Hypoxie (paO2/FiO2 \u2264150 mm Hg) und Atemfrequenzen >30/min sollten eine Intubation und invasive Beatmung erfolgen.", [["Hg", "CHEMICAL", 265, 267], ["FFP", "TREATMENT", 99, 102], ["Invasive BeatmungBei", "TEST", 188, 208], ["Hypoxie", "TEST", 238, 245], ["paO2", "TEST", 247, 251], ["FiO2", "TEST", 252, 256], ["Atemfrequenzen", "TEST", 273, 287], ["sollten eine Intubation", "TREATMENT", 296, 319]]], ["Allgemein gelten die Ziele einer lungenprotektiven Beatmung beim ARDS gem\u00e4\u00df der S3-Leitlinie [34] auch bei einer COVID-19-Pneumonie.", [["COVID-19-Pneumonie", "CHEMICAL", 113, 131], ["Allgemein gelten die Ziele einer lungenprotektiven Beatmung beim ARDS gem\u00e4\u00df der S3-Leitlinie [34] auch bei einer COVID-19-Pneumonie", "SPECIES", 0, 131], ["Allgemein", "TREATMENT", 0, 9], ["ARDS", "PROBLEM", 65, 69], ["COVID", "TEST", 113, 118], ["Pneumonie", "PROBLEM", 122, 131]]], ["Allerdings zeigt sich gerade in der Fr\u00fchphase (L-Typ) ein niedriges Rekrutierungspotenzial und eine weitgehend erhaltene Compliance der Lunge.", [["L-Typ)", "TREATMENT", 47, 53]]], ["Daher gibt es keine klaren Empfehlungen zur H\u00f6he des PEEP.", [["PEEP", "TREATMENT", 53, 57]]], ["Mit zunehmender Konsolidierung und \u00dcbergang in einen H\u2011Typ sollte der PEEP nach der ARDS-Network-Tabelle (FiO2/PEEP) gew\u00e4hlt werden [34].", [["ARDS", "DISEASE", 84, 88], ["Mit zunehmender Konsolidierung", "TREATMENT", 0, 30], ["ARDS", "PROBLEM", 84, 88], ["FiO2", "TREATMENT", 106, 110], ["PEEP", "TREATMENT", 111, 115]]], ["Wie beim klassischen ARDS wird bei einem paO2/FiO2 <150 mm Hg eine Bauchlagerung des Patienten f\u00fcr mindestens 16 h empfohlen [35].", [["Hg", "CHEMICAL", 59, 61], ["ARDS", "PROBLEM", 21, 25], ["paO2", "TEST", 41, 45], ["FiO2", "TREATMENT", 46, 50]]], ["Im Gegensatz dazu ist der Nutzen einer Bauchlagerung wacher Patienten noch nicht ausreichend gut belegt, aber durchaus ein interessanter Therapieansatz [36].Invasive BeatmungZeigt sich unter lungenprotektiver Beatmung eine therapierefrakt\u00e4re Hypoxamie (paO2/FiO2 ) <80 bzw. unter 60 mm Hg, stellt der Einsatz einer venoven\u00f6sen extrakorporale Membranoxygenierung (ECMO) eine Therapieoption dar [27].", [["Hg", "CHEMICAL", 286, 288], ["Im Gegensatz dazu ist der Nutzen einer", "TREATMENT", 0, 38], ["Invasive BeatmungZeigt sich", "TREATMENT", 157, 184], ["Hypoxamie", "TEST", 242, 251], ["paO2", "TEST", 253, 257], ["FiO2", "TEST", 258, 262], ["stellt der Einsatz einer venoven\u00f6sen", "TREATMENT", 290, 326]]], ["Allerdings ist die Prognose in dieser Patientengruppe sehr schlecht [37].Thrombembolische Komplikationen ::: KomplikationenThrombembolische Ereignisse sind h\u00e4ufige Komplikationen bei COVID-19-Patienten [38, 39], die auch unter einer Thromboseprophylaxe auftreten k\u00f6nnen.", [["KomplikationenThrombembolische Ereignisse sind h\u00e4ufige Komplikationen bei COVID-19-Patienten", "SPECIES", 109, 201], ["Komplikationen", "TEST", 109, 123], ["Ereignisse", "TEST", 140, 150], ["COVID", "TEST", 183, 188]]], ["Ob eine therapeutische Antikoagulation bei allen Intensivpatienten gerechtfertigt ist, ist zurzeit noch unklar.", [["Ob eine therapeutische Antikoagulation bei allen Intensivpatienten gerechtfertigt ist, ist zurzeit noch unklar", "SPECIES", 0, 110]]], ["B. bei raschem Anstieg der D\u2011Dimere, in Abh\u00e4ngigkeit des individuellen Blutungsrisikos, eine intensivierte Antikoagulation begonnen werden [27].Pneumothorax ::: KomplikationenUnter den nichtinfekti\u00f6sen Lungenkomplikationen bei COVID-19-Patienten findet man vereinzelt Berichte zu Pneumothoraces.", [["Pneumothorax", "DISEASE", 144, 156], ["man", "SPECIES", 253, 256], ["KomplikationenUnter den nichtinfekti\u00f6sen Lungenkomplikationen bei COVID-19-Patienten findet man vereinzelt Berichte zu Pneumothoraces", "SPECIES", 161, 294], ["Pneumothorax", "PROBLEM", 144, 156], ["bei COVID", "TEST", 223, 232], ["Pneumothoraces", "PROBLEM", 280, 294], ["zu Pneumothoraces", "OBSERVATION", 277, 294]]], ["Der Gesamtanteil an Pneumothoraces liegt jedoch im unteren einstelligen Prozentbereich, und auch hier\u00fcber gibt es wenig systematische Publikationen.Pneumothorax ::: KomplikationenIn einer chinesischen Publikation wurden bei 2 % der Patienten ein Pneumothorax bei manifester, schwerer COVID-19-Infektion festgestellt [40].", [["Pneumothorax", "DISEASE", 148, 160], ["Pneumothorax bei", "DISEASE", 246, 262], ["KomplikationenIn einer chinesischen Publikation wurden bei 2 % der Patienten ein Pneumothorax bei manifester, schwerer COVID-19-Infektion festgestellt", "SPECIES", 165, 315], ["Der Gesamtanteil", "TREATMENT", 0, 16], ["Pneumothorax", "PROBLEM", 148, 160], ["KomplikationenIn einer chinesischen Publikation", "TREATMENT", 165, 212], ["COVID", "TEST", 284, 289], ["Pneumothoraces", "OBSERVATION", 20, 34], ["Pneumothorax", "OBSERVATION", 246, 258]]], ["Oftmals ist hierbei aber eine strukturelle Lungenvorsch\u00e4digung ma\u00dfgeblich (Abb.", [["Oftmals", "TEST", 0, 7]]], ["2).Sekund\u00e4rinfektionen ::: KomplikationenDie Gefahr bakterieller Superinfektionen scheint bei COVID-19-Patienten weitaus seltener zu sein als beispielsweise bei Influenza, und eine prophylaktische antibiotische Therapie, auch bei hospitalisierten Patienten oder intensivpflichtigen COVID-19-Patienten, ist generell nicht indiziert [41].Sekund\u00e4rinfektionen ::: KomplikationenDennoch m\u00fcssen diese Patienten regelm\u00e4\u00dfig und engmaschig auf pulmonale Superinfektionen oder nosokomiale Infektionen \u00fcberwacht werden.", [["pulmonale", "DISEASE", 435, 444], ["KomplikationenDie Gefahr bakterieller Superinfektionen scheint bei COVID-19-Patienten weitaus seltener zu sein als beispielsweise bei Influenza, und eine prophylaktische antibiotische Therapie, auch bei hospitalisierten Patienten oder intensivpflichtigen COVID-19-Patienten, ist generell nicht indiziert", "SPECIES", 27, 330], ["Komplikationen", "TREATMENT", 27, 41], ["COVID", "TEST", 94, 99], ["Influenza", "PROBLEM", 161, 170], ["COVID", "TEST", 282, 287]]], ["Die Hauptkomplikation von COVID-19-Patienten mit schwerem Verlauf, die etwa 10 % des Gesamtkollektivs der SARS-CoV-2-infizierten Patienten darstellen, ist das ARDS.Sekund\u00e4rinfektionen ::: KomplikationenWie allgemein bei schweren viralen Infektionen der Lunge kommt es im Verlauf einer COVID-19-Infektion u.", [["ARDS", "DISEASE", 159, 163], ["Die Hauptkomplikation von COVID-19-Patienten mit schwerem Verlauf, die etwa 10 % des Gesamtkollektivs der SARS-CoV-2-infizierten Patienten darstellen", "SPECIES", 0, 149], ["KomplikationenWie allgemein bei schweren viralen Infektionen der Lunge kommt es im Verlauf einer COVID-19-Infektion u.", "SPECIES", 188, 306], ["COVID", "TEST", 26, 31], ["CoV", "TEST", 111, 114], ["infizierten", "TREATMENT", 117, 128], ["ARDS", "PROBLEM", 159, 163], ["COVID", "TEST", 285, 290]]], ["U. zu bakteriellen Superinfektionen, auch Pilzinfektionen manifestieren sich in diesem Kollektiv als zus\u00e4tzliche Komplikation.", [["sich", "PROBLEM", 72, 76]]], ["Neben Staphylokokken und Klebsiellen spielen hierbei auch atypische Erreger (Legionellen, Chlamydien) eine entscheidende Rolle, und unter den Pilzen pr\u00e4dominieren Aspergillen ([42]; Abb.", [["Neben", "TEST", 0, 5], ["Legionellen, Chlamydien)", "TREATMENT", 77, 101]]], ["Insgesamt muss man anhand der aktuell vorliegenden Daten bei etwa 8 % der hospitalisierten COVID-19-Patienten von Koinfektionen ausgehen [43].Medikament\u00f6se TherapieDas Bestreben, eine m\u00f6glichst effiziente Therapie zu entwickeln, war aufgrund der hohen kontagi\u00f6sen Potenz und der rasch zunehmenden Erkrankungsf\u00e4lle von Anfang an sehr gro\u00df und f\u00fchrte zu einer Vielzahl klinisch-pharmakologischer Studien sowie empirischer Therapieversuche.Medikament\u00f6se TherapieLopinavir/Ritonavir oder auch Chloroquin waren bei den ersten Medikamenten, denen eine antivirale Wirkung zugeschrieben worden ist.", [["man", "SPECIES", 15, 18], ["Insgesamt muss man anhand der aktuell vorliegenden Daten bei etwa 8 % der hospitalisierten COVID-19-Patienten von Koinfektionen ausgehen", "SPECIES", 0, 136], ["der hohen kontagi\u00f6sen Potenz und der rasch zunehmenden Erkrankungsf\u00e4lle von Anfang an sehr gro\u00df und f\u00fchrte zu einer Vielzahl klinisch-pharmakologischer Studien sowie empirischer", "SPECIES", 242, 419], ["Medikament\u00f6se TherapieLopinavir", "TREATMENT", 437, 468], ["Ritonavir", "TREATMENT", 469, 478], ["Chloroquin waren bei den ersten Medikamenten", "TREATMENT", 489, 533]]], ["Jedoch erwiesen sich beide Substanzen sehr bald als unwirksam und teilweise sogar unvorteilhaft aufgrund des Nebenwirkungsprofils und werden auch seitens der Weltgesundheitsorganisation (WHO) negativ bewertet [44].Medikament\u00f6se TherapieEinen vielversprechenden und interessanten Therapieansatz boten sehr bald auch antiinflammatorische Interventionsversuche.", [["Jedoch erwiesen sich beide Substanzen sehr bald als unwirksam und teilweise sogar unvorteilhaft aufgrund des Nebenwirkungsprofils und werden auch seitens der Weltgesundheitsorganisation (WHO) negativ bewertet", "SPECIES", 0, 208], ["Medikament\u00f6se TherapieEinen vielversprechenden", "TREATMENT", 214, 260]]], ["Interleukin 6 zu sein [45].", [["Interleukin 6", "GENE_OR_GENE_PRODUCT", 0, 13], ["Interleukin 6", "PROTEIN", 0, 13]]], ["Leider sind aber die bisherigen Studienergebnisse zur Wirksamkeit von IL-6-Antik\u00f6rpern sehr ern\u00fcchternd und zeigen keine Vorteile gegen\u00fcber Placebo (Pressemitteilung des Herstellers Ende Juli 2020, Daten bisher nicht publiziert).Medikament\u00f6se TherapieLediglich Kortikosteroide scheinen in der Phase der Hyperinflammation, also i. d.", [["Leider sind aber die bisherigen Studienergebnisse zur Wirksamkeit von IL-6-Antik\u00f6rpern sehr ern\u00fcchternd und zeigen keine Vorteile gegen\u00fcber Placebo (Pressemitteilung des Herstellers Ende Juli 2020, Daten bisher nicht publiziert", "SPECIES", 0, 227], ["Antik\u00f6rpern sehr ern\u00fcchternd", "TREATMENT", 75, 103], ["Placebo (Pressemitteilung des", "TREATMENT", 140, 169], ["Medikament\u00f6se TherapieLediglich Kortikosteroide scheinen", "TREATMENT", 229, 285]]], ["Krankheitswoche einen nachweisbaren Nutzen zu zeigen.", [["Krankheitswoche einen nachweisbaren Nutzen zu zeigen", "SPECIES", 0, 52]]], ["Insbesondere scheint Dexamethason protektiv zu sein bez\u00fcglich der Ausbildung einer kryptogen-organisierenden Pneumonie oder einer Lungenfibrose [46, 47].Medikament\u00f6se TherapieUnter den direkt antiviral wirkenden Medikamenten kann derzeit einzig Remdesivir eine in gro\u00dfen multizentrischen Studien nachgewiesene Verk\u00fcrzung der Krankheitsdauer bewirken.", [["Insbesondere scheint Dexamethason protektiv zu sein bez\u00fcglich der Ausbildung einer kryptogen-organisierenden Pneumonie oder einer Lungenfibrose", "SPECIES", 0, 143], ["Medikament\u00f6se TherapieUnter", "TREATMENT", 153, 180], ["antiviral wirkenden", "TREATMENT", 192, 211], ["kann derzeit einzig Remdesivir eine", "TREATMENT", 225, 260]]], ["Voraussetzung f\u00fcr einen Benefit bei Einsatz von Remdesivir ist allerdings, dass es m\u00f6glichst fr\u00fch im Krankheitsverlauf gegeben wird.", [["Voraussetzung f\u00fcr einen Benefit bei Einsatz von Remdesivir ist allerdings, dass es m\u00f6glichst fr\u00fch im Krankheitsverlauf gegeben wird", "SPECIES", 0, 131], ["Voraussetzung", "TREATMENT", 0, 13]]], ["Bei bereits schwer erkrankten COVID-19-Patienten mit z.", [["Bei bereits schwer erkrankten COVID-19-Patienten mit z.", "SPECIES", 0, 55], ["COVID", "TEST", 30, 35]]], ["B. invasiver Beatmung und fortgeschrittenem Organversagen vor Remdesivir-Gabe zeigt sich dagegen keine positive Wirkung [48\u201351].Fazit f\u00fcr die PraxisNotfallmedizinische Aufgaben in der Corona-Pandemie sind:Fr\u00fchzeitige Detektion von SARS-CoV\u20112 infizierten PatientenEntscheidung \u00fcber die Notwendigkeit der station\u00e4ren WeiterbehandlungTrennung von SARS-CoV-2-Infektions- und Verdachtsf\u00e4llen von nichtinfizierten PatientenBeurteilung des Schweregrads der SARS-CoV-2-Infektion anhand klinischer, sonographischer und radiologischer KriterienFeststellung und Einleitung der Behandlung relevanter Komorbidit\u00e4tenEinleitung einer atemunterst\u00fctzenden TherapieFazit f\u00fcr die PraxisIntensivmedizinische Aufgaben in der Corona-Pandemie sind:Durchf\u00fchrung der Therapie bei SARS-CoV-2-induziertem Organversagen, insbesondere des Lungenversagens mittels differenzierten Atemunterst\u00fctzungsverfahrenBehandlung lebensbedrohlicher Komorbidit\u00e4tenBehandlung von spezifischen SARS-CoV-2-induzierten KomplikationenMedikament\u00f6se Therapie schwerster SARS-CoV-2-Infektionen", [["B. invasiver Beatmung und fortgeschrittenem Organversagen vor Remdesivir-Gabe zeigt sich dagegen keine", "SPECIES", 0, 102], ["Fazit f\u00fcr die PraxisNotfallmedizinische Aufgaben in der Corona-Pandemie sind:Fr\u00fchzeitige Detektion von SARS-CoV\u20112 infizierten PatientenEntscheidung \u00fcber die Notwendigkeit der station\u00e4ren WeiterbehandlungTrennung von SARS-CoV-2-Infektions- und Verdachtsf\u00e4llen von nichtinfizierten PatientenBeurteilung des Schweregrads der SARS-CoV-2-Infektion anhand klinischer, sonographischer und radiologischer KriterienFeststellung und Einleitung der Behandlung relevanter Komorbidit\u00e4tenEinleitung einer atemunterst\u00fctzenden TherapieFazit f\u00fcr die PraxisIntensivmedizinische Aufgaben in der Corona-Pandemie sind:Durchf\u00fchrung der Therapie bei SARS-CoV-2-induziertem Organversagen, insbesondere des Lungenversagens mittels differenzierten Atemunterst\u00fctzungsverfahrenBehandlung lebensbedrohlicher Komorbidit\u00e4tenBehandlung von spezifischen SARS-CoV-2-induzierten KomplikationenMedikament\u00f6se Therapie schwerster SARS-CoV-2-Infektionen", "SPECIES", 128, 1042], ["B. invasiver Beatmung", "TEST", 0, 21], ["fortgeschrittenem", "TEST", 26, 43], ["Organversagen", "TEST", 44, 57], ["Remdesivir", "TEST", 62, 72], ["von SARS", "TEST", 340, 348], ["CoV", "TEST", 349, 352], ["Infektions", "TEST", 355, 365], ["der SARS", "TEST", 446, 454], ["CoV", "TEST", 455, 458], ["Komorbidit\u00e4ten", "TREATMENT", 588, 602], ["Einleitung einer atemunterst\u00fctzenden TherapieFazit", "TREATMENT", 602, 652], ["CoV", "TEST", 760, 763], ["induziertem", "TREATMENT", 766, 777], ["Organversagen", "TEST", 778, 791], ["Lungenversagens", "TEST", 810, 825], ["mittels", "TEST", 826, 833], ["differenzierten", "TEST", 834, 849], ["Atemunterst", "TEST", 850, 861], ["tzungsverfahren", "TEST", 862, 877], ["Behandlung", "TEST", 877, 887], ["lebensbedrohlicher", "TEST", 888, 906], ["Komorbidit\u00e4ten", "TEST", 907, 921], ["Behandlung", "TEST", 921, 931], ["SARS", "TEST", 949, 953], ["CoV", "TEST", 954, 957], ["induzierten", "TREATMENT", 960, 971], ["Infektionen", "TREATMENT", 1031, 1042]]]], "PMC7537000": [["So far, we do not have any published database regarding HCT patients during the present pandemic.", [["HCT", "CANCER", 56, 59], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["HCT", "TEST", 56, 59]]], ["We herein describe the first case of COVID\u201019 presenting in the early hematopoietic cell transplantation (HCT) setting.", [["hematopoietic cell", "ANATOMY", 70, 88], ["HCT", "ANATOMY", 106, 109], ["hematopoietic cell", "CELL", 70, 88], ["the early hematopoietic cell transplantation", "TREATMENT", 60, 104], ["hematopoietic cell transplantation", "OBSERVATION", 70, 104]]]], "eb16c47f68d3008696b450ae3cfc6d1f56e3db56": [["INTRODUCTIONA growing global human population and expanding economic activities are exerting unsustainable demands on natural resource extraction and the conversion of forested land for industrial agriculture, cattle production, and the expansion of urban centers (Rockstr\u00f6m et al., 2009; Crist, Mora & Engelman, 2017; Crist, 2018; https://populationmatters.org/the-issue).", [["human", "ORGANISM", 29, 34], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["cattle", "SPECIES", 210, 216], ["growing global human population", "PROBLEM", 14, 45], ["expanding economic activities", "PROBLEM", 50, 79], ["natural resource extraction", "TREATMENT", 118, 145], ["forested land", "TREATMENT", 168, 181], ["growing", "OBSERVATION_MODIFIER", 14, 21], ["global", "OBSERVATION_MODIFIER", 22, 28], ["human population", "OBSERVATION", 29, 45]]], ["These pressures are negatively impacting critical global commons needed to sustain life on Earth through air, water, and soil pollution, carbon emissions, deforestation and the critical loss of biodiversity (Rockstr\u00f6m et al., 2009; Otero et al., 2020; UNGEF, 2020) .", [["carbon", "CHEMICAL", 137, 143], ["These pressures", "TEST", 0, 15], ["carbon emissions", "TREATMENT", 137, 153], ["deforestation", "TREATMENT", 155, 168], ["pressures", "OBSERVATION_MODIFIER", 6, 15]]], ["For example, the atmosphere is being degraded by increased greenhouse gas emissions, ocean acidification is increasing, and tropical forests are being cut at a rate of ca 10 million ha per year (Rockstr\u00f6m et al., 2009; Steffen et al., 2015; GFW, 2019) .", [["increased greenhouse gas emissions", "PROBLEM", 49, 83], ["ocean acidification", "PROBLEM", 85, 104], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["greenhouse", "OBSERVATION", 59, 69], ["gas emissions", "OBSERVATION", 70, 83], ["ocean", "OBSERVATION_MODIFIER", 85, 90], ["acidification", "OBSERVATION_MODIFIER", 91, 104], ["increasing", "OBSERVATION_MODIFIER", 108, 118]]], ["Regrettably, recent estimates indicate that some one million animal and plant species are threatened with extinction as a result of human activities (IPBES, 2019) .", [["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["plant species", "OBSERVATION", 72, 85]]], ["This includes many of the world's non-human primates, our closest living biological relatives.", [["non-human", "ORGANISM", 34, 43], ["primates", "ORGANISM", 44, 52]]], ["Primates represent the third most speciose mammalian radiation (ca 512 species; Estrada et al., 2017) after bats and rodents.", [["radiation", "OBSERVATION", 53, 62]]], ["They (prosimians, tarsiers, monkeys and apes) are distributed across 91 countries, principally in the Neotropics, mainland Africa, Madagascar, South Asia and Southeast Asia, and are a critical part of our planet's biodiversity ( Fig. 1; Table S1 ).", [["prosimians", "ANATOMY", 6, 16], ["tarsiers", "ANATOMY", 18, 26], ["monkeys", "ORGANISM", 28, 35], ["monkeys", "SPECIES", 28, 35], ["S1", "ANATOMY", 243, 245]]], ["Primates are essential models for understanding human evolution, behavior and health (Phillips et al., 2014) .", [["human", "ORGANISM", 48, 53], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53]]], ["The activities of lemur, lorises, tarsiers, monkeys and apes sustain a range of community-wide ecological functions and services (e.g., seed dispersal, pollination, predator-prey relationships) in tropical and temperate forests, that also benefit local human communities (Estrada et al., 2017) .", [["lemur", "ORGANISM_SUBDIVISION", 18, 23], ["monkeys", "ORGANISM", 44, 51], ["human", "ORGANISM", 253, 258], ["monkeys", "SPECIES", 44, 51], ["human", "SPECIES", 253, 258], ["human", "SPECIES", 253, 258]]], ["Alarmingly, 65% of primate species are threatened with extinction and 75% have declining populations as a result of relentless human pressures on natural environments leading to widespread loss and degradation of tropical forests (Estrada et al., 2017; IUCN Red List, 2019) (Table S1) .INTRODUCTIONA major driver of primate population decline is land use changes driven by global market demands.", [["primate", "ORGANISM", 19, 26], ["human", "ORGANISM", 127, 132], ["primate", "ORGANISM", 316, 323], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["Alarmingly", "TEST", 0, 10], ["declining populations", "PROBLEM", 79, 100], ["relentless human pressures", "PROBLEM", 116, 142], ["widespread loss", "PROBLEM", 178, 193], ["tropical forests", "TREATMENT", 213, 229], ["widespread", "OBSERVATION_MODIFIER", 178, 188], ["loss", "OBSERVATION", 189, 193]]], ["This has resulted in the widespread loss of primate habitats in order to expand agricultural and cattle production, and the extraction of natural resources (e.g., minerals, oil, wood) to feed and sustain a growing global human population (now ca 8 billion set to approach ca 10 billion by 2050; https://www.un.org/en/sections/ issues-depth/population/) and a rapidly expanding global middle-class diet that emphasizes greater meat consumption (UNGEF, 2019) .", [["oil", "ANATOMY", 173, 176], ["wood", "ANATOMY", 178, 182], ["meat", "ANATOMY", 426, 430], ["oil", "ORGANISM_SUBSTANCE", 173, 176], ["wood", "ORGANISM_SUBDIVISION", 178, 182], ["human", "ORGANISM", 221, 226], ["meat", "ORGANISM_SUBDIVISION", 426, 430], ["human", "SPECIES", 221, 226], ["cattle", "SPECIES", 97, 103], ["human", "SPECIES", 221, 226], ["the widespread loss of primate habitats", "PROBLEM", 21, 60], ["natural resources", "TREATMENT", 138, 155], ["a growing global human population", "PROBLEM", 204, 237], ["widespread", "OBSERVATION_MODIFIER", 25, 35], ["loss", "OBSERVATION", 36, 40], ["middle", "ANATOMY_MODIFIER", 384, 390]]], ["Hunting for bushmeat, the illegal primate trade, infectious disease transmission among humans-domesticated animals-wild animals, and the spread of invasive species constitute important additional pressures that negatively impact primate populations (IUCN Red List, 2019; Estrada et al., 2017; Lappin et al., 2020) .INTRODUCTIONRecent evidence suggests that the human population has expanded beyond the Earth's sustainable means and that we are using resources faster than our planet can regenerate, with devastating consequences (Steffen et al., 2015) .", [["bushmeat", "DISEASE", 12, 20], ["infectious disease", "DISEASE", 49, 67], ["humans", "ORGANISM", 87, 93], ["primate", "ORGANISM", 229, 236], ["human", "ORGANISM", 361, 366], ["humans", "SPECIES", 87, 93], ["human", "SPECIES", 361, 366], ["humans", "SPECIES", 87, 93], ["human", "SPECIES", 361, 366], ["invasive species", "PROBLEM", 147, 163], ["the human population", "PROBLEM", 357, 377], ["infectious", "OBSERVATION", 49, 59]]], ["It took humanity ca 200,000 years to go from an estimated population size of a few hundred thousand to a population size of one billion, and just 200 years to go from one billion to a population size of almost eight billion (Population Matters, 2019) .", [["size", "OBSERVATION_MODIFIER", 69, 73], ["size", "OBSERVATION_MODIFIER", 116, 120], ["population", "OBSERVATION_MODIFIER", 184, 194], ["size", "OBSERVATION_MODIFIER", 195, 199], ["almost", "OBSERVATION_MODIFIER", 203, 209], ["eight", "OBSERVATION_MODIFIER", 210, 215], ["billion", "OBSERVATION", 216, 223]]], ["At present we are adding close to 80 million people each year, as the world moves towards a human population that may exceed 11 billion by 2100 (UNDESA, 2019a).INTRODUCTIONWhile a growing global human population and activities associated with land conversion have historically been the major factors contributing to global biodiversity loss via deforestation, habitat degradation and resource extraction activities (IPBES, 2019) , it is clear that initiatives solely designed to limit human population growth as a means to solve immediate environmental problems are largely unrealistic (Bradshaw & Brook, 2014) .", [["people", "ORGANISM", 45, 51], ["human", "ORGANISM", 92, 97], ["human", "ORGANISM", 195, 200], ["human", "ORGANISM", 485, 490], ["people", "SPECIES", 45, 51], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 485, 490], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 485, 490], ["a growing global human population", "PROBLEM", 178, 211], ["land conversion", "TREATMENT", 243, 258], ["global biodiversity loss via deforestation", "PROBLEM", 316, 358], ["habitat degradation", "PROBLEM", 360, 379], ["resource extraction", "TREATMENT", 384, 403], ["biodiversity loss", "OBSERVATION", 323, 340]]], ["For example, Brazil, a country suffering significant deforestation in past decades has one of the lowest population growth rates among the countries that harbor primates.", [["primates", "ORGANISM", 161, 169], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["deforestation", "OBSERVATION", 53, 66]]], ["Also, extensive deforestation in Brazil has occurred in both highly populated areas (i.e., the Atlantic Forest, the Cerrado), as well as in areas of extremely low population density Figure 1 Geographic distribution of primate species richness.", [["primate", "ORGANISM", 218, 225], ["extensive deforestation in Brazil", "PROBLEM", 6, 39], ["extremely low population density", "PROBLEM", 149, 181], ["primate species richness", "PROBLEM", 218, 242], ["extensive", "OBSERVATION_MODIFIER", 6, 15], ["deforestation", "OBSERVATION", 16, 29], ["Brazil", "OBSERVATION_MODIFIER", 33, 39], ["both", "OBSERVATION_MODIFIER", 56, 60], ["highly", "OBSERVATION_MODIFIER", 61, 67], ["populated", "OBSERVATION", 68, 77], ["extremely", "OBSERVATION_MODIFIER", 149, 158], ["low population", "OBSERVATION_MODIFIER", 159, 173], ["density", "OBSERVATION", 174, 181], ["Geographic", "OBSERVATION_MODIFIER", 191, 201], ["distribution", "OBSERVATION_MODIFIER", 202, 214], ["species richness", "OBSERVATION", 226, 242]]], ["Species richness in the main regions where primates are naturally found: the Neotropics, mainland Africa (includes small associated islands), Madagascar, South Asia, and Southeast Asia.", [["primates", "ORGANISM", 43, 51], ["small associated islands)", "PROBLEM", 115, 140], ["richness", "OBSERVATION", 8, 16], ["main", "ANATOMY_MODIFIER", 24, 28], ["regions", "ANATOMY_MODIFIER", 29, 36], ["small", "OBSERVATION_MODIFIER", 115, 120]]], ["The country colors indicate the number of primate species in each country.", [["primate", "ORGANISM", 42, 49]]], ["Number by each region indicates the regional number of primate species.", [["primate", "ORGANISM", 55, 62], ["primate species", "PROBLEM", 55, 70], ["regional", "OBSERVATION_MODIFIER", 36, 44], ["number", "OBSERVATION_MODIFIER", 45, 51], ["primate species", "OBSERVATION", 55, 70]]], ["Madagascar stands out with its rich and endemic lemur fauna.", [["lemur", "ORGANISM", 48, 53], ["endemic", "OBSERVATION_MODIFIER", 40, 47], ["lemur fauna", "OBSERVATION", 48, 59]]], ["Black dots in open spaces between continents are small islands.", [["Black dots in open spaces", "PROBLEM", 0, 25], ["small islands", "PROBLEM", 49, 62], ["dots", "OBSERVATION_MODIFIER", 6, 10], ["open spaces", "OBSERVATION", 14, 25], ["continents", "OBSERVATION_MODIFIER", 34, 44], ["small", "OBSERVATION_MODIFIER", 49, 54], ["islands", "OBSERVATION", 55, 62]]], ["Raw data in Table S1 .INTRODUCTIONFull-size \ue90d DOI: 10.7717/peerj.9816/ fig-1 such as the Amazon.", [["DOI", "CHEMICAL", 46, 49], ["DOI", "CHEMICAL", 46, 49], ["S1", "ANATOMY", 18, 20], ["size", "OBSERVATION_MODIFIER", 39, 43]]], ["The reasons for deforestation and consequent biodiversity impacts in Brazil and other countries represent a combination of historical, economic, political and social factors.", [["deforestation", "PROBLEM", 16, 29], ["biodiversity", "OBSERVATION_MODIFIER", 45, 57]]], ["Here we use the I = PAT framework, which examines the environmental impact (I) as a function of population (P), affluence (A) and technology (T) (see for example, Dietz & Rosa, 1997) .INTRODUCTIONTo further our understanding of the interdependent relationship between human well-being and primate population persistence, we examine current and future trends in several socio-economic, ecological and demographic indicators in countries within primate range regions.", [["human", "ORGANISM", 268, 273], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273]]], ["These are: tropical forest loss, human population, GDP per capita, human development index (HDI), extreme poverty, food security, corruption, governance quality and civil unrest/conflict status.", [["forest loss", "DISEASE", 20, 31], ["GDP", "CHEMICAL", 51, 54], ["human", "ORGANISM", 33, 38], ["GDP", "SIMPLE_CHEMICAL", 51, 54], ["human", "ORGANISM", 67, 72], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 67, 72], ["tropical forest loss", "PROBLEM", 11, 31], ["tropical", "OBSERVATION_MODIFIER", 11, 19], ["forest loss", "OBSERVATION", 20, 31]]], ["We acknowledge that our review of these indicators is by no means complete and primate conservation requires global action to limit both the long-term environmental and economic footprint of the world's human population, and the overconsumption of natural resources from the tropics by citizens in a small number of developed nations (Estrada, Garber & Chaudhary, 2019) .", [["human", "ORGANISM", 203, 208], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208], ["small", "OBSERVATION_MODIFIER", 300, 305]]], ["Finally, by focusing on the level of primate regions rather than individual countries, our manuscript emphasizes broad patterns rather than country-specific historical, demographic, cultural, and religious factors that affect primate survivorship.", [["primate", "ORGANISM", 226, 233]]], ["It is in light of these considerations that we present our evaluation.SURVEY METHODOLOGYThe information we present is based on a review of the literature and analysis of information from several open access databases.", [["our evaluation", "TEST", 55, 69]]], ["Our analysis of these databases included information on each of the 91 countries that harbor wild primate populations.", [["primate", "ORGANISM", 98, 105], ["Our analysis", "TEST", 0, 12], ["these databases", "TEST", 16, 31]]], ["For purposes of this evaluation we consider the following regions as discrete entities due to their unique primate fauna: the Neotropics (Mexico, Central and South American tropics), mainland Africa (including small islands off its Atlantic coast), Madagascar, South Asia and Southeast Asia.", [["this evaluation", "TEST", 16, 31]]], ["Because Madagascar harbors a nonoverlapping set of the world's nonhuman primate species (i.e., some 100 endemic lemur species), the result of over 100 million years of isolation from the African continent, it merits separate evaluation.", [["nonhuman", "ORGANISM", 63, 71], ["primate", "ORGANISM", 72, 79], ["lemur", "ORGANISM", 112, 117], ["some 100 endemic lemur species", "PROBLEM", 95, 125], ["isolation", "TREATMENT", 168, 177], ["separate evaluation", "TEST", 216, 235]]], ["Information on the conservation status of living primates is from Estrada et al., 2017 and from the International Union for the Conservation of Nature https://www.iucnredlist.org/ (IUCN Red List, 2019).SURVEY METHODOLOGYWe report human population growth from 1960 to 2018 in each primate range country (n = 91) based on information from the World Bank (https://data.worldbank.org/ indicator/SP.POP.TOTL) and from the UN Population Division (https://population.un. org/wpp/Download/Standard/Population).", [["primates", "ORGANISM", 49, 57], ["human", "ORGANISM", 230, 235], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 230, 235], ["org", "TEST", 464, 467]]], ["Human population growth projections for 2050 and 2100 were obtained from the UN Population Division (https://ourworldindata. org/grapher/un-population-projection-medium-variant).", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["https://ourworldindata", "SPECIES", 101, 123], ["org", "TEST", 125, 128]]], ["Additional information on population growth trends was obtained from the UN e-Handbook of Statistics (https://stats.unctad.org/handbook/Population/Total.html).SURVEY METHODOLOGYWe describe the extent of tropical forest loss in primate range countries from 2001 to 2018 using data from the open access Global Forest Watch database (http://www.globalforestwatch.org/).", [["forest loss", "DISEASE", 212, 223], ["tropical forest loss", "PROBLEM", 203, 223], ["tropical", "OBSERVATION_MODIFIER", 203, 211], ["forest loss", "OBSERVATION", 212, 223]]], ["These estimates are based on remote sensing procedures.SURVEY METHODOLOGYWe use the Gross Domestic Product Per Capita (GDPPC) for the period from 1960 to 2018 as an indicator of economic progress in each primate range country.", [["remote sensing procedures", "TREATMENT", 29, 54]]], ["We are aware of the limitations of using the GDPPC as a measure of economic development.", [["the GDPPC", "TREATMENT", 41, 50]]], ["This indicator is an average, and consequently overlooks the distribution of incomes across each country.", [["average", "OBSERVATION_MODIFIER", 21, 28], ["distribution", "OBSERVATION_MODIFIER", 61, 73]]], ["In this regard, the GDPPC of a country may be high or above that of another country, however, most of that wealth could be concentrated in a relatively small number of individuals or families, with the overwhelming majority of citizens extremely poor.", [["high", "OBSERVATION", 46, 50], ["small", "OBSERVATION_MODIFIER", 152, 157]]], ["Examples of high levels of income inequality in primate range nations include China, Brazil and DRC (Estrada et al., 2018) .SURVEY METHODOLOGYWe used information from the International Institute for Applied Systems Analysis (IIASA) SSPd database (https://tntcat.iiasa.ac.at/SspDb/dsd?Action=htmlpage&page=about) (Table S11) to model future projections of GDPPC for all primate hosting countries under different Shared Socioeconomic Pathways scenarios (SSPs).SURVEY METHODOLOGYData used to examine human development in primate range countries (1990-2018) were from the UN HDI, which represents a combined measure of life expectancy, school enrollment, literacy, and income.", [["human", "ORGANISM", 497, 502], ["human", "SPECIES", 497, 502], ["human", "SPECIES", 497, 502], ["SSPd database (https://tntcat.iiasa.ac.at/SspDb/dsd?Action=htmlpage&page=about) (Table S11)", "TREATMENT", 232, 323], ["high levels", "OBSERVATION_MODIFIER", 12, 23]]], ["HDI ranges from 0 (lowest) to 1 (highest) (http://worldpopulationreview.com/countries/hdi-by-country/).SURVEY METHODOLOGYWe used the 2015 World Bank percent of the population living on 30% canopy cover) were lost between 2001 and 2018 as a result of human activities in the five primate range regions (Figs.", [["human", "ORGANISM", 250, 255], ["human", "SPECIES", 250, 255], ["human", "SPECIES", 250, 255], ["HDI ranges", "TEST", 0, 10]]], ["This represents an area equivalent to ca 43% of the EU land mass.", [["ca", "TEST", 38, 40], ["area", "OBSERVATION_MODIFIER", 19, 23], ["land", "OBSERVATION_MODIFIER", 55, 59], ["mass", "OBSERVATION", 60, 64]]], ["Forty six percent of this loss was in the Neotropics followed by Southeast Asia (30%), mainland Africa (21%), Madagascar (2%) and South Asia (1%).", [["this loss", "PROBLEM", 21, 30], ["Madagascar", "TEST", 110, 120], ["loss", "OBSERVATION", 26, 30]]], ["Madagascar is home to more than 100 species of lemurs (second richest primate country after Brazil), and over 93% of lemur species are threatened with extinction.", [["lemurs", "ORGANISM_SUBDIVISION", 47, 53], ["lemur", "ORGANISM", 117, 122], ["lemur species", "OBSERVATION", 117, 130], ["extinction", "OBSERVATION_MODIFIER", 151, 161]]], ["Current estimates indicate that Madagascar has lost some 90% of its original forest (Estrada et al., 2018) .Tropical forest lossCountries with the highest losses of tree cover between 2001 and 2018 were Brazil (53.8 Mha), Indonesia (25.6 Mha), DRC (13.4 Mha), China (9.4 Mha) and Malaysia (7.7 Mha).", [["Tropical forest lossCountries", "PROBLEM", 108, 137], ["Indonesia", "TEST", 222, 231], ["DRC", "TEST", 244, 247], ["forest loss", "OBSERVATION", 117, 128]]], ["These five countries totaled 109.9 Mha or ca 57% of total tree cover loss (191 Mha) in primate range regions (Fig. S1 ).", [["Mha", "TEST", 35, 38], ["ca", "TEST", 42, 44], ["total tree cover loss", "PROBLEM", 52, 73], ["tree", "OBSERVATION_MODIFIER", 58, 62], ["S1", "ANATOMY", 115, 117]]], ["Together these countries harbor about 50% of extant primate species.", [["primate", "ORGANISM", 52, 59]]], ["A region by region examination indicates that between 2001 and 2018, the Neotropics lost 88.6 Mha of forest ( Fig. S1A) , with Brazil, the primate richest country in the world (120 species) accounting for 60% (53.8Mha).", [["region examination", "TEST", 12, 30], ["Brazil", "TREATMENT", 127, 133]]], ["During the same period, Indonesia, the third primate richest country accounted for 44% of southeast Asian forest loss (Fig. S1B ).", [["Indonesia", "PROBLEM", 24, 33], ["southeast Asian forest loss", "PROBLEM", 90, 117]]], ["An estimated 83% of Indonesian primate species are threatened with extinction.", [["primate", "ORGANISM", 31, 38], ["Indonesian primate species", "PROBLEM", 20, 46], ["83%", "OBSERVATION_MODIFIER", 13, 16], ["extinction", "OBSERVATION_MODIFIER", 67, 77]]], ["Countries such as China, Malaysia, Myanmar, Lao, Vietnam, Cambodia and Thailand, accounted for an additional 52% of forest loss.", [["forest loss", "DISEASE", 116, 127], ["forest loss", "PROBLEM", 116, 127], ["forest loss", "OBSERVATION", 116, 127]]], ["Each of these countries has a high proportion of primate species listed as Vulnerable, Endangered or Critically Endangered (Table S1 ).", [["primate", "ORGANISM", 49, 56]]], ["We note that in other countries, for example, Madagascar, so much native forest has already been cut, that even small amounts of new forest loss will have a dramatic impact on primate survivorship.", [["forest loss", "DISEASE", 133, 144], ["primate", "ORGANISM", 176, 183], ["new forest loss", "PROBLEM", 129, 144], ["small", "OBSERVATION_MODIFIER", 112, 117], ["amounts", "OBSERVATION_MODIFIER", 118, 125], ["new", "OBSERVATION_MODIFIER", 129, 132], ["forest loss", "OBSERVATION", 133, 144]]], ["The primary drivers of continued forest loss in the five primate range regions include subsistence and industrial agriculture, commodity-driven deforestation, and the expansion of urban areas (Estrada et al., 2017 (Estrada et al., , 2018 Chaudhary & Kastner, 2016; Chaudhary & Brooks, 2019; Estrada, Garber & Chaudhary, 2019) .", [["forest loss", "DISEASE", 33, 44], ["continued forest loss", "PROBLEM", 23, 44], ["forest loss", "OBSERVATION", 33, 44], ["expansion", "OBSERVATION_MODIFIER", 167, 176]]], ["This is unfolding in the context of expanding global economic activities driven principally by the exploitative practices of a small set of multinational corporations and the over-consumption of citizens in a small number of consumer nations who are disproportionately contributing to climate change, pollution, food insecurity, habitat destruction, and income inequality worldwide (Estrada, Garber & Chaudhary, 2019; Chaudhary & Kastner, 2016; Chaudhary & Brooks, 2018 .Human population growth in primate range regionsThe world\u00b4s human population has grown exponentially over the past several decades and a significant segment of this growth has occurred in primate regions (Fig. 4) .", [["food insecurity", "DISEASE", 312, 327], ["habitat destruction", "DISEASE", 329, 348], ["Human", "ORGANISM", 471, 476], ["human", "ORGANISM", 531, 536], ["primate", "ORGANISM", 659, 666], ["Human", "SPECIES", 471, 476], ["human", "SPECIES", 531, 536], ["Human", "SPECIES", 471, 476], ["human", "SPECIES", 531, 536], ["expanding global economic activities", "PROBLEM", 36, 72], ["habitat destruction", "PROBLEM", 329, 348], ["Human population growth in primate range regions", "TREATMENT", 471, 519], ["this growth", "PROBLEM", 631, 642], ["unfolding", "OBSERVATION_MODIFIER", 8, 17], ["expanding", "OBSERVATION_MODIFIER", 36, 45], ["global", "OBSERVATION_MODIFIER", 46, 52], ["economic activities", "OBSERVATION", 53, 72], ["small", "OBSERVATION_MODIFIER", 127, 132], ["small", "OBSERVATION_MODIFIER", 209, 214], ["habitat destruction", "OBSERVATION", 329, 348], ["growth", "OBSERVATION_MODIFIER", 488, 494], ["grown", "OBSERVATION_MODIFIER", 552, 557], ["exponentially", "OBSERVATION_MODIFIER", 558, 571], ["significant", "OBSERVATION_MODIFIER", 608, 619], ["segment", "OBSERVATION_MODIFIER", 620, 627], ["growth", "OBSERVATION", 636, 642]]], ["In 1960 Table S3 for country data.Human population growth in primate range regionsFull-size \ue90d DOI: 10.7717/peerj.9816/ fig-4 there were 1.4 bn people in primate habitat countries and this number reached 5.6 bn by 2018.", [["DOI", "CHEMICAL", 94, 97], ["DOI", "CHEMICAL", 94, 97], ["Human", "ORGANISM", 34, 39], ["people", "ORGANISM", 143, 149], ["Human", "SPECIES", 34, 39], ["people", "SPECIES", 143, 149], ["Human", "SPECIES", 34, 39], ["Human population growth in primate range regions", "TREATMENT", 34, 82], ["peerj", "TEST", 107, 112], ["fig", "TEST", 119, 122], ["growth", "OBSERVATION_MODIFIER", 51, 57], ["size", "OBSERVATION_MODIFIER", 87, 91]]], ["Currently human populations in primate range regions account for 74% of the world's population.", [["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15]]], ["United Nations' population division estimates predict that fully 80% of the world's population by 2050 (total human population estimated at 9.8 bn) and 83% by 2100 (total human population estimated at 11.2 bn) will reside in primate habitat countries (Fig. 4 ).", [["human", "ORGANISM", 110, 115], ["human", "ORGANISM", 171, 176], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 171, 176], ["total human population", "TEST", 104, 126], ["total human population", "TEST", 165, 187]]], ["Significant human population growth is expected in all primate regions up to 2050, after which Africa will surpass the other four regions with accelerated human population growth continuing to the year 2100 ( Fig. 4) .", [["human", "ORGANISM", 12, 17], ["human", "ORGANISM", 155, 160], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 155, 160], ["Significant human population growth", "PROBLEM", 0, 35], ["accelerated human population growth", "PROBLEM", 143, 178], ["population", "OBSERVATION_MODIFIER", 18, 28], ["growth", "OBSERVATION_MODIFIER", 29, 35]]], ["Populations in South Asia and Southeast Asia are expected to exhibit reduced growth after 2050.", [["reduced growth", "PROBLEM", 69, 83], ["reduced", "OBSERVATION_MODIFIER", 69, 76], ["growth", "OBSERVATION_MODIFIER", 77, 83]]], ["Populations in the Neotropics and Madagascar will grow exponentially, but in the Neotropics growth is expected to decrease slightly after 2050 (Fig. 4) .Human population growth in primate range regionsDemographic models indicate that primate range countries, and especially those with developing economies, are driving the world's population growth.", [["Human", "ORGANISM", 153, 158], ["Human", "SPECIES", 153, 158], ["Human", "SPECIES", 153, 158], ["Human population growth", "PROBLEM", 153, 176], ["growth", "OBSERVATION_MODIFIER", 170, 176]]], ["The population of Africa is increasing at a particularly rapid rate.", [["Africa", "PROBLEM", 18, 24], ["population", "OBSERVATION_MODIFIER", 4, 14], ["Africa", "OBSERVATION_MODIFIER", 18, 24], ["increasing", "OBSERVATION_MODIFIER", 28, 38]]], ["In 2018, the population growth rate in Africa averaged 2.5%, which was more than double the world average (1.08%) (UNDESA, 2019a; UNCTAD, 2019).", [["the population growth rate", "TEST", 9, 35]]], ["Several central and east-central African countries, such as Niger, Uganda, Equatorial Guinea, Angola and the Democratic Republic of the Congo recorded growth rates well above 3 per cent.", [["central", "OBSERVATION_MODIFIER", 8, 15], ["central African", "OBSERVATION", 25, 40]]], ["Several of these countries are among the most primate species-rich in Africa.", [["most primate", "OBSERVATION_MODIFIER", 41, 53]]], ["Rates slightly above the world average were found in South and Southeast Asia (1.2%), with the Neotropics (1.0%) below the world average (World Bank, 2019).Population in rural and urban areasSignificantly, population growth in primate range regions is expected to occur in urban areas with populations in rural areas declining dramatically (Fig. 5) .", [["Rates", "TEST", 0, 5], ["the Neotropics", "TREATMENT", 91, 105], ["population growth", "PROBLEM", 206, 223], ["rural", "OBSERVATION_MODIFIER", 170, 175], ["growth", "OBSERVATION_MODIFIER", 217, 223], ["populations", "OBSERVATION_MODIFIER", 290, 301], ["rural", "ANATOMY_MODIFIER", 305, 310]]], ["A sizeable segment of the population in the Neotropics (88%) and Southeast Asia (66%) will reside in urban areas by 2050.", [["the Neotropics", "TREATMENT", 40, 54], ["sizeable", "OBSERVATION_MODIFIER", 2, 10], ["segment", "OBSERVATION_MODIFIER", 11, 18], ["population", "OBSERVATION_MODIFIER", 26, 36], ["Neotropics", "OBSERVATION_MODIFIER", 44, 54]]], ["The values for mainland Africa are 59%, for Madagascar 53%, and for South Asia also 53% (Fig. 5 ).", [["The values", "TEST", 0, 10], ["mainland Africa", "TEST", 15, 30], ["Madagascar", "TEST", 44, 54], ["South Asia", "TEST", 68, 78]]], ["While more than half of the increase in the urban population in primate harboring countries is caused by in situ population increase, migration from rural areas into cities also is a contributing factor (Hecht et al., 2015) .", [["increase", "OBSERVATION_MODIFIER", 28, 36], ["situ", "OBSERVATION_MODIFIER", 108, 112], ["population", "OBSERVATION_MODIFIER", 113, 123], ["increase", "OBSERVATION_MODIFIER", 124, 132], ["migration", "OBSERVATION_MODIFIER", 134, 143]]], ["While cities cover <2% of the earth's surface, they use about 78% of the energy produced, including large quantities of nonfood and food products, much of which is wasted, adding to environmental pressures locally and globally (Ulgiati & Zacaro, 2019) .", [["environmental pressures locally", "TREATMENT", 182, 213]]], ["Urbanization produces land-cover changes (Grimm et al., 2008 ) that drive habitat loss, air and water pollution, and the extinction of local animal and plant populations (Hahs et al., 2009) .", [["habitat loss", "DISEASE", 74, 86], ["habitat loss", "PROBLEM", 74, 86], ["air and water pollution", "PROBLEM", 88, 111], ["habitat loss", "OBSERVATION", 74, 86], ["air", "OBSERVATION", 88, 91]]], ["Urban growth entails the movement of goods and services into and out of cities, necessitating the construction of extensive road and rail networks, and the conversion of nearby forests for purposes of agricultural production and industry (Seto, Kaufmann & Woodcock, 2000; Seto et al., 2011) .", [["rail networks", "MULTI-TISSUE_STRUCTURE", 133, 146], ["movement", "OBSERVATION_MODIFIER", 25, 33]]], ["A study of 41 countries in the humid tropics found that forest loss was positively associated with both urban population growth and the export of agricultural products (e.g., cattle, crops) and non-food crops (e.g., palm oil, corn and sugar cane for biofuels), much of which were sold to international markets (DeFries et al., 2010).", [["palm oil", "ANATOMY", 216, 224], ["forest loss", "DISEASE", 56, 67], ["corn", "ORGANISM_SUBDIVISION", 226, 230], ["cattle", "SPECIES", 175, 181], ["corn", "SPECIES", 226, 230], ["cattle", "SPECIES", 175, 181], ["corn", "SPECIES", 226, 230], ["A study", "TEST", 0, 7], ["forest loss", "PROBLEM", 56, 67], ["agricultural products", "TREATMENT", 146, 167], ["sugar cane", "TREATMENT", 235, 245], ["forest loss", "OBSERVATION", 56, 67]]], ["However, many of the new immigrants to large urban centers are the rural poor, who are under-educated and only qualify for low paying jobs in agriculture, manufacturing, and the service sector (S\u00e1nchez-Triana et al., 2013) .", [["new", "OBSERVATION_MODIFIER", 21, 24], ["large", "OBSERVATION_MODIFIER", 39, 44]]], ["Moreover, there is evidence indicating that urban expansion near protected areas pose important conservation challenges to biodiversity, as protected areas become islands or isolated refuges with limited buffer zones and barriers to animal migration and gene flow (Seto et al., 2011) .Population in rural and urban areasThe continued growth and expansion of urban areas is expected to exacerbate the negative consequences that deforestation and habitat fragmentation, bushmeat hunting, and capture for the local, regional and international pet trade will have on primate population decline.", [["urban expansion", "PROBLEM", 44, 59], ["limited buffer zones", "TREATMENT", 196, 216], ["The continued growth", "PROBLEM", 320, 340], ["expansion of urban areas", "PROBLEM", 345, 369], ["habitat fragmentation", "PROBLEM", 445, 466], ["evidence indicating", "UNCERTAINTY", 19, 38], ["urban", "OBSERVATION_MODIFIER", 44, 49], ["expansion", "OBSERVATION_MODIFIER", 50, 59], ["rural", "ANATOMY_MODIFIER", 299, 304], ["growth", "OBSERVATION_MODIFIER", 334, 340], ["expansion", "OBSERVATION_MODIFIER", 345, 354], ["habitat fragmentation", "OBSERVATION", 445, 466]]], ["Given recent assessments that the capture, killing, and trade of wild animals in urban \"wet markets\" likely represents the source point for the COVID-19 pandemic (Shereen et al., 2020) , it is clear that establishing and enforcing laws that promote reforestation in order to expand the physical separation between urban areas and wildlife refuges, and the strict control of unsustainable hunting and live animal capture, are essential components of a successful urban planning strategy.", [["recent assessments", "TEST", 6, 24], ["the COVID", "TEST", 140, 149], ["wildlife refuges", "TREATMENT", 330, 346], ["a successful urban planning strategy", "TREATMENT", 449, 485]]], ["Such a strategy also must include the development of new technologies to increase agricultural yields on non-forested lands and to reduce food waste to more efficiently satisfy the demands for agricultural products in urban areas (DeFries et al., 2010; Seto et al., 2011) .Population in rural and urban areasAdditional forest loss has resulted from the expansion of dams and mega dams to supply water and electricity to urban areas and nearby industries and to agricultural land (Laurance et al., 2014; Benchimol & Peres, 2015) .", [["dams", "ORGANISM", 366, 370], ["non-forested lands", "TREATMENT", 105, 123], ["food waste", "TREATMENT", 138, 148], ["agricultural products", "TREATMENT", 193, 214], ["forest loss", "PROBLEM", 319, 330], ["forest loss", "OBSERVATION", 319, 330]]], ["This has been accompanied by expansion of road and rail networks to transport people, goods and services to resident human populations in urban areas (Alamgir et al., 2017; Clancy, 2008; Laurance, 2006; UNSTATS, 2019) .", [["rail networks", "MULTI-TISSUE_STRUCTURE", 51, 64], ["human", "ORGANISM", 117, 122], ["people", "SPECIES", 78, 84], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["expansion", "OBSERVATION_MODIFIER", 29, 38]]], ["Moreover, the establishment of irregular or unauthorized settlements in the vicinity of cities is an additional factor adding to the cities' footprint, increasing human-primate conflict and primate population decline (Boyle, 2008) .Population in rural and urban areasAlthough cities harbor poverty, they also are places of innovation and knowledge, and can offer economic opportunities in terms of employment and improved living and health conditions (https://sustainabledevelopment.un.org/topics/sustainablecities).", [["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["irregular", "OBSERVATION_MODIFIER", 31, 40], ["rural", "OBSERVATION_MODIFIER", 246, 251]]], ["Cities also offer spaces for social and political involvement and the fusion of cultures, reasons why city life is more desirable to some people, especially young adults.", [["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["the fusion of cultures", "TEST", 66, 88]]], ["For example, a study of 27 countries in Sub-Saharan Africa demonstrated that for the average child under five years of age, living in a rural area and isolated from basic health services and adequate sanitation, the mortality rate (deaths per 1,000 live births) was 49.2% compared to 21.8% for children living in urban areas (Issaka, Agho & Renzaho, 2017) .Population in rural and urban areasUnfortunately, rapid urbanization in primate range countries has resulted in a growing number of slum dwellers, a reduction in food security, and inadequate and overburdened infrastructure and services (such as waste collection and water and sanitation systems, roads and transport), leading to unhealthy levels of air and water pollution and unplanned urban sprawl (UNSTATS, 2019).", [["deaths", "DISEASE", 232, 238], ["children", "ORGANISM", 294, 302], ["children", "SPECIES", 294, 302], ["a study", "TEST", 13, 20], ["sanitation systems", "TREATMENT", 634, 652], ["rapid", "OBSERVATION_MODIFIER", 407, 412], ["urbanization", "OBSERVATION_MODIFIER", 413, 425], ["growing", "OBSERVATION_MODIFIER", 471, 478], ["number", "OBSERVATION_MODIFIER", 479, 485], ["slum dwellers", "OBSERVATION", 489, 502], ["reduction", "OBSERVATION_MODIFIER", 506, 515], ["food security", "OBSERVATION", 519, 532], ["air", "ANATOMY", 707, 710]]], ["Crowding also can have a devastating effect on disease transmission, especially in developing nations (Hotez, 2017) .", [["Crowding", "DISEASE", 0, 8], ["disease transmission", "PROBLEM", 47, 67], ["devastating", "OBSERVATION_MODIFIER", 25, 36], ["effect", "OBSERVATION_MODIFIER", 37, 43], ["disease", "OBSERVATION", 47, 54]]], ["We found that the proportion of the urban population living in slums is high in primate harboring nations when compared with developed nations.", [["high", "OBSERVATION_MODIFIER", 72, 76]]], ["While cities and metropolitan areas are centers of economic growth-contributing about 60 per cent of global GDP, they also account for some 70 per cent of global carbon emissions and over 60 per cent of resource use (Li et al., 2019; UNSTATS, 2019) .", [["carbon", "CHEMICAL", 162, 168], ["GDP", "SIMPLE_CHEMICAL", 108, 111], ["economic growth", "PROBLEM", 51, 66], ["global GDP", "PROBLEM", 101, 111], ["global carbon emissions", "TREATMENT", 155, 178], ["carbon emissions", "OBSERVATION", 162, 178]]], ["Policy decisions and urban planners need to prioritize reducing the ecological footprint of city residents and industry in order to promote 'green' cities, reduce the urban footprint on biodiversity, and actively engage in programs designed to restore native forests (Butler & Laurance, 2008) .Population in rural and urban areasUnsurprisingly, the increase in human population size means that more food, water, energy, living space and public health services are required together with additional housing, transportation hubs and networks, road building, and other essential services (Crist, Mora & Engelman, 2017).", [["human", "ORGANISM", 361, 366], ["human", "SPECIES", 361, 366], ["human", "SPECIES", 361, 366], ["increase", "OBSERVATION_MODIFIER", 349, 357], ["human population", "OBSERVATION_MODIFIER", 361, 377], ["size", "OBSERVATION_MODIFIER", 378, 382]]], ["At the same time, while the human population in developed economies is not growing as rapidly, their economies continue to expand in order to sustain and increase the quality of life of their citizens (UNDESA, 2019a).", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33]]], ["This has important consequences for biodiversity conservation because these developed nations are characterized by overconsumption and excessive waste (Neff, Spiker & Truant, 2015) of agricultural and nonagricultural commodities, much of which are produced in primate range countries (Estrada, Garber & Chaudhary, 2019) .", [["biodiversity conservation", "TREATMENT", 36, 61]]], ["This pattern of \"colonial\" exploitation, that is, the over-extraction of resources, taking advantage of cheap labor, and environmental degradation, has significantly taxed the natural resources of most primate range nations, and resulted in food insecurity as food is grown to support global supply chains rather than for local consumption (Chaudhary & Kastner, 2016; Chaudhary & Mooers, 2018).GDPPC in primate range countriesSuccessful and longstanding primate conservation requires economic resources, satisfactory conservation strategies, efficient implementation of environmental law, public interest, and the practice of sustained and long-term conservation-oriented research.", [["GDPPC", "CHEMICAL", 394, 399], ["cheap labor", "TREATMENT", 104, 115], ["economic resources", "TREATMENT", 484, 502], ["colonial", "OBSERVATION_MODIFIER", 17, 25]]], ["Information on the growth of GDPPC between 1960 and 2018 indicates an enormous gap between countries in primate range regions and the top 25 developed nations of the world ( Fig. 6 ; Table S5 ).", [["enormous", "OBSERVATION_MODIFIER", 70, 78], ["gap", "OBSERVATION", 79, 82]]], ["And although there has been a gradual increase in the average GDPPC between 1960 and 2018 in countries in primate range regions, only the Neotropics and Southeast Asia have experienced gains that closely match the world average (Fig. 6) .", [["a gradual increase", "PROBLEM", 28, 46], ["gradual", "OBSERVATION_MODIFIER", 30, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46]]], ["In contrast, in mainland Africa, Madagascar and South Asia the level of GDPPC has remained stagnant since 1960, with a small increase between 2000 and 2018 ( Fig. 6; Table S5 ), probably the result of increased exports of agricultural and nonagricultural commodities (Estrada, Garber & Chaudhary, 2019 ).", [["GDPPC", "CHEMICAL", 72, 77], ["a small increase", "PROBLEM", 117, 133], ["stagnant", "OBSERVATION", 91, 99], ["small", "OBSERVATION_MODIFIER", 119, 124], ["increase", "OBSERVATION_MODIFIER", 125, 133], ["increased", "OBSERVATION_MODIFIER", 201, 210]]], ["In general, weak per capita income growth is anticipated over the next few years in mainland Africa, Madagascar and South Asia, regions that harbor a significant part of the global population living in extreme poverty (UNDESA, 2019b).", [["weak", "OBSERVATION_MODIFIER", 12, 16], ["significant", "OBSERVATION_MODIFIER", 150, 161]]], ["The steep growth curve in the GDPPC for the top 25 developed nations in the world is notable, indicating significant improvements in the standard of living of their populations, and Table S5 for country data.GDPPC in primate range countriesFull-size \ue90d DOI: 10.7717/peerj.9816/ fig-6 significant differences in the quality of life between citizens in primate range nations and citizens in developed nations (Fig. 6) .", [["DOI", "CHEMICAL", 252, 255], ["DOI", "CHEMICAL", 252, 255], ["The steep growth curve", "TEST", 0, 22], ["fig", "TEST", 277, 280], ["steep", "OBSERVATION_MODIFIER", 4, 9], ["growth", "OBSERVATION_MODIFIER", 10, 16], ["curve", "OBSERVATION_MODIFIER", 17, 22], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["improvements", "OBSERVATION", 117, 129], ["significant", "OBSERVATION_MODIFIER", 283, 294], ["differences", "OBSERVATION_MODIFIER", 295, 306]]], ["Data on the GDPPC for all primate countries at a decadal interval (2010-2100) under five different shared socioeconomic pathway models (SSP-1 to SSP-5) (Samir & Lutz, 2017) show that the highest increase in GDPPC is forecasted under the SSP-5 scenario, which assumes rapid and unconstrained growth in economic output, energy use, and environmental degradation.", [["SSP", "TEST", 136, 139], ["SSP", "TEST", 145, 148], ["rapid and unconstrained growth in economic output", "PROBLEM", 267, 316], ["rapid", "OBSERVATION_MODIFIER", 267, 272], ["unconstrained", "OBSERVATION_MODIFIER", 277, 290], ["growth", "OBSERVATION_MODIFIER", 291, 297]]], ["However, relatively high GDPPC for primate range countries also is predicted under the SSP-1 scenario, which is based on sustainability-focused growth and greater income equality (see Table S11 ).", [["GDPPC", "PROTEIN", 25, 30], ["high", "OBSERVATION_MODIFIER", 20, 24]]], ["Similar to projections of population growth, the SSP-1 scenario is a win-win for human development and primate conservation because the growth in GDPPC under this scenario minimizes tropical deforestation and biodiversity loss Estrada, Garber & Chaudhary, 2019) .The HDIInformation from the 2018 UN HDI (a combination of life expectancy, school enrollment, literacy, and income, with the lowest human development = 0 and the highest = 1.0) indicates that while the average HDI has increased over the past decades in all primate regions, Madagascar and countries in mainland Africa and South Asia have remained consistently low and below the world's average (Fig. 6) .", [["SSP-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["human", "ORGANISM", 81, 86], ["human", "ORGANISM", 395, 400], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 395, 400], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 395, 400], ["population growth", "PROBLEM", 26, 43], ["human development", "TREATMENT", 81, 98], ["primate conservation", "TREATMENT", 103, 123], ["the growth", "PROBLEM", 132, 142], ["tropical deforestation", "TREATMENT", 182, 204], ["population", "OBSERVATION_MODIFIER", 26, 36], ["growth", "OBSERVATION_MODIFIER", 37, 43], ["increased", "OBSERVATION_MODIFIER", 481, 490]]], ["The HDI for the Neotropics and Southeast Asia has tended to increase, but this has been driven by a small set of countries including Japan, Brunei, Singapore, Taiwan, Argentina, and Costa Rica (Fig. 7) .", [["The HDI", "TREATMENT", 0, 7], ["the Neotropics", "TREATMENT", 12, 26], ["Southeast Asia", "TREATMENT", 31, 45]]], ["Table S6 for country data.The HDIFull-size \ue90d DOI: 10.7717/peerj.9816/ fig-7 These are among the least primate-rich countries per region.", [["DOI", "CHEMICAL", 45, 48], ["DOI", "CHEMICAL", 45, 48], ["S6", "PROTEIN", 6, 8], ["The HDIFull", "TEST", 26, 37], ["fig", "TEST", 70, 73], ["size", "OBSERVATION_MODIFIER", 38, 42]]], ["In contrast, the average HDI values for the 25 top developed nations in the world have consistently increased over the same period and are well above the average of all primate range regions (Fig. 7) .", [["the average HDI values", "TEST", 13, 35], ["consistently", "OBSERVATION_MODIFIER", 87, 99], ["increased", "OBSERVATION_MODIFIER", 100, 109]]], ["Low levels of development are commonly associated with political instability, extreme income inequality, and limited environmental protection (Alsamawi et al., 2014; UNDP, 2019) .", [["political instability", "PROBLEM", 55, 76]]], ["Thus, it is clear that despite the enormous biological wealth and natural resources of primate range countries, poverty, deep-rooted income inequality, illiteracy, low levels of education, political instability, and over-exploitation of their natural resources by the consumer nations of the world make the task of preserving primates and their habitats extremely difficult (Alsamawi et al., 2014; UNDP, 2019) .The HDIThe challenges of devoting sufficient resources to environmental and biodiversity conservation in the majority of primate range countries is further underscored by the percentage of the population living on less than US $1.90 a day, an internationally recognized indicator of extreme poverty (World Bank, 2020b).", [["poverty", "DISEASE", 112, 119], ["primates", "ORGANISM", 326, 334], ["political instability", "PROBLEM", 189, 210], ["biodiversity conservation", "TREATMENT", 487, 512]]], ["The World Bank indicates that in 2015 Madagascar had the largest percentage (77%) of the population living on less than US $1.90 a day, followed by mainland Africa (41%) and in South Asia (14%) (Fig. 8A) .", [["largest", "OBSERVATION_MODIFIER", 57, 64]]], ["In Europe (n = 28), the US and Canada the proportion of the population living on less than US$1.90 a day was essentially zero (World Bank, 2020b; Fig. 8A ).The HDIMoreover, low human development and high poverty levels in primate range regions are related to high levels of mortality for children under five years of age.", [["human", "ORGANISM", 177, 182], ["children", "ORGANISM", 288, 296], ["human", "SPECIES", 177, 182], ["children", "SPECIES", 288, 296], ["human", "SPECIES", 177, 182], ["the US", "TEST", 20, 26], ["low human development", "PROBLEM", 173, 194], ["high poverty levels", "PROBLEM", 199, 218], ["low human", "OBSERVATION_MODIFIER", 173, 182], ["high", "OBSERVATION_MODIFIER", 199, 203]]], ["In South Asia, it totaled 1.47 million children (Fig. 8B ).", [["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47]]], ["In the Neotropics and in Southeast Asia under-five mortality was significantly lower, 0.17 million and 0.46 million, respectively.", [["Neotropics", "OBSERVATION_MODIFIER", 7, 17]]], ["High levels of poverty and its consequences for under-five mortality underscore the challenges faced in prioritizing primate conservation in primate range regions.", [["primate", "ORGANISM", 117, 124], ["the challenges", "TREATMENT", 80, 94]]], ["Poor governance promotes poverty, civil unrest, food insecurity unsustainable use of natural resources, hunting, the illegal wildlife trade, and the necessity to colonize intact forest areas, including legally designated protected areas, thus expanding pressure on primate habitats and populations (Adams & Hutton, 2007; Kates & Dasgupta, 2007) .Food securityFood security in primate range countries is a critical factor affecting primate conservation.", [["primate", "ORGANISM", 431, 438], ["legally designated protected areas", "PROBLEM", 202, 236], ["pressure", "OBSERVATION_MODIFIER", 253, 261]]], ["High levels of population growth, poverty, inequality, and corruption, accompanied by extensive loss of natural capital, have a direct impact on food security.", [["poverty", "DISEASE", 34, 41], ["population growth", "PROBLEM", 15, 32], ["population", "OBSERVATION_MODIFIER", 15, 25], ["growth", "OBSERVATION_MODIFIER", 26, 32], ["extensive", "OBSERVATION_MODIFIER", 86, 95], ["loss", "OBSERVATION", 96, 100], ["natural capital", "OBSERVATION", 104, 119]]], ["The World Food Summit of 1996 defined food security as the situation in which people have physical, social and economic access to sufficient and nutritive food that meets their dietary requirements for a healthy and active life (http://www.fao.org/WFS/).", [["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84]]], ["The index also considers a country's exposure to the impacts of a changing climate; its susceptibility to natural resource risks; and how the country is adapting to these risks.", [["a changing climate", "TREATMENT", 64, 82]]], ["The GFSI is based on data from 113 countries and ranges from zero (lowest food security) to 100 (highest food security) (https://foodsecurityindex.eiu.com/Index).Food securityThe GFSI for primate range countries for which the index is available indicates that lowest values are found for Madagascar and mainland Africa, followed by South Asia, the Neotropics, and Southeast Asia.", [["GFSI", "DNA", 4, 8], ["GFSI", "PROTEIN", 179, 183], ["The GFSI", "TEST", 0, 8], ["The GFSI", "TEST", 175, 183], ["the index", "TEST", 222, 231], ["Madagascar", "PROBLEM", 288, 298]]], ["A few Southeast Asian nations such as Japan, Singapore and Malaysia have food security indices comparable to those of Western nations.", [["few", "OBSERVATION_MODIFIER", 2, 5]]], ["The average value of the index for primate range regions was 53.9, while the GFSI for 25 of the most developed nations in the world was 80.8 ( Fig. 9 ; Table S8 ).", [["the index", "TEST", 21, 30], ["the GFSI", "TEST", 73, 81], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["The United Nations expects that in 2020, 47 of 91 primate range countries (52%), the majority of which are in Africa, will encounter acute food insecurity (GNAFC/FSIN, 2020).", [["acute food insecurity", "DISEASE", 133, 154]]], ["Given the economic effects of the coronavirus, it is likely that food insecurity in other primate regions also will increase (Torero-Cullen, 2020).", [["coronavirus", "DISEASE", 34, 45], ["food insecurity", "DISEASE", 65, 80], ["coronavirus", "ORGANISM", 34, 45], ["primate", "ORGANISM", 90, 97], ["the coronavirus", "PROBLEM", 30, 45], ["food insecurity in other primate regions", "PROBLEM", 65, 105], ["is likely", "UNCERTAINTY", 50, 59], ["increase", "OBSERVATION_MODIFIER", 116, 124]]], ["Human populations in primate range countries lag far behind developed nations in GDPPC, in human development, and in food security despite the fact they produce billions of metric tonnes of food per year.", [["GDPPC", "CHEMICAL", 81, 86], ["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 91, 96], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["Human populations", "TREATMENT", 0, 17]]], ["This is a direct result of land use practices that are controlled by a small set of multinational corporations and a system of industrial agricultural production for global export (including beef) to satisfy overconsumption by developed and developing nations rather than for domestic consumption (Estrada, Garber & Chaudhary, 2019; Chen, Chaudhary & Mathys, 2020).Food securityHere it is important to note that poverty, corruption, poor governance, and income inequality in many primate range countries, along with debt that must be repaid in dollars, have led countries to allow large areas of their land converted to agricultural and nonagricultural commodities production (e.g., soy fields, oil palm and rubber plantations and the extraction of minerals, fossil fuels and gems) mainly for global markets (Bradshaw & Brook, 2014; Chen et al., 2020; Dietz & Rosa, 1997; Estrada, Garber & Chaudhary, 2019) .", [["beef", "ORGANISM_SUBDIVISION", 191, 195], ["oil", "ORGANISM_SUBDIVISION", 695, 698], ["palm", "ORGANISM_SUBDIVISION", 699, 703], ["rubber plantations", "TREATMENT", 708, 726], ["the extraction of minerals", "TREATMENT", 731, 757], ["rubber plantations", "OBSERVATION", 708, 726]]], ["Land use dedicated to the production and export of food and nonfood commodities by primate range nations has not increased local food security, human safety, or political stability (FAO, 2019a (FAO, , 2019b .Food securityAdding to the global challenges of income inequality, access to adequate food and health care, conflict, climate impacts, and unforeseen events like the COVID-19 pandemic are Figure 9 Food security in primate range regions.", [["human", "ORGANISM", 144, 149], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149], ["the COVID", "TEST", 370, 379]]], ["See Table S5 for country data.Food securityFull-size \ue90d DOI: 10.7717/peerj.9816/ fig-9 expected to have a greater negative impact on health and food security in primate range nations than in more prosperous countries (GNAFC/FSIN, 2020).", [["DOI", "CHEMICAL", 55, 58], ["DOI", "CHEMICAL", 55, 58], ["size", "OBSERVATION_MODIFIER", 48, 52]]], ["COVID-19 is expected to overwhelm civil society, increase food insecurity, and devastate the healthcare systems and livelihoods of millions of citizens who work in the informal agricultural and nonagricultural sectors of the economy across the globe (GNAFC/FSIN, 2020) .Food securityThe COVID-19 pandemic has resulted in the disruption of local and global food chains and this may result in scarcities of food and higher prices (Torero-Cullen, 2020), which in turn may lead to increased hunting of bushmeat and an expansion of wildlife trade in many primate range nations (Lappin et al., 2020) .Food securityClearly, primate-range countries must develop a more balanced set of national priorities to build their internal economies in order to ensure food security for their growing human populations.", [["bushmeat", "DISEASE", 498, 506], ["human", "ORGANISM", 782, 787], ["human", "SPECIES", 782, 787], ["human", "SPECIES", 782, 787], ["The COVID", "TEST", 283, 292], ["the disruption of local and global food chains", "PROBLEM", 321, 367], ["scarcities of food", "PROBLEM", 391, 409], ["increased hunting of bushmeat", "PROBLEM", 477, 506], ["globe", "ANATOMY", 244, 249], ["local", "OBSERVATION_MODIFIER", 339, 344], ["food chains", "OBSERVATION", 356, 367], ["increased", "OBSERVATION_MODIFIER", 477, 486], ["hunting", "OBSERVATION", 487, 494], ["expansion", "OBSERVATION_MODIFIER", 514, 523]]], ["These same countries must also safeguard their biodiversity by building their economies using sustainable practices, green technologies, reducing water, air and soil pollution, and mitigating the effects of climate change on their citizens and environment (Estrada et al., 2017; Sillman et al., 2019) .", [["sustainable practices", "TREATMENT", 94, 115], ["green technologies", "TREATMENT", 117, 135], ["air and soil pollution", "TREATMENT", 153, 175]]], ["While poverty, food security and protection of primate habitats are intricately linked, there are other social factors at play that impede human well-being, protecting biodiversity, and prioritizing primate conservation.", [["human", "ORGANISM", 139, 144], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144]]], ["These are corruption and poor governance.CorruptionCorruption is a major threat to humans, biodiversity, and the environment because it destabilizes democratic institutions, causes governmental and societal uncertainty, and destroys public trust.", [["CorruptionCorruption", "DISEASE", 41, 61], ["humans", "ORGANISM", 83, 89], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89], ["corruption", "OBSERVATION", 10, 20], ["poor governance", "OBSERVATION", 25, 40]]], ["Corruption rewards criminal activity, weakens economic development, promotes inequality, and hinders country-wide prosperity (UNDOC, 2020).", [["criminal activity", "OBSERVATION", 19, 36]]], ["Corruption adversely affect human communities and leads to policies and practices that foster habitat degradation and loss of biodiversity.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["loss of biodiversity", "PROBLEM", 118, 138]]], ["It also contributes to poverty and to social and political volatility.", [["poverty", "DISEASE", 23, 30]]], ["The more a country's political system is affected by corruption, the poorer the country's environmental performance (Murshed & Mredula, 2018; Transparency International, 2020) .CorruptionThe Corruption Perceptions Index (CPI), which has been released annually by Transparency International since 1995, ranks countries by their perceived levels of public sector corruption, as validated by expert evaluations and attitude surveys.", [["expert evaluations", "TEST", 389, 407], ["attitude surveys", "TEST", 412, 428]]], ["The 2019 Perception Corruption Index (PCI) of Transparency International (https://www.transparency.org; 0 = most corrupt, 100 = least corrupt) for primate range countries, for which PCI scores are available, and for the top 25 most developed countries indicates that high levels of corruption are widespread in primate range nations compared to the top 25 economies (Fig. 10A) .", [["PCI scores", "TEST", 182, 192], ["high levels of corruption", "PROBLEM", 267, 292], ["widespread", "OBSERVATION_MODIFIER", 297, 307]]], ["The distribution of the 2019 PCI scores across primate range countries and in the 25 developed nations is shown in Fig. 10B .", [["10B", "GENE_OR_GENE_PRODUCT", 120, 123], ["PCI scores", "TEST", 29, 39], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["The most corrupt country was Venezuela (CPI: 16) ( Fig. 10B; Table S9 ).", [["CPI", "TEST", 40, 43]]], ["In mainland Africa, Botswana, Rwanda and Namibia were the least corrupt (CPI: >50) and the most corrupt were Somalia (CPI: 9), South Sudan (CPI: 12), Equatorial Guinea (CPI: 16), Sudan (CPI: 16), Congo DR (CPI: 18), Guinea-Bissau (CPI: 18), Burundi (CPI: 19) and Republic of Congo (CPI: 19) .", [["CPI", "TEST", 73, 76], ["Equatorial Guinea (CPI", "TEST", 150, 172], ["Congo DR (CPI", "TEST", 196, 209], ["Guinea", "TEST", 216, 222], ["CPI", "TEST", 231, 234], ["Burundi (CPI", "TEST", 241, 253], ["Congo (CPI", "TEST", 275, 285]]], ["For the remainder of mainland African countries, the CPI ranged from 20-45.", [["the CPI", "TEST", 49, 56]]], ["Primates species-rich Madagascar had a CPI score of 24, indicating very high levels of corruption ( Fig. 10B; Tables S9) .", [["a CPI score", "TEST", 37, 48], ["very", "OBSERVATION_MODIFIER", 67, 71], ["high", "OBSERVATION", 72, 76]]], ["In South Asia the CPI ranged from 15 in Yemen to 68 in Bhutan.", [["the CPI", "TEST", 14, 21]]], ["In Southeast Asia the CPI ranged from 29 Myanmar/Lao to 85 in Singapore ( Fig. 10B ; Table S9 ).CorruptionCorruption is a major contributor to primate population decline because it results in incentives to misrepresent the negative consequences of environmental degradation Table S9 for the complete list.", [["the CPI", "TEST", 18, 25], ["primate population decline", "PROBLEM", 143, 169]]], ["See Table S9 for country data.CorruptionFull-size \ue90d DOI: 10.7717/peerj.9816/ fig-10 and/or not comply with environmental laws.", [["DOI", "CHEMICAL", 52, 55], ["DOI", "CHEMICAL", 52, 55], ["CorruptionFull", "TEST", 30, 44], ["fig", "TEST", 77, 80], ["size", "OBSERVATION_MODIFIER", 45, 49]]], ["This has resulted in illegal deforestation and land speculation fostering poverty and criminal activities by individuals and corporations.", [["illegal deforestation", "PROBLEM", 21, 42], ["illegal deforestation", "OBSERVATION", 21, 42]]], ["In many cases these criminal enterprises are associated with the mining of precious metals and gems, which pollutes streams, lakes, rivers, and soil and promotes hunting, logging in protected areas and outside of government concessions, poaching, and the illegal primate pet trade (Human Rights Watch, 2019; Laurance, 2004; Estrada et al., 2018; Estrada, Garber & Chaudhary, 2019) .", [["Human", "SPECIES", 282, 287], ["lakes", "OBSERVATION_MODIFIER", 125, 130]]], ["Corruption hinders the conservation efforts of NGOs, governments, and local communities and undermines the capacity of guards and law enforcement to combat drivers of primate habitat loss and local species extirpation (Ivory, 2017; Packer & Polasky, 2018) .", [["primate habitat loss", "DISEASE", 167, 187], ["primate habitat loss", "PROBLEM", 167, 187], ["local species extirpation", "TREATMENT", 192, 217], ["habitat loss", "OBSERVATION", 175, 187]]], ["In Madagascar, the illegal harvest and export of rosewood in protected areas has been enabled by political ineffectiveness and corruption (Freudenberger, 2010; Gore, Ratsimbazafy & Lute, 2013; Randriamalala & Liu, 2010; Schwitzer et al., 2014) .", [["rosewood", "CHEMICAL", 49, 57], ["the illegal harvest", "TREATMENT", 15, 34], ["illegal harvest", "OBSERVATION", 19, 34]]], ["Bushmeat and the trade for body parts are important drivers in the population decline of great ape species-bonobos, chimpanzees, and gorillas in Africa and orangutans in Indonesia (IUCN Red List, 2019).", [["body parts", "ANATOMY", 27, 37], ["Bushmeat", "CHEMICAL", 0, 8], ["body", "ORGANISM_SUBDIVISION", 27, 31], ["ape", "ORGANISM", 95, 98], ["bonobos", "ORGANISM", 107, 114], ["chimpanzees", "ORGANISM", 116, 127], ["gorillas", "ORGANISM", 133, 141], ["orangutans", "ORGANISM", 156, 166], ["great ape species", "PROBLEM", 89, 106], ["great", "OBSERVATION_MODIFIER", 89, 94], ["ape species", "OBSERVATION", 95, 106]]], ["It was estimated that the domestic trade in primates for pets and bushmeat in Peru is likely to number in the hundreds of thousands per year, with larger-bodied primates being the main targets (Shanee, Mendoza & Shanee, 2017) .", [["primates", "ORGANISM", 44, 52], ["primates", "ORGANISM", 161, 169], ["larger", "OBSERVATION_MODIFIER", 147, 153], ["main", "OBSERVATION_MODIFIER", 180, 184]]], ["In short, corruption at various levels of society render ineffective the laws that protect wildlife and feed a vicious cycle across many levels of society.", [["short", "OBSERVATION_MODIFIER", 3, 8]]], ["High levels of corruption seem to have an important impact on the quality of governance in primate range regions and make social reforms needed to enhance the health, income, and well-being of average citizens, impossible.Governance indicators and implications for primate conservationGood governance entails justly implementing the practices and laws that maintain the institutions and constitution of the country.", [["governance", "OBSERVATION", 290, 300]]], ["This involves the process by which governments are chosen, scrutinized and replaced; the capability of the government to successfully create and apply sound policies; and the respect of people and the state for the institutions that govern social and economic interactions (World Bank, 2020d; European Commission, 2019).", [["people", "ORGANISM", 186, 192], ["people", "SPECIES", 186, 192]]], ["An examination of four key World Bank indicators of governance quality in 2018 (political stability and absence of violence/terrorism, government effectiveness, rule of law and control of corruption) found that all countries in primate range regions ranked significantly below the average value for 35 high-income countries.", [["An examination", "TEST", 0, 14], ["terrorism", "PROBLEM", 124, 133]]], ["Sub-Saharan Africa and Madagascar ranked lowest among primate regions (Fig. 11) .", [["Saharan Africa", "PROBLEM", 4, 18], ["Madagascar", "PROBLEM", 23, 33], ["Saharan", "OBSERVATION_MODIFIER", 4, 11]]], ["A global study showed that high governance scores frequently relate to lower rates of deforestation (Fischera, Giessenb & G\u00fcnterc, 2020) .", [["deforestation", "DISEASE", 86, 99], ["A global study", "TEST", 0, 14], ["high governance scores", "PROBLEM", 27, 49], ["deforestation", "OBSERVATION", 86, 99]]], ["Rule of law and control of corruption are critical factors in successfully establishing effective conservation programs.", [["effective conservation programs", "TREATMENT", 88, 119], ["law", "OBSERVATION", 8, 11]]], ["Countries will not be successful in implementing policies of conservation and environmental protection if government effectiveness and political stability are low.", [["conservation", "TREATMENT", 61, 73], ["environmental protection", "TREATMENT", 78, 102], ["political stability", "TEST", 135, 154]]], ["They are rich in natural resources, and they enable residents to maintain their traditional beliefs, economies, and cultures in balance with the environment.", [["cultures", "TEST", 116, 124]]], ["Many indigenous cultures view tropical forests as sacred places and view their role as stewards of the environment (Fuentes, 2012) .", [["Many indigenous cultures", "TEST", 0, 24], ["tropical forests", "TREATMENT", 30, 46]]], ["Tropical forests are places of dynamic social, ecological, political, and economic change, which in some cases has led to armed conflict over forest resources and land (McNeely, 2003 (McNeely, , 2008 .Civil conflict and primate conservationHere we examine the 2019 GPI of the Institute of Economics and Peace (https://economicsandpeace.org/).", [["Tropical forests", "TREATMENT", 0, 16], ["forests", "OBSERVATION", 9, 16]]], ["The GPI covers 99.7 per cent of the world's population and uses 23 qualitative and quantitative indicators to measure the state of peace using three thematic domains, Ongoing Domestic and International Conflict (ODIC), Societal Safety and Security (SSS) and Militarization (IEPGPI, 2019).", [["The GPI covers", "TEST", 0, 14]]], ["The 2019 GPI (one most peaceful, five least peaceful) for 91 countries harboring primates had, on average, higher values (GPI: 2.232) than did the top high-income 25 nations in the world (GPI: 1.523) ( Fig. 12; Table S10 ), suggesting that primate countries more commonly face sustained civil conflict.", [["primates", "ORGANISM", 81, 89], ["GPI", "TEST", 122, 125], ["GPI", "TEST", 188, 191]]], ["Among primate range nations, countries of Southeast Asia (GPI: 1.904) and Madagascar had the lowest values of the GPI (GPI: 1.867) (Fig. 12) .", [["GPI", "TEST", 58, 61], ["Madagascar", "TEST", 74, 84], ["the GPI", "TEST", 110, 117], ["GPI", "TEST", 119, 122], ["GPI", "ANATOMY", 114, 117]]], ["Civil conflict negatively affects primate population persistence due to random bombing, the use of toxic chemicals and defoliants, increased availability of firearms, and the upsurge in bushmeat hunting both by soldiers and displaced people as local supply chains breakdown (Douglas & Alie, 2014; Loucks et al., 2009) .", [["people", "ORGANISM", 234, 240], ["people", "SPECIES", 234, 240], ["chains", "OBSERVATION_MODIFIER", 257, 263], ["breakdown", "OBSERVATION_MODIFIER", 264, 273]]], ["For example, the poaching of bonobos (Pan paniscus) and gorillas (Gorilla gorilla and Gorilla beringei) increased considerably in DRC and Rwanda as a result of ongoing civil wars (Douglas & Alie, 2014).", [["bonobos", "ORGANISM", 29, 36], ["Pan paniscus", "ORGANISM", 38, 50], ["gorillas", "ORGANISM", 56, 64], ["Gorilla gorilla", "ORGANISM", 66, 81], ["Gorilla beringei", "ORGANISM", 86, 102], ["Pan paniscus", "SPECIES", 38, 50], ["gorillas", "SPECIES", 56, 64], ["Gorilla gorilla", "SPECIES", 66, 81], ["Gorilla beringei", "SPECIES", 86, 102], ["Pan paniscus", "SPECIES", 38, 50], ["Gorilla gorilla", "SPECIES", 66, 81], ["Gorilla beringei", "SPECIES", 86, 102], ["gorillas (Gorilla gorilla", "PROBLEM", 56, 81]]], ["In Cambodia, armed conflicts have severely affected populations of the black-shanked douc (Pygathrix nigripes) (Loucks et al., 2009) .", [["douc", "ORGANISM", 85, 89], ["Pygathrix nigripes", "ORGANISM", 91, 109], ["Pygathrix nigripes", "SPECIES", 91, 109], ["black-shanked douc", "SPECIES", 71, 89], ["Pygathrix nigripes", "SPECIES", 91, 109], ["severely affected populations", "PROBLEM", 34, 63], ["severely", "OBSERVATION_MODIFIER", 34, 42], ["affected", "OBSERVATION_MODIFIER", 43, 51], ["populations", "OBSERVATION_MODIFIER", 52, 63], ["black", "OBSERVATION_MODIFIER", 71, 76]]], ["Heavily armed militias in DRC are currently fighting for ethnic and political control and, jointly with illegal miners, prospect for \"conflict minerals\" (e.g., coltan, tin, tantalum, tungsten and gold) and diamonds, and hunt primates for bushmeat (Gavin, 2017; Nellemann, Redmond & Refisch, 2010) .", [["tungsten", "CHEMICAL", 183, 191], ["primates", "ORGANISM", 225, 233], ["Heavily armed militias in DRC", "PROBLEM", 0, 29], ["political control", "TREATMENT", 68, 85], ["militias", "OBSERVATION", 14, 22]]], ["Likewise, past border conflicts in Southeast Asia, including the war in Vietnam which lasted some 20 years, caused significant damage to the forest and wiped out entire wildlife populations (McNeely, 2003) .", [["significant damage to the forest", "PROBLEM", 115, 147], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["damage", "OBSERVATION", 127, 133]]], ["At present 86% (19/22) of primate species in Vietnam are considered threatened (Table S1 ).", [["primate", "ORGANISM", 26, 33], ["primate species", "PROBLEM", 26, 41]]], ["Civil conflict also alters traditional land use patterns and can lead to increased unregulated forest conversion.", [["increased unregulated forest conversion", "PROBLEM", 73, 112], ["forest conversion", "OBSERVATION", 95, 112]]], ["In northern Sumatra, between 1990 and 2010 human conflicts combined with forest fires and illegal and legal logging caused major reductions in forest cover (>30%) (Margono et al., 2012) .", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["forest fires", "TREATMENT", 73, 85], ["legal logging", "TREATMENT", 102, 115], ["major reductions", "PROBLEM", 123, 139]]], ["Disputes over land rights, actions by corporation, and governmental policies also have led to forest burning and land-clearing in several primate range regions in Southeast Asia, Africa and the Neotropics endangering many primates (Lanjouw, 2014; Meijaard & Nijman, 2000; Supriatna et al., 2017; Human Rights Watch, 2019) .Civil conflict and primate conservationClearly, civil unrest, inter-country wars, terrorism, and continued militarization contribute to the dislocation of the large numbers of innocent civilians resulting in refugee crises, increased poverty, insecurity, the spread of disease, environmental damage, and reduced food security.", [["dislocation", "DISEASE", 463, 474], ["poverty", "DISEASE", 557, 564], ["environmental damage", "DISEASE", 601, 621], ["Human", "SPECIES", 296, 301], ["forest burning", "PROBLEM", 94, 108], ["the dislocation", "PROBLEM", 459, 474], ["refugee crises", "PROBLEM", 531, 545], ["disease", "PROBLEM", 592, 599], ["environmental damage", "PROBLEM", 601, 621], ["dislocation", "OBSERVATION", 463, 474], ["large", "OBSERVATION_MODIFIER", 482, 487], ["increased", "OBSERVATION_MODIFIER", 547, 556], ["poverty", "OBSERVATION_MODIFIER", 557, 564], ["spread", "OBSERVATION_MODIFIER", 582, 588], ["disease", "OBSERVATION", 592, 599]]], ["10 and 11).Socioeconomic pathways and primate conservationDecadal interval data (2010-2100) compiled and modeled from all primate countries under five different shared socioeconomic pathways (SSP-1 to SSP-5) (Samir & Lutz, 2017) showed that the lowest human population increase is forecasted under conditions of rapid and unconstrained growth in economic output and energy (SSP-5) that would significantly harm the environment as well as under conditions of sustainability-focused growth and economic equality (SSP-1).", [["SSP-5", "CHEMICAL", 374, 379], ["human", "ORGANISM", 252, 257], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["the lowest human population", "PROBLEM", 241, 268], ["rapid and unconstrained growth in economic output", "PROBLEM", 312, 361], ["SSP", "TEST", 511, 514], ["growth", "OBSERVATION_MODIFIER", 336, 342]]], ["The greatest increase in human population growth in the five primate range regions is projected under the SSP-3 scenario, in which globalization is fragmented and countries around the world see a \"resurgence of nationalism\" (Fig. 13 ; Table S11) (Samir & Lutz, 2017) .Socioeconomic pathways and primate conservationThe SSP-1 (sustainability-taking the green road) scenario represents a world that together respects and protects the environment and is shifting towards a green and sustainable path.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["The greatest increase", "PROBLEM", 0, 21], ["human population growth", "PROBLEM", 25, 48], ["Socioeconomic pathways", "TREATMENT", 268, 290], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["human", "OBSERVATION_MODIFIER", 25, 30], ["population", "OBSERVATION_MODIFIER", 31, 41], ["growth", "OBSERVATION_MODIFIER", 42, 48], ["fragmented", "OBSERVATION_MODIFIER", 148, 158]]], ["Under this scenario, tropical deforestation is reduced due to strict regulations, crop yields and international trade increase, people reduce their consumption of meat, adopt healthier diets, and obtain the benefits of a cleaner environment .", [["meat", "ANATOMY", 163, 167], ["people", "ORGANISM", 128, 134], ["meat", "ORGANISM_SUBDIVISION", 163, 167], ["people", "SPECIES", 128, 134], ["tropical deforestation", "TREATMENT", 21, 43], ["a cleaner environment", "TREATMENT", 219, 240], ["deforestation", "OBSERVATION", 30, 43]]], ["Past studies have gathered both quantitative and qualitative evidence on several local and national interventions that can generate positive outcomes for primates and biodiversity in general.", [["Past studies", "TEST", 0, 12], ["national interventions", "TREATMENT", 91, 113]]], ["For example, shifting to diets (sustainable consumption) with fewer animal-based products and thus a reduced environmental footprint can relieve some of the existing pressure on species' habitat, resulting in lower species extinction risk (see Willett et al., 2019; Machovina, Feeley & Ripple, 2015; Chaudhary & Krishna, 2019) .", [["a reduced environmental footprint", "PROBLEM", 99, 132], ["lower species extinction risk", "PROBLEM", 209, 238]]], ["Similarly, adopting sustainable tropical forest management practices such as reduced impact logging, can reduce species losses and environmental degradation (Chaudhary et al., 2016) .", [["sustainable tropical forest management practices", "TREATMENT", 20, 68], ["reduced impact logging", "PROBLEM", 77, 99], ["species losses", "PROBLEM", 112, 126]]], ["In the agriculture sector, improved technology, reduced food loss and sustainable intensification farming practices leading to higher yields can result in the release of more land for biodiversity conservation (Krause & Ness, 2017; Willett et al., 2019) .", [["food loss", "DISEASE", 56, 65], ["reduced food loss", "PROBLEM", 48, 65], ["reduced", "OBSERVATION_MODIFIER", 48, 55], ["food loss", "OBSERVATION", 56, 65]]], ["Assuming that continued human population expansion results in a significant increase in the demand for food, in tropical regions characterized by water scarcity, the cultivation of bioengineered drought-tolerant crops can result in increased production without expanding farming into forested areas (Rosa et al., 2020) .", [["human", "ORGANISM", 24, 29], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["continued human population expansion", "PROBLEM", 14, 50], ["bioengineered drought", "TREATMENT", 181, 202], ["increased production", "PROBLEM", 232, 252], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["increase", "OBSERVATION_MODIFIER", 76, 84], ["water scarcity", "OBSERVATION", 146, 160], ["increased", "OBSERVATION_MODIFIER", 232, 241]]], ["No net loss (NNL) biodiversity policies, which are design to reconcile the increased need for infrastructure development with biodiversity conservation are also being formulated (https://tntcat.iiasa.ac.at/SspDb/dsd?Action=htmlpage&page=about).", [["net loss (NNL) biodiversity policies", "PROBLEM", 3, 39], ["infrastructure development", "TREATMENT", 94, 120], ["biodiversity conservation", "TREATMENT", 126, 151], ["net loss", "OBSERVATION", 3, 11]]], ["These pathways include: (A) a world of sustainability-focused growth and equality (SSP1); (B) a \"middle of the road\" world where trends broadly follow their historical patterns (SSP2); (C) a fragmented world of \"resurgent nationalism\" (SSP3); (D) a world of ever-increasing inequality (SSP4); and (E) a world of rapid and unconstrained growth in economic output and energy use (SSP5).", [["rapid and unconstrained growth in economic output", "PROBLEM", 312, 361], ["middle", "ANATOMY_MODIFIER", 97, 103], ["growth", "OBSERVATION_MODIFIER", 336, 342]]], ["Under the SSP-5 (fossil fueled development-taking the highway) scenario, there is rapid technological progress, increase in crop yields and international trade and diets are unhealthy with high food waste.", [["SSP-5", "CHEMICAL", 10, 15], ["increase", "OBSERVATION_MODIFIER", 112, 120]]], ["Tropical deforestation continues, but at more modest yearly rates in response to recognition of the need for regulation, however the resulting habitat reduction and fragmentation leads to significant declines in biodiversity, including many primate species .", [["Tropical deforestation", "PROBLEM", 0, 22], ["the resulting habitat reduction", "TREATMENT", 129, 160], ["fragmentation", "PROBLEM", 165, 178], ["significant declines in biodiversity", "PROBLEM", 188, 224], ["many primate species", "PROBLEM", 236, 256], ["deforestation", "OBSERVATION", 9, 22], ["habitat", "OBSERVATION_MODIFIER", 143, 150], ["reduction", "OBSERVATION_MODIFIER", 151, 160], ["fragmentation", "OBSERVATION", 165, 178], ["significant", "OBSERVATION_MODIFIER", 188, 199], ["declines", "OBSERVATION_MODIFIER", 200, 208], ["biodiversity", "OBSERVATION_MODIFIER", 212, 224]]], ["Although the rate of human population increase is similar in both the SSP-1 and SSP-5 scenarios, the SSP-1 scenario forebodes better outcomes for environmental justice, human health and global primate conservation (Table S11) .Socioeconomic pathways and primate conservationWe note that by 2050, there will be ca 700 million more people in primate range countries under the SSP-2 (business-as-usual, middle of the road scenario where development happens along historical patterns) scenario compared with SSP-1 scenario (Table S11) .", [["human", "ORGANISM", 21, 26], ["human", "ORGANISM", 169, 174], ["people", "ORGANISM", 330, 336], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 169, 174], ["people", "SPECIES", 330, 336], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 169, 174], ["human population increase", "PROBLEM", 21, 46], ["the SSP", "TEST", 66, 73], ["SSP", "TEST", 80, 83], ["the SSP", "TEST", 97, 104], ["population", "OBSERVATION_MODIFIER", 27, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46]]], ["Under the worst case SSP-3 scenario (regional rivalry-a rocky road), the increase will be even more severe and there will be ca 1.6 billion additional people in primate hosting countries compared to SSP-1 scenario (see Supplemental Excel).", [["people", "ORGANISM", 151, 157], ["people", "SPECIES", 151, 157], ["SSP", "TEST", 199, 202]]], ["The SSP-3 scenario is characterized by trade barriers, nationalism, limited technology transfer leading to stagnant crop yields, almost no land use change regulations and the Figure 14 Socioeconomic challenges in primate range regions and primate conservation.", [["stagnant crop yields", "PROBLEM", 107, 127], ["change regulations", "TREATMENT", 148, 166], ["the Figure 14 Socioeconomic challenges in primate range regions", "TREATMENT", 171, 234]]], ["Diagram summarizing key socioeconomic challenges facing primate range regions that affect the conservation of their primate fauna.", [["primate", "ORGANISM", 116, 123]]], ["The relative importance of population and governance aspects vary from country to country, but in general these challenges are common to all primate range nations, except Japan, Brunei and Singapore which rank high in Gross Domestic Product per Capita (GDPPC) and in the Human Development Index (HDI) (see Tables S5 and S6) .Socioeconomic pathways and primate conservationFull-size \ue90d DOI: 10.7717/peerj.9816/ fig-14 prevalence of unhealthy diets high in food waste and meat products .", [["meat", "ANATOMY", 469, 473], ["DOI", "CHEMICAL", 384, 387], ["DOI", "CHEMICAL", 384, 387], ["Human", "ORGANISM", 271, 276], ["meat", "ORGANISM_SUBDIVISION", 469, 473], ["S6", "PROTEIN", 320, 322], ["Human", "SPECIES", 271, 276], ["fig", "TEST", 409, 412]]], ["This will certainly be the most disastrous scenarios for primates and humans on Earth.", [["primates", "ORGANISM", 57, 65], ["humans", "ORGANISM", 70, 76], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76]]], ["From these population projections under different SSP scenarios, one can infer that unless sustainability measures associated with the SSP-1 scenario are adopted in the coming decade, the activities of the human population will exert harmful pressures on primates leading to a large number of species extinctions by as early as 2050.", [["human", "ORGANISM", 206, 211], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 206, 211], ["harmful pressures", "PROBLEM", 234, 251], ["large", "OBSERVATION_MODIFIER", 277, 282]]], ["However, it also is important to consider that while it is generally assumed that global biodiversity and sustainability policies should be designed to promote economic growth, a recent evaluation has pointed out that increased economic growth may not be required to protect biodiversity and increase human prosperity (IPBES, 2019; Otero et al., 2020) .CONCLUSIONS AND KEY CHALLENGES AHEADAs we have stressed throughout this manuscript, many historical, socio-economic, political, demographic and cultural factors, in addition to population size, affect patterns of resource consumption, environmental degradation and biodiversity loss.", [["biodiversity loss", "DISEASE", 618, 635], ["human", "ORGANISM", 301, 306], ["human", "SPECIES", 301, 306], ["human", "SPECIES", 301, 306], ["sustainability policies", "TREATMENT", 106, 129], ["a recent evaluation", "TEST", 177, 196], ["increased economic growth", "PROBLEM", 218, 243], ["cultural factors", "TEST", 497, 513], ["environmental degradation", "PROBLEM", 588, 613], ["biodiversity loss", "PROBLEM", 618, 635], ["global", "OBSERVATION_MODIFIER", 82, 88], ["biodiversity", "OBSERVATION", 89, 101], ["size", "OBSERVATION_MODIFIER", 541, 545], ["biodiversity loss", "OBSERVATION", 618, 635]]], ["The immediate challenges for primate conservation lie in developing sustainable methods of food production, reducing meat consumption, moving toward a greener lifestyle, limiting the threat of emerging diseases, implementing programs of reforestation, reducing food instability and income inequality, and better governance.", [["meat", "ANATOMY", 117, 121], ["food instability", "DISEASE", 261, 277], ["meat", "ORGANISM_SUBDIVISION", 117, 121], ["The immediate challenges", "TREATMENT", 0, 24], ["emerging diseases", "PROBLEM", 193, 210]]], ["That said, the increase in human population size predicted for Africa by the end of the century (estimated population size of 4 billion people), will have an extremely negative impact on primate population persistence, especially for Old World monkeys and apes, and will require very different solutions for environmental protection and human well-being than faced in other parts of the world.CONCLUSIONS AND KEY CHALLENGES AHEADOur review reveals that the well-being, health, and security of the human population in primate range countries is of paramount importance if we are to move forward with effective and long-lasting policies to promote primate conservation.", [["human", "ORGANISM", 27, 32], ["human", "ORGANISM", 337, 342], ["human", "ORGANISM", 497, 502], ["primate", "ORGANISM", 646, 653], ["human", "SPECIES", 27, 32], ["people", "SPECIES", 136, 142], ["monkeys", "SPECIES", 244, 251], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 497, 502], ["human", "SPECIES", 27, 32], ["Old World monkeys", "SPECIES", 234, 251], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 497, 502], ["the increase in human population size", "PROBLEM", 11, 48], ["very different solutions", "TREATMENT", 279, 303], ["environmental protection", "TREATMENT", 308, 332], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["size", "OBSERVATION_MODIFIER", 44, 48], ["size", "OBSERVATION_MODIFIER", 118, 122], ["negative", "OBSERVATION", 168, 176]]], ["However, high levels of poverty, inequality, food insecurity, and the loss of natural wealth triggered by weak governance, and corruption, along with widespread land-cover changes driven by profiteering and the global market demands of a small number of consumer nations and multinational corporations are the catalysts driving both the primate extinction crisis and the persistence of low human development and poverty (Estrada, Garber & Chaudhary, 2019) .", [["poverty", "DISEASE", 24, 31], ["food insecurity", "DISEASE", 45, 60], ["human", "ORGANISM", 390, 395], ["human", "SPECIES", 390, 395], ["human", "SPECIES", 390, 395], ["high", "OBSERVATION_MODIFIER", 9, 13], ["small", "OBSERVATION_MODIFIER", 238, 243], ["extinction crisis", "OBSERVATION", 345, 362], ["low human", "OBSERVATION_MODIFIER", 386, 395]]], ["According to the UN Department of Economic and Social Affairs, the human cost of climate change disasters will fall devastatingly on low-income and lowermiddle-income countries (UNDESA, 2019b).", [["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72]]], ["Most of these are primate range nations in Africa, South Asia, and Southeast Asia (Xu et al., 2020) .CONCLUSIONS AND KEY CHALLENGES AHEADSolutions to these challenges should involve global approaches to slow human population growth, advance health, lower poverty and improve education, empower women, develop sustainable land-use programs, maintain traditional ways of life of indigenous communities, and adopt green policies of food and natural resource production and consumption, as delineated in the UN Sustainable Development Goals (https://sustainabledevelopment.un.org/#) (Fig. 14) .", [["human", "ORGANISM", 208, 213], ["women", "ORGANISM", 294, 299], ["human", "SPECIES", 208, 213], ["women", "SPECIES", 294, 299], ["human", "SPECIES", 208, 213], ["slow human population growth", "PROBLEM", 203, 231]]], ["Based on the SSPs-1 model we can accomplish these goals, if global citizens and consumer nations adopt green environmental, economic, and social policies moving forward (Fig. 13) .CONCLUSIONS AND KEY CHALLENGES AHEADBy 2050, the global population is projected to surge from ca 8 to ca 10 billion, and estimates are that food production will need to rise from the current 8.4 billion tonnes per year to almost 13.5 billion tonnes (FAO, 2014) .", [["the SSPs", "TEST", 9, 17]]], ["The human population in primate range regions is projected to increase from ca 6 bn in 2018 to ca 8 bn by 2050 adding to the pressures of ensuring food security while at the same time preserving tropical forests to avoid extinctions (Davila & Dyball, 2018; Willett et al., 2019) .", [["human", "ORGANISM", 4, 9], ["primate", "ORGANISM", 24, 31], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human population", "TREATMENT", 0, 20], ["tropical forests", "TREATMENT", 195, 211], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["In the face of globalized market demands, we need global actions to limit the long-term environmental and economic footprint of overconsumption of natural resources from the tropics by citizens in a small number of developed nations as well as an imperative for governments of primate habitat countries to promote human development and well-being (Xu et al., 2020) .", [["human", "ORGANISM", 314, 319], ["human", "SPECIES", 314, 319], ["human", "SPECIES", 314, 319], ["global actions", "TREATMENT", 50, 64], ["primate habitat countries", "TREATMENT", 277, 302], ["small", "OBSERVATION_MODIFIER", 199, 204]]], ["This will require substantial changes in human behavior in order to provide economic opportunities for the world's poor by reducing our emphasis on global supply chains and promoting local food production, local manufacture, and local distribution of goods for local markets and consumers.", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["substantial changes in human behavior", "PROBLEM", 18, 55], ["global supply chains", "TREATMENT", 148, 168], ["local", "OBSERVATION_MODIFIER", 183, 188], ["food production", "OBSERVATION", 189, 204]]], ["Similarly, we must act to protect tropical forests and the ecosystem services on which agriculture and sustainable use of natural resources depend (FAO, 2014 (FAO, , 2017 (FAO, , 2018 (FAO, , 2019a (FAO, , 2019b Willett et al., 2019) .CONCLUSIONS AND KEY CHALLENGES AHEADWhile each region differs from each other in their primate richness and taxonomic diversity, countries in each region have several socioeconomic and sociopolitical traits in common.", [["tropical forests", "TREATMENT", 34, 50], ["several socioeconomic and sociopolitical traits in common", "PROBLEM", 394, 451], ["taxonomic diversity", "OBSERVATION", 343, 362], ["several", "OBSERVATION_MODIFIER", 394, 401], ["socioeconomic", "OBSERVATION_MODIFIER", 402, 415], ["sociopolitical traits", "OBSERVATION", 420, 441]]], ["Our review indicates that all primate range regions are losing tropical forests, and thus natural resources at an alarming rate.", [["tropical forests", "TREATMENT", 63, 79]]], ["Moreover, low human development, low levels of food security and low governance quality are predominant across these regions (Fig. 14) .CONCLUSIONS AND KEY CHALLENGES AHEADAlthough some primate conservation issues, such as climate change, are common to many primate range countries, it is also true that underlying causes of primate population decline vary from country to country, region to region, and differ across primate taxa.", [["human", "ORGANISM", 14, 19], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["low human development", "PROBLEM", 10, 31], ["some primate conservation issues", "PROBLEM", 181, 213], ["primate population decline", "PROBLEM", 325, 351], ["low human", "OBSERVATION_MODIFIER", 10, 19], ["low levels", "OBSERVATION_MODIFIER", 33, 43], ["low governance", "OBSERVATION_MODIFIER", 65, 79]]], ["Hence, each country will need to identify the set of effective conservation policies and practices required to conserve populations of primate species and their habitats.", [["primate", "ORGANISM", 135, 142]]], ["Moreover, political instability and within country and between country civil unrest are also factors that acting in synergy with other drivers, jeopardize primate conservation, human well-being and the integrity of protected areas (Hammill, 2020) .CONCLUSIONS AND KEY CHALLENGES AHEADDespite the collective actions of the world's countries and international institutions such as the IUCN, UN, World Bank and the UN International Court of Justice, among others, which have led to policies such as the International Convention on Biological diversity (https://www.cbd.int/) and the Paris Climate Agreement (https://unfccc.int/process-andmeetings/the-paris-agreement/the-paris-agreement), biodiversity continues to decline at an accelerated rate (IPBES, 2019).", [["human", "ORGANISM", 177, 182], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["political instability", "PROBLEM", 10, 31], ["jeopardize primate conservation", "TREATMENT", 144, 175], ["political instability", "OBSERVATION", 10, 31]]], ["If corrective measures are not soon implemented, we will reach a tipping point and lose our closest living biological relatives along with the complex ecosystem services and benefits they provide to forests and people.", [["people", "ORGANISM", 211, 217], ["people", "SPECIES", 211, 217], ["corrective measures", "TREATMENT", 3, 22]]], ["We also will lose the social, historical, and cultural relationships that have persisted between human primates and nonhuman primates over millennia (Chandra, 2017; Fuentes, 2012; Voigt et al., 2018) .CONCLUSIONS AND KEY CHALLENGES AHEADMoreover, in any discussion of the conservation of natural resources, we need to consider the role played by Indigenous Peoples.", [["human", "ORGANISM", 97, 102], ["nonhuman primates", "ORGANISM", 116, 133], ["human", "SPECIES", 97, 102], ["human primates", "SPECIES", 97, 111]]], ["Indigenous People inhabit a quarter of the world's land area and many live in biologically vulnerable environments (e.g., rain forests).", [["People", "SPECIES", 11, 17]]], ["Acknowledging and protecting the rights of Indigenous Peoples' to their lands and traditional ways of life are critical if we are to maintain local, regional, and global biodiversity and achieve primate conservation targets (Garnett et al., 2018) .CONCLUSIONS AND KEY CHALLENGES AHEADOur review indicates that as human populations are expanding across primate range regions, high levels of poverty, food insecurity and income inequality, among other forces, directly or indirectly, weaken the ability of primate habitat countries to protect tropical forests and biodiversity (Fig. 14) .", [["poverty", "DISEASE", 390, 397], ["food insecurity", "DISEASE", 399, 414], ["human", "ORGANISM", 313, 318], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 313, 318], ["tropical forests", "TREATMENT", 541, 557]]], ["The world community must adopt green technologies and green policies that improve the lives and well-being of poor-and middle-income people and contribute to protect their natural environment.", [["people", "ORGANISM", 133, 139], ["people", "SPECIES", 133, 139]]], ["We are at a historic moment in which urgent local and global action must be taken to reverse the impending extinction of the world's primates (Estrada et al., 2017) .", [["primates", "ORGANISM", 133, 141]]], ["If we can put in place the changes required to save the world's primates, then we will have put the changes in place to save humans as well.", [["primates", "ORGANISM", 64, 72], ["humans", "ORGANISM", 125, 131], ["humans", "SPECIES", 125, 131], ["humans", "SPECIES", 125, 131]]]], "PMC7250611": [["IntroductionTabular data in the form of CSV files is the common input format in a data analytics pipeline.", [["IntroductionTabular data", "TEST", 0, 24]]], ["However, there does not exist a common framework to conduct a systematic evaluation of these systems, which leads to experimental results that are not easy to compare as they use different notions for true/false positives and performance measures.", [["a systematic evaluation", "TEST", 60, 83], ["true/false positives", "PROBLEM", 201, 221], ["false positives", "OBSERVATION", 206, 221]]], ["Furthermore, available datasets are either small in size (e.g., [19, 20]) or low in quality and messy (e.g., [8]).", [["small in size", "PROBLEM", 43, 56], ["small", "OBSERVATION_MODIFIER", 43, 48], ["size", "OBSERVATION_MODIFIER", 52, 56]]], ["The creation of the Semantic Web Challenge on Tabular Data to Knowledge Graph Matching (SemTab) [12] aims at filling this gap.IntroductionThe main contributions of this paper are summarized as follows:(i) We introduce an automated method for generating benchmark datasets for tabular data to KG matching.(ii) We release 4 generated benchmark datasets (see Zenodo repository [13]), and the code for evaluating the systems results (see GitHub repository [3]).(iii) We report and analyze the results of the systems that participated in the first edition of the SemTab challenge, using our 4 benchmark datasets.", [["the SemTab challenge", "TREATMENT", 554, 574], ["main", "OBSERVATION_MODIFIER", 142, 146]]]], "PMC7492684": [], "PMC7470731": [["IntroductionPatients with Corona virus disease 2019 (COVID-19) have been reported prone to develop thrombotic and thromboembolic disease [[1], [2], [3], [4]].", [["Corona virus disease", "DISEASE", 26, 46], ["thrombotic and thromboembolic disease", "DISEASE", 99, 136], ["Corona virus", "ORGANISM", 26, 38], ["[2], [3], [4]]", "SIMPLE_CHEMICAL", 143, 157], ["Corona virus disease", "PROBLEM", 26, 46], ["COVID", "TEST", 53, 58], ["thrombotic and thromboembolic disease", "PROBLEM", 99, 136], ["Corona virus", "ANATOMY", 26, 38], ["thrombotic", "OBSERVATION", 99, 109], ["thromboembolic", "OBSERVATION", 114, 128]]], ["Microthrombosis has been suggested to contribute to both respiratory failure and neurological complications [5,6] and emerging data describe coagulation abnormalities as a marker of poor prognosis [[7], [8], [9]].IntroductionLow molecular weight heparins (LMWH) are often prescribed to decrease the risk of thromboembolic complications in hospitalized patients and treatment with LMWH was recently shown to reduce mortality in high-risk patients with COVID-19 [10].", [["respiratory", "ANATOMY", 57, 68], ["neurological", "ANATOMY", 81, 93], ["Microthrombosis", "DISEASE", 0, 15], ["respiratory failure", "DISEASE", 57, 76], ["neurological complications", "DISEASE", 81, 107], ["coagulation abnormalities", "DISEASE", 141, 166], ["LMWH", "CHEMICAL", 256, 260], ["thromboembolic", "DISEASE", 307, 321], ["LMWH", "CHEMICAL", 380, 384], ["COVID-19", "CHEMICAL", 451, 459], ["[8], [9]", "SIMPLE_CHEMICAL", 203, 211], ["IntroductionLow molecular weight heparins", "SIMPLE_CHEMICAL", 213, 254], ["LMWH", "SIMPLE_CHEMICAL", 256, 260], ["patients", "ORGANISM", 352, 360], ["LMWH", "SIMPLE_CHEMICAL", 380, 384], ["patients", "ORGANISM", 437, 445], ["patients", "SPECIES", 352, 360], ["patients", "SPECIES", 437, 445], ["Microthrombosis", "PROBLEM", 0, 15], ["both respiratory failure", "PROBLEM", 52, 76], ["neurological complications", "PROBLEM", 81, 107], ["coagulation abnormalities", "PROBLEM", 141, 166], ["poor prognosis", "PROBLEM", 182, 196], ["IntroductionLow molecular weight heparins (LMWH)", "TREATMENT", 213, 261], ["thromboembolic complications", "PROBLEM", 307, 335], ["treatment", "TREATMENT", 365, 374], ["LMWH", "TREATMENT", 380, 384], ["COVID", "TEST", 451, 456], ["suggested to contribute to", "UNCERTAINTY", 25, 51], ["both", "OBSERVATION_MODIFIER", 52, 56], ["respiratory failure", "OBSERVATION", 57, 76], ["thromboembolic", "OBSERVATION_MODIFIER", 307, 321], ["complications", "OBSERVATION", 322, 335]]], ["However, data is limited on the mechanisms underlying the coagulation deficits associated with COVID-19 and how they are affected by LMWH.IntroductionThromboelastography (TEG) offers a comprehensive assessment of coagulation in whole blood samples, describing plasmatic coagulation as well as platelet function and fibrinolysis.", [["whole blood samples", "ANATOMY", 228, 247], ["platelet", "ANATOMY", 293, 301], ["coagulation deficits", "DISEASE", 58, 78], ["COVID-19", "CHEMICAL", 95, 103], ["LMWH", "CHEMICAL", 133, 137], ["COVID-19", "CHEMICAL", 95, 103], ["LMWH", "SIMPLE_CHEMICAL", 133, 137], ["blood samples", "ORGANISM_SUBSTANCE", 234, 247], ["plasmatic", "ORGANISM_SUBSTANCE", 260, 269], ["platelet", "CELL", 293, 301], ["the coagulation deficits", "PROBLEM", 54, 78], ["COVID", "TEST", 95, 100], ["IntroductionThromboelastography (TEG", "TEST", 138, 174], ["a comprehensive assessment", "TEST", 183, 209], ["coagulation in whole blood samples", "TEST", 213, 247], ["plasmatic coagulation", "TEST", 260, 281], ["platelet function", "TEST", 293, 310], ["fibrinolysis", "PROBLEM", 315, 327], ["coagulation", "OBSERVATION", 58, 69], ["LMWH", "OBSERVATION", 133, 137], ["fibrinolysis", "OBSERVATION", 315, 327]]], ["Furthermore, the addition of heparinase to the sample eliminates the iatrogenic heparin effect in blood samples thus allowing estimation of the effect of LMWH.IntroductionThe aim was to characterize coagulation abnormalities and the effect of LMWH with respect to TEG profile with and without heparinase, anti-factor Xa activity and clinical manifestations (i.e. bleeding and thrombosis) in 31 COVID-19 patients admitted to intensive care units at Uppsala University Hospital, Uppsala, Sweden.Data collection and patient groups ::: Materials and methodsAll adult patients with COVID-19 consecutively admitted to the ICU March 13th to April 14th 2020 with informed consent and routinely performed TEG results accessible were included in the study.", [["sample", "ANATOMY", 47, 53], ["blood samples", "ANATOMY", 98, 111], ["heparin", "CHEMICAL", 80, 87], ["LMWH", "CHEMICAL", 154, 158], ["coagulation abnormalities", "DISEASE", 199, 224], ["LMWH", "CHEMICAL", 243, 247], ["bleeding", "DISEASE", 363, 371], ["thrombosis", "DISEASE", 376, 386], ["heparinase", "GENE_OR_GENE_PRODUCT", 29, 39], ["heparin", "SIMPLE_CHEMICAL", 80, 87], ["blood samples", "ORGANISM_SUBSTANCE", 98, 111], ["LMWH", "SIMPLE_CHEMICAL", 154, 158], ["LMWH", "SIMPLE_CHEMICAL", 243, 247], ["heparinase", "GENE_OR_GENE_PRODUCT", 293, 303], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 305, 319], ["patients", "ORGANISM", 403, 411], ["patient", "ORGANISM", 513, 520], ["patients", "ORGANISM", 563, 571], ["heparinase", "PROTEIN", 29, 39], ["TEG", "PROTEIN", 264, 267], ["heparinase", "PROTEIN", 293, 303], ["anti-factor Xa", "PROTEIN", 305, 319], ["TEG", "PROTEIN", 696, 699], ["patients", "SPECIES", 403, 411], ["patient", "SPECIES", 513, 520], ["patients", "SPECIES", 563, 571], ["heparinase", "TREATMENT", 29, 39], ["the iatrogenic heparin effect", "TREATMENT", 65, 94], ["blood samples", "TEST", 98, 111], ["LMWH", "TREATMENT", 154, 158], ["coagulation abnormalities", "PROBLEM", 199, 224], ["LMWH", "TREATMENT", 243, 247], ["TEG profile", "TEST", 264, 275], ["heparinase", "TREATMENT", 293, 303], ["anti-factor Xa activity", "PROBLEM", 305, 328], ["clinical manifestations", "PROBLEM", 333, 356], ["bleeding", "PROBLEM", 363, 371], ["thrombosis", "PROBLEM", 376, 386], ["the study", "TEST", 736, 745], ["iatrogenic", "OBSERVATION_MODIFIER", 69, 79], ["heparin", "OBSERVATION", 80, 87], ["LMWH", "OBSERVATION", 154, 158], ["thrombosis", "OBSERVATION", 376, 386]]], ["COVID-19 was diagnosed with positive reverse-transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swabs.Data collection and patient groups ::: Materials and methodsDalteparin (Fragmin\u00ae, Pfizer AB, Sollentuna, Sweden) subcutaneously was used for thrombosis prophylaxis.", [["nasopharyngeal swabs", "ANATOMY", 97, 117], ["subcutaneously", "ANATOMY", 231, 245], ["Dalteparin", "CHEMICAL", 178, 188], ["Fragmin\u00ae", "CHEMICAL", 190, 198], ["thrombosis", "DISEASE", 259, 269], ["Dalteparin", "CHEMICAL", 178, 188], ["Fragmin\u00ae", "CHEMICAL", 190, 198], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 97, 117], ["patient", "ORGANISM", 138, 145], ["Dalteparin", "SIMPLE_CHEMICAL", 178, 188], ["Fragmin\u00ae", "SIMPLE_CHEMICAL", 190, 198], ["COVID-19", "DNA", 0, 8], ["patient", "SPECIES", 138, 145], ["COVID", "TEST", 0, 5], ["positive reverse-transcription polymerase chain reaction", "PROBLEM", 28, 84], ["RT-PCR", "TEST", 86, 92], ["nasopharyngeal swabs", "TREATMENT", 97, 117], ["Materials", "TREATMENT", 157, 166], ["methodsDalteparin", "TREATMENT", 171, 188], ["Fragmin\u00ae", "TREATMENT", 190, 198], ["Pfizer AB, Sollentuna, Sweden)", "TREATMENT", 200, 230], ["thrombosis prophylaxis", "TREATMENT", 259, 281], ["nasopharyngeal swabs", "ANATOMY", 97, 117], ["thrombosis", "OBSERVATION", 259, 269]]], ["COVID-19 patients with body weight below 70 kg were given 5000 IU dalteparin, those with body weight 70\u201390 kg were given 7500 IU dalteparin and those above 90 kg were given 10,000 IU dalteparin.", [["body", "ANATOMY", 23, 27], ["body", "ANATOMY", 89, 93], ["dalteparin", "CHEMICAL", 66, 76], ["dalteparin", "CHEMICAL", 129, 139], ["dalteparin", "CHEMICAL", 183, 193], ["dalteparin", "CHEMICAL", 66, 76], ["dalteparin", "CHEMICAL", 129, 139], ["dalteparin", "CHEMICAL", 183, 193], ["patients", "ORGANISM", 9, 17], ["body", "ORGANISM_SUBDIVISION", 23, 27], ["dalteparin", "SIMPLE_CHEMICAL", 66, 76], ["body", "ORGANISM_SUBDIVISION", 89, 93], ["dalteparin", "SIMPLE_CHEMICAL", 129, 139], ["dalteparin", "SIMPLE_CHEMICAL", 183, 193], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["body weight", "TEST", 23, 34], ["dalteparin", "TREATMENT", 66, 76], ["body weight", "TEST", 89, 100], ["dalteparin", "TREATMENT", 129, 139], ["dalteparin", "TREATMENT", 183, 193]]], ["The anti-factor Xa target range for thrombosis prophylaxis was 0.2\u20130.4 kIU/L. [11]Data collection and patient groups ::: Materials and methodsClinical data were recorded prospectively daily.", [["thrombosis", "DISEASE", 36, 46], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 4, 18], ["patient", "ORGANISM", 102, 109], ["anti-factor Xa", "PROTEIN", 4, 18], ["patient", "SPECIES", 102, 109], ["The anti-factor Xa", "TREATMENT", 0, 18], ["thrombosis prophylaxis", "TREATMENT", 36, 58], ["Clinical data", "TEST", 142, 155], ["thrombosis", "OBSERVATION", 36, 46]]], ["Simplified acute physiology score 3 (SAPS3) [12], renal function, circulatory support and respiratory support data were collected as reported in the results.", [["renal", "ANATOMY", 50, 55], ["renal", "ORGAN", 50, 55], ["Simplified acute physiology score", "PROBLEM", 0, 33], ["renal function", "TEST", 50, 64], ["circulatory support", "TREATMENT", 66, 85], ["respiratory support data", "TEST", 90, 114], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["renal", "ANATOMY", 50, 55], ["circulatory", "ANATOMY", 66, 77]]], ["Blood samples were collected on ICU admission and daily during the ICU stay.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13]]], ["Blood count (CBC), high sensitivity C-reactive protein (CRP), kidney and liver function tests were performed.", [["Blood", "ANATOMY", 0, 5], ["kidney", "ANATOMY", 62, 68], ["liver", "ANATOMY", 73, 78], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 36, 54], ["CRP", "GENE_OR_GENE_PRODUCT", 56, 59], ["kidney", "ORGAN", 62, 68], ["liver", "ORGAN", 73, 78], ["high sensitivity C-reactive protein", "PROTEIN", 19, 54], ["CRP", "PROTEIN", 56, 59], ["Blood count", "TEST", 0, 11], ["CBC", "TEST", 13, 16], ["high sensitivity C", "TEST", 19, 37], ["reactive protein", "TEST", 38, 54], ["CRP", "TEST", 56, 59], ["kidney and liver function tests", "TEST", 62, 93], ["kidney", "ANATOMY", 62, 68], ["liver", "ANATOMY", 73, 78]]], ["CBC was analyzed on a Sysmex XN\u2122 instrument (Sysmex, Kobe, Japan) while hsCRP, ferritin, kidney and liver markers were analyzed on an Architect ci16200 (Abbott Laboratories, Abbott Park, IL, US).Coagulation tests ::: Materials and methodsThe viscoelastic properties were analyzed using the TEG 6 s\u00ae platform (Haemonetics, Boston, MA), [13] the citrated multichannel cartridge facilitates the simultaneous performance of the citrated kaolin (CK), citrated kaolin with heparinase (CKH), citrated rapidTEG\u00ae (CRT), and citrated functional fibrinogen (CFF) assays.", [["kidney", "ANATOMY", 89, 95], ["liver", "ANATOMY", 100, 105], ["kaolin", "CHEMICAL", 433, 439], ["CBC", "CELL", 0, 3], ["hsCRP", "GENE_OR_GENE_PRODUCT", 72, 77], ["ferritin", "GENE_OR_GENE_PRODUCT", 79, 87], ["kidney", "ORGAN", 89, 95], ["liver", "ORGAN", 100, 105], ["kaolin", "SIMPLE_CHEMICAL", 433, 439], ["CK", "SIMPLE_CHEMICAL", 441, 443], ["citrated kaolin", "SIMPLE_CHEMICAL", 446, 461], ["heparinase", "SIMPLE_CHEMICAL", 467, 477], ["CKH", "SIMPLE_CHEMICAL", 479, 482], ["citrated rapidTEG\u00ae", "SIMPLE_CHEMICAL", 485, 503], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 535, 545], ["hsCRP", "PROTEIN", 72, 77], ["ferritin", "PROTEIN", 79, 87], ["kidney and liver markers", "PROTEIN", 89, 113], ["citrated kaolin", "PROTEIN", 424, 439], ["CK", "PROTEIN", 441, 443], ["citrated kaolin", "PROTEIN", 446, 461], ["heparinase", "PROTEIN", 467, 477], ["CKH", "PROTEIN", 479, 482], ["citrated rapidTEG\u00ae", "PROTEIN", 485, 503], ["CRT", "PROTEIN", 505, 508], ["citrated functional fibrinogen", "PROTEIN", 515, 545], ["CFF", "PROTEIN", 547, 550], ["CBC", "TEST", 0, 3], ["a Sysmex", "TEST", 20, 28], ["instrument", "TEST", 33, 43], ["Sysmex", "TEST", 45, 51], ["hsCRP", "TEST", 72, 77], ["ferritin", "TEST", 79, 87], ["liver markers", "TEST", 100, 113], ["Coagulation tests", "TEST", 195, 212], ["the TEG", "TEST", 286, 293], ["the citrated multichannel cartridge", "TREATMENT", 340, 375], ["the citrated kaolin", "TREATMENT", 420, 439], ["citrated kaolin", "TREATMENT", 446, 461], ["heparinase (CKH", "TREATMENT", 467, 482], ["citrated rapidTEG", "TEST", 485, 502], ["CRT", "TEST", 505, 508], ["citrated functional fibrinogen (CFF) assays", "TEST", 515, 558], ["kidney", "ANATOMY", 89, 95], ["liver", "ANATOMY", 100, 105]]], ["R-time (R), angle (A), maximal amplitude (MA), and lysis at 30 min (Lys30) from the standard (kaolin) and heparinase curves were analyzed.Coagulation tests ::: Materials and methodsInternational Normalized Ratio (INR), activated partial thromboplastin time, anti-factor Xa and Fibrin D-dimer were all analyzed on a STA-R Max2 (Stago, Asni\u00e8res-sur-Seine, France).", [["thromboplastin", "GENE_OR_GENE_PRODUCT", 237, 251], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 258, 272], ["Fibrin D-dimer", "GENE_OR_GENE_PRODUCT", 277, 291], ["INR", "PROTEIN", 213, 216], ["anti-factor Xa", "PROTEIN", 258, 272], ["Fibrin D-dimer", "PROTEIN", 277, 291], ["lysis", "TREATMENT", 51, 56], ["the standard (kaolin)", "TREATMENT", 80, 101], ["heparinase curves", "TREATMENT", 106, 123], ["Coagulation tests", "TEST", 138, 155], ["methods", "TEST", 174, 181], ["Ratio", "TEST", 206, 211], ["INR", "TEST", 213, 216], ["activated partial thromboplastin time", "TREATMENT", 219, 256], ["anti-factor Xa", "TEST", 258, 272], ["Fibrin D-dimer", "TEST", 277, 291], ["a STA", "TEST", 313, 318], ["Stago", "TEST", 327, 332], ["Asni\u00e8res", "TEST", 334, 342]]], ["The reagent used for the PK/INR method was STA SPA+ from Stago, Catalogue number 00330 STA.", [["PK", "GENE_OR_GENE_PRODUCT", 25, 27], ["The reagent", "TREATMENT", 0, 11], ["the PK/INR method", "TEST", 21, 38], ["STA SPA", "PROBLEM", 43, 50]]], ["The reagent is used for determination of the combined Factors II, VII and X. Coagulation samples were taken every morning except anti-factor Xa which was taken approximately 4 h after subcutaneous injection of dalteparin.", [["samples", "ANATOMY", 89, 96], ["subcutaneous", "ANATOMY", 184, 196], ["dalteparin", "CHEMICAL", 210, 220], ["dalteparin", "CHEMICAL", 210, 220], ["VII", "GENE_OR_GENE_PRODUCT", 66, 69], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 129, 143], ["dalteparin", "SIMPLE_CHEMICAL", 210, 220], ["VII", "PROTEIN", 66, 69], ["anti-factor Xa", "PROTEIN", 129, 143], ["Coagulation samples", "TEST", 77, 96], ["anti-factor Xa", "TREATMENT", 129, 143], ["dalteparin", "TREATMENT", 210, 220]]], ["The limit of quantification for the anti-factor Xa assay was 0.1 kIU/L and the total coefficient of variation was 4.5% at 0.56 kIU/L. The limits of quantification for the D-dimer assay was 0.27 mg/L and the total coefficient of variation was 4.2% at 2.16 mg/L.Statistical analysis ::: Materials and methodsContinuous variables are presented as median (IQR, interquartile range) and categorical variables as number of observations (percent of total number of observations).", [["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 36, 50], ["anti-factor Xa", "PROTEIN", 36, 50], ["the anti-factor Xa assay", "TEST", 32, 56], ["the D-dimer assay", "TEST", 167, 184]]], ["Mann-Whitney U test was used for group comparisons and Spearman Rank to assess correlation between variables.", [["Spearman Rank", "DNA", 55, 68], ["Whitney U test", "TEST", 5, 19], ["group comparisons", "TEST", 33, 50], ["Spearman Rank", "TEST", 55, 68]]], ["Repeated tests were compared using Skillings-Mack test.", [["Repeated tests", "TEST", 0, 14], ["Skillings", "TEST", 35, 44], ["Mack test", "TEST", 45, 54]]], ["Calculations were performed using Statistica (version 13.2, Stat.", [["Stat", "PROTEIN", 60, 64], ["Calculations", "TEST", 0, 12], ["Statistica (version", "TEST", 34, 53]]], ["Inc. Tulsa, OK, USA) and Stata (version 15.1, StataCorp, College Station, TX, USA).ResultsA total of 31 patients diagnosed with COVID-19 treated in ICU were enrolled in the study.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["COVID", "TEST", 128, 133], ["the study", "TEST", 169, 178]]], ["Characteristics of patients with and without thromboembolic events in the study cohort are listed in Table 1.", [["thromboembolic", "DISEASE", 45, 59], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["thromboembolic events", "PROBLEM", 45, 66], ["the study", "TEST", 70, 79], ["without", "UNCERTAINTY", 37, 44], ["thromboembolic", "OBSERVATION", 45, 59]]], ["Most patients were male and the median BMI in the cohort was 30.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["One fourth of the cohort had a history of smoking, but ongoing smoking was unusual.", [["smoking", "CHEMICAL", 42, 49], ["smoking", "CHEMICAL", 63, 70]]], ["The most common comorbidities were hypertension, diabetes mellitus and chronic lung disease.ResultsThe median ICU admission was 10 days after the initial COVID-19 symptoms.", [["lung", "ANATOMY", 79, 83], ["hypertension", "DISEASE", 35, 47], ["diabetes mellitus", "DISEASE", 49, 66], ["chronic lung disease", "DISEASE", 71, 91], ["lung", "ORGAN", 79, 83], ["hypertension", "PROBLEM", 35, 47], ["diabetes mellitus", "PROBLEM", 49, 66], ["chronic lung disease", "PROBLEM", 71, 91], ["the initial COVID-19 symptoms", "PROBLEM", 142, 171], ["hypertension", "OBSERVATION", 35, 47], ["diabetes mellitus", "OBSERVATION", 49, 66], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["lung", "ANATOMY", 79, 83], ["disease", "OBSERVATION", 84, 91]]], ["During their ICU stay 24 patients (77%) were subjected to invasive ventilation and 25 patients (81%) were treated with vasopressors (noradrenalin) at some point.ResultsFive patients developed clinical symptomatic thromboembolic events, (four with pulmonary embolism and one with deep vein thrombosis), all thromboembolic events diagnosed day 11\u201316 after onset of COVID-19 symptoms.", [["pulmonary", "ANATOMY", 247, 256], ["deep vein", "ANATOMY", 279, 288], ["noradrenalin", "CHEMICAL", 133, 145], ["thromboembolic", "DISEASE", 213, 227], ["pulmonary embolism", "DISEASE", 247, 265], ["deep vein thrombosis", "DISEASE", 279, 299], ["thromboembolic", "DISEASE", 306, 320], ["noradrenalin", "CHEMICAL", 133, 145], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 86, 94], ["noradrenalin", "SIMPLE_CHEMICAL", 133, 145], ["patients", "ORGANISM", 173, 181], ["pulmonary", "ORGAN", 247, 256], ["deep vein", "MULTI-TISSUE_STRUCTURE", 279, 288], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 173, 181], ["invasive ventilation", "TREATMENT", 58, 78], ["vasopressors", "TREATMENT", 119, 131], ["noradrenalin", "TREATMENT", 133, 145], ["clinical symptomatic thromboembolic events", "PROBLEM", 192, 234], ["pulmonary embolism", "PROBLEM", 247, 265], ["deep vein thrombosis", "PROBLEM", 279, 299], ["all thromboembolic events", "PROBLEM", 302, 327], ["COVID-19 symptoms", "PROBLEM", 363, 380], ["symptomatic", "OBSERVATION_MODIFIER", 201, 212], ["thromboembolic", "OBSERVATION", 213, 227], ["pulmonary", "ANATOMY", 247, 256], ["embolism", "OBSERVATION", 257, 265], ["deep", "ANATOMY_MODIFIER", 279, 283], ["vein", "ANATOMY", 284, 288], ["thrombosis", "OBSERVATION", 289, 299], ["thromboembolic", "OBSERVATION", 306, 320]]], ["No clinically significant bleeding was registered.", [["bleeding", "DISEASE", 26, 34], ["clinically significant bleeding", "PROBLEM", 3, 34], ["clinically", "OBSERVATION_MODIFIER", 3, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["bleeding", "OBSERVATION", 26, 34]]], ["Patients developing thromboembolism had a shorter activated partial thromboplastin time (APTT) and higher D-dimer compared to patients not developing thromboembolism.", [["thromboembolism", "DISEASE", 20, 35], ["thromboembolism", "DISEASE", 150, 165], ["Patients", "ORGANISM", 0, 8], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 68, 82], ["D-dimer", "GENE_OR_GENE_PRODUCT", 106, 113], ["patients", "ORGANISM", 126, 134], ["APTT", "PROTEIN", 89, 93], ["D-dimer", "PROTEIN", 106, 113], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 126, 134], ["Patients developing thromboembolism", "PROBLEM", 0, 35], ["a shorter activated partial thromboplastin time", "PROBLEM", 40, 87], ["APTT", "TEST", 89, 93], ["higher D-dimer", "PROBLEM", 99, 113], ["thromboembolism", "PROBLEM", 150, 165], ["thromboembolism", "OBSERVATION", 20, 35], ["thromboembolism", "OBSERVATION", 150, 165]]], ["There were no differences in INR or platelet count.", [["platelet", "ANATOMY", 36, 44], ["platelet", "CELL", 36, 44], ["INR", "PROTEIN", 29, 32], ["INR", "TEST", 29, 32], ["platelet count", "TEST", 36, 50], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["platelet count", "OBSERVATION", 36, 50]]], ["Comparison of coagulation markers are listed in Table 2.", [["coagulation markers", "PROTEIN", 14, 33], ["coagulation markers", "TEST", 14, 33]]], ["Out of 31 patients included in the study, 20 had elevated MA on TEG.", [["patients", "ORGANISM", 10, 18], ["MA", "GENE_OR_GENE_PRODUCT", 58, 60], ["TEG", "PROTEIN", 64, 67], ["patients", "SPECIES", 10, 18], ["the study", "TEST", 31, 40], ["elevated MA", "PROBLEM", 49, 60], ["TEG", "TEST", 64, 67]]], ["There were no differences in TEG variables in patients with or without thromboembolic events.", [["thromboembolic", "DISEASE", 71, 85], ["patients", "ORGANISM", 46, 54], ["TEG", "PROTEIN", 29, 32], ["patients", "SPECIES", 46, 54], ["TEG variables", "TEST", 29, 42], ["thromboembolic events", "PROBLEM", 71, 92], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["without", "UNCERTAINTY", 63, 70], ["thromboembolic", "OBSERVATION", 71, 85]]], ["All patients had a MA > 65 mm, while 23 patients (74%) had MA > 69 mm and 13 (42%) had MA > 72 mm at some point during ICU stay.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 40, 48], ["a MA", "TEST", 17, 21], ["MA", "TEST", 59, 61], ["MA", "TEST", 87, 89]]], ["No signs of increased thrombolysis were seen.ResultsNo major changes were seen in laboratory variables during the ICU stay, except for decreasing CRP (Table 3).ResultsIn the patients without thromboembolic events, i.e. with prophylaxis dose of dalteparin, 6 of the 26 (23%) had an anti-factor Xa at least once below the target range, while 12 of 26 (46%) had and anti-factor Xa at least once above the target range.", [["thromboembolic", "DISEASE", 191, 205], ["dalteparin", "CHEMICAL", 244, 254], ["dalteparin", "CHEMICAL", 244, 254], ["CRP", "GENE_OR_GENE_PRODUCT", 146, 149], ["patients", "ORGANISM", 174, 182], ["dalteparin", "SIMPLE_CHEMICAL", 244, 254], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 281, 295], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 363, 377], ["CRP", "PROTEIN", 146, 149], ["anti-factor Xa", "PROTEIN", 281, 295], ["anti-factor Xa", "PROTEIN", 363, 377], ["patients", "SPECIES", 174, 182], ["increased thrombolysis", "PROBLEM", 12, 34], ["major changes", "PROBLEM", 55, 68], ["decreasing CRP", "PROBLEM", 135, 149], ["thromboembolic events", "PROBLEM", 191, 212], ["dalteparin", "TREATMENT", 244, 254], ["an anti-factor Xa", "TREATMENT", 278, 295], ["anti-factor Xa", "TEST", 363, 377], ["signs of", "UNCERTAINTY", 3, 11], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["thrombolysis", "OBSERVATION", 22, 34], ["without", "UNCERTAINTY", 183, 190], ["thromboembolic", "OBSERVATION", 191, 205]]], ["There was no correlation between dalteparin dose and anti-factor Xa (Fig. 1).DiscussionIn this cohort study of 31 COVID-19 patients admitted to intensive care, a majority of patients show a hyper-coagulopathic phenotype during the course of illness.", [["dalteparin", "CHEMICAL", 33, 43], ["illness", "DISEASE", 241, 248], ["dalteparin", "CHEMICAL", 33, 43], ["dalteparin", "SIMPLE_CHEMICAL", 33, 43], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 53, 67], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 174, 182], ["anti-factor Xa", "PROTEIN", 53, 67], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 174, 182], ["dalteparin dose", "TREATMENT", 33, 48], ["anti-factor Xa", "TREATMENT", 53, 67], ["this cohort study", "TEST", 90, 107], ["a hyper-coagulopathic phenotype", "PROBLEM", 188, 219], ["illness", "PROBLEM", 241, 248], ["hyper", "OBSERVATION", 190, 195], ["coagulopathic phenotype", "OBSERVATION", 196, 219]]], ["Further, standard prophylactic doses of LMWH may be insufficient to protect patients from thromboembolic complications.", [["LMWH", "CHEMICAL", 40, 44], ["thromboembolic", "DISEASE", 90, 104], ["LMWH", "SIMPLE_CHEMICAL", 40, 44], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["standard prophylactic doses of LMWH", "TREATMENT", 9, 44], ["thromboembolic complications", "PROBLEM", 90, 118], ["thromboembolic", "OBSERVATION", 90, 104]]], ["Analysis of anti-factor Xa activity and TEG appear inadequate to monitor the effect of LMWH in these patients.DiscussionThe increased risk of thromboembolic complications in COVID-19 has been widely discussed, and early reports have indicated an associated coagulation abnormality predisposing thromboembolic disease.", [["LMWH", "CHEMICAL", 87, 91], ["thromboembolic", "DISEASE", 142, 156], ["COVID-19", "CHEMICAL", 174, 182], ["coagulation abnormality", "DISEASE", 257, 280], ["thromboembolic disease", "DISEASE", 294, 316], ["COVID-19", "CHEMICAL", 174, 182], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 12, 26], ["TEG", "GENE_OR_GENE_PRODUCT", 40, 43], ["LMWH", "SIMPLE_CHEMICAL", 87, 91], ["patients", "ORGANISM", 101, 109], ["anti-factor Xa", "PROTEIN", 12, 26], ["TEG", "PROTEIN", 40, 43], ["patients", "SPECIES", 101, 109], ["Analysis", "TEST", 0, 8], ["anti-factor Xa activity", "TEST", 12, 35], ["TEG", "TEST", 40, 43], ["LMWH", "TREATMENT", 87, 91], ["thromboembolic complications", "PROBLEM", 142, 170], ["COVID", "TEST", 174, 179], ["an associated coagulation abnormality", "PROBLEM", 243, 280], ["thromboembolic disease", "PROBLEM", 294, 316], ["LMWH", "OBSERVATION", 87, 91], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["thromboembolic", "OBSERVATION_MODIFIER", 142, 156], ["complications", "OBSERVATION", 157, 170], ["coagulation", "OBSERVATION", 257, 268], ["thromboembolic disease", "OBSERVATION", 294, 316]]], ["Standard coagulation parameters classically show marked elevation of fibrin-D-dimer, marginal increases in prothrombin time and slight thrombocytopenia [7].", [["thrombocytopenia", "DISEASE", 135, 151], ["fibrin", "GENE_OR_GENE_PRODUCT", 69, 75], ["D-dimer", "SIMPLE_CHEMICAL", 76, 83], ["prothrombin", "GENE_OR_GENE_PRODUCT", 107, 118], ["fibrin", "PROTEIN", 69, 75], ["D-dimer", "PROTEIN", 76, 83], ["prothrombin", "PROTEIN", 107, 118], ["Standard coagulation parameters", "TEST", 0, 31], ["marked elevation of fibrin-D-dimer", "PROBLEM", 49, 83], ["marginal increases", "PROBLEM", 85, 103], ["prothrombin time", "TEST", 107, 123], ["slight thrombocytopenia", "PROBLEM", 128, 151], ["marked", "OBSERVATION_MODIFIER", 49, 55], ["elevation", "OBSERVATION_MODIFIER", 56, 65], ["fibrin", "OBSERVATION", 69, 75], ["marginal", "OBSERVATION_MODIFIER", 85, 93], ["increases", "OBSERVATION_MODIFIER", 94, 103], ["prothrombin time", "OBSERVATION_MODIFIER", 107, 123], ["slight", "OBSERVATION_MODIFIER", 128, 134], ["thrombocytopenia", "OBSERVATION", 135, 151]]], ["In addition, Ranucci et al. recently demonstrated increased clot strength with significant platelet and fibrinogen contribution [14].DiscussionThe present study reports the results of 31 patients using TEG, showing that hypercoagulability is a general feature across this population.", [["clot", "ANATOMY", 60, 64], ["platelet", "ANATOMY", 91, 99], ["hypercoagulability", "DISEASE", 220, 238], ["clot", "ORGANISM_SUBSTANCE", 60, 64], ["platelet", "CELL", 91, 99], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 104, 114], ["patients", "ORGANISM", 187, 195], ["fibrinogen", "PROTEIN", 104, 114], ["TEG", "PROTEIN", 202, 205], ["patients", "SPECIES", 187, 195], ["increased clot strength", "PROBLEM", 50, 73], ["significant platelet", "PROBLEM", 79, 99], ["fibrinogen contribution", "TEST", 104, 127], ["TEG", "TEST", 202, 205], ["hypercoagulability", "PROBLEM", 220, 238], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["clot", "OBSERVATION", 60, 64], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["platelet", "OBSERVATION", 91, 99], ["hypercoagulability", "OBSERVATION", 220, 238]]], ["This was seen in the form of increased maximum amplitude (MA) but not as a decreased R-time.", [["increased maximum amplitude", "PROBLEM", 29, 56], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["maximum", "OBSERVATION_MODIFIER", 39, 46], ["amplitude", "OBSERVATION_MODIFIER", 47, 56], ["decreased", "OBSERVATION", 75, 84]]], ["This is in partial agreement with previous studies that have shown both decreased clot formation time and increased maximum amplitude [15,16].", [["clot", "ANATOMY", 82, 86], ["clot", "ORGANISM_SUBSTANCE", 82, 86], ["previous studies", "TEST", 34, 50], ["decreased clot formation time", "PROBLEM", 72, 101], ["both", "OBSERVATION_MODIFIER", 67, 71], ["decreased", "OBSERVATION_MODIFIER", 72, 81], ["clot", "OBSERVATION", 82, 86], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["maximum", "OBSERVATION_MODIFIER", 116, 123], ["amplitude", "OBSERVATION_MODIFIER", 124, 133]]], ["A greater than normal MA has been able to predict thromboembolism in trauma and postoperatively [17].", [["thromboembolism", "DISEASE", 50, 65], ["trauma", "DISEASE", 69, 75], ["thromboembolism", "PROBLEM", 50, 65], ["trauma", "PROBLEM", 69, 75], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["thromboembolism", "OBSERVATION", 50, 65]]], ["In orthopedic trauma patients the risk of developing venous thromboembolism increases already when MA \u2265 65 mm, and further doubles if MA \u2265 72 mm [18].", [["venous", "ANATOMY", 53, 59], ["trauma", "DISEASE", 14, 20], ["venous thromboembolism", "DISEASE", 53, 75], ["patients", "ORGANISM", 21, 29], ["venous", "MULTI-TISSUE_STRUCTURE", 53, 59], ["patients", "SPECIES", 21, 29], ["developing venous thromboembolism", "PROBLEM", 42, 75], ["MA", "TEST", 99, 101], ["venous", "ANATOMY", 53, 59], ["thromboembolism", "OBSERVATION", 60, 75]]], ["This can be compared to our results where all patients had MA \u2265 65 mm and 42% had MA \u2265 72 mm.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["MA", "TEST", 59, 61], ["72 mm", "OBSERVATION_MODIFIER", 87, 92]]], ["However, MA was not different in patients with or without thromboembolic events.", [["thromboembolic", "DISEASE", 58, 72], ["MA", "GENE_OR_GENE_PRODUCT", 9, 11], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["thromboembolic events", "PROBLEM", 58, 79], ["different", "OBSERVATION_MODIFIER", 20, 29], ["without", "UNCERTAINTY", 50, 57], ["thromboembolic", "OBSERVATION", 58, 72]]], ["Our results also indicate a higher than usual incidence of thromboembolic disease compared to the standard ICU population [19].", [["thromboembolic disease", "DISEASE", 59, 81], ["thromboembolic disease", "PROBLEM", 59, 81], ["higher", "OBSERVATION_MODIFIER", 28, 34], ["thromboembolic", "OBSERVATION", 59, 73]]], ["Still, it is not in the range of early clinical reports describing patients with COVID-19 [1].", [["COVID-19", "CHEMICAL", 81, 89], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["COVID", "TEST", 81, 86]]], ["This may reflect rapid implementation of supra normal prophylactic dosing of LMWH in our ICU.DiscussionCOVID-19 patients have several factors predisposing to thrombotic disease, including immobilization, inflammation, venous catheterization and sometimes complex underlying illness.", [["venous", "ANATOMY", 218, 224], ["LMWH", "CHEMICAL", 77, 81], ["thrombotic disease", "DISEASE", 158, 176], ["inflammation", "DISEASE", 204, 216], ["LMWH", "SIMPLE_CHEMICAL", 77, 81], ["patients", "ORGANISM", 112, 120], ["venous", "MULTI-TISSUE_STRUCTURE", 218, 224], ["patients", "SPECIES", 112, 120], ["supra normal prophylactic dosing of LMWH", "TREATMENT", 41, 81], ["thrombotic disease", "PROBLEM", 158, 176], ["immobilization", "TREATMENT", 188, 202], ["inflammation", "PROBLEM", 204, 216], ["venous catheterization", "TEST", 218, 240], ["complex underlying illness", "PROBLEM", 255, 281], ["may reflect", "UNCERTAINTY", 5, 16], ["rapid", "OBSERVATION_MODIFIER", 17, 22], ["prophylactic", "OBSERVATION_MODIFIER", 54, 66], ["LMWH", "OBSERVATION", 77, 81], ["thrombotic", "OBSERVATION_MODIFIER", 158, 168], ["disease", "OBSERVATION", 169, 176], ["inflammation", "OBSERVATION", 204, 216], ["venous", "ANATOMY", 218, 224], ["catheterization", "OBSERVATION", 225, 240], ["illness", "OBSERVATION", 274, 281]]], ["LMWH reduces the risk of lower extremity deep vein thrombosis and pulmonary embolism in critically ill patients [19] and the International Society on Thrombosis and Haemostasis recommends the use of LMWH for all COVID-19 patients admitted to hospital [20].", [["lower extremity deep vein", "ANATOMY", 25, 50], ["pulmonary", "ANATOMY", 66, 75], ["LMWH", "CHEMICAL", 0, 4], ["thrombosis", "DISEASE", 51, 61], ["pulmonary embolism", "DISEASE", 66, 84], ["critically ill", "DISEASE", 88, 102], ["Thrombosis", "DISEASE", 150, 160], ["Haemostasis", "DISEASE", 165, 176], ["LMWH", "CHEMICAL", 199, 203], ["LMWH", "SIMPLE_CHEMICAL", 0, 4], ["lower extremity", "ORGANISM_SUBDIVISION", 25, 40], ["deep vein", "MULTI-TISSUE_STRUCTURE", 41, 50], ["pulmonary", "ORGAN", 66, 75], ["patients", "ORGANISM", 103, 111], ["LMWH", "SIMPLE_CHEMICAL", 199, 203], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 221, 229], ["LMWH", "TREATMENT", 0, 4], ["lower extremity deep vein thrombosis", "PROBLEM", 25, 61], ["pulmonary embolism", "PROBLEM", 66, 84], ["Thrombosis", "PROBLEM", 150, 160], ["Haemostasis", "TREATMENT", 165, 176], ["LMWH", "TREATMENT", 199, 203], ["all COVID", "TREATMENT", 208, 217], ["lower extremity", "ANATOMY", 25, 40], ["deep vein", "ANATOMY", 41, 50], ["thrombosis", "OBSERVATION", 51, 61], ["pulmonary", "ANATOMY", 66, 75], ["embolism", "OBSERVATION", 76, 84], ["Thrombosis", "OBSERVATION", 150, 160]]], ["LMWH exert their effect by augmenting the inhibiting impact on activated factor X and thrombin by antitrombin III.", [["LMWH", "CHEMICAL", 0, 4], ["LMWH", "SIMPLE_CHEMICAL", 0, 4], ["factor X", "GENE_OR_GENE_PRODUCT", 73, 81], ["thrombin", "GENE_OR_GENE_PRODUCT", 86, 94], ["antitrombin III", "GENE_OR_GENE_PRODUCT", 98, 113], ["activated factor X", "PROTEIN", 63, 81], ["thrombin", "PROTEIN", 86, 94], ["antitrombin III", "PROTEIN", 98, 113], ["LMWH", "TREATMENT", 0, 4], ["activated factor X", "TREATMENT", 63, 81], ["thrombin", "TREATMENT", 86, 94], ["antitrombin III", "TREATMENT", 98, 113], ["effect", "OBSERVATION_MODIFIER", 17, 23]]], ["This can be monitored by measuring plasma levels of anti-factor Xa activity, as recommended when dosing may be difficult [21].", [["plasma", "ANATOMY", 35, 41], ["plasma", "ORGANISM_SUBSTANCE", 35, 41], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 52, 66], ["anti-factor Xa", "PROTEIN", 52, 66], ["plasma levels", "TEST", 35, 48], ["anti-factor Xa activity", "TREATMENT", 52, 75]]], ["A substantial number of patients in the present cohort had sub-prophylactic LMWH activity compared to current recommendations [11] despite normal dosing.", [["LMWH", "CHEMICAL", 76, 80], ["patients", "ORGANISM", 24, 32], ["LMWH", "SIMPLE_CHEMICAL", 76, 80], ["patients", "SPECIES", 24, 32], ["sub-prophylactic LMWH activity", "TREATMENT", 59, 89], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["This may lead to the conclusion that measuring anti-factor X activation may be useful.", [["anti-factor X", "GENE_OR_GENE_PRODUCT", 47, 60], ["anti-factor X", "PROTEIN", 47, 60], ["measuring anti-factor X activation", "TREATMENT", 37, 71]]], ["However, our results indicate that COVID-19 may be associated with thromboembolic complications even with anti-factor Xa activation in the accepted prophylactic range.", [["COVID-19", "CHEMICAL", 35, 43], ["thromboembolic", "DISEASE", 67, 81], ["COVID-19", "CHEMICAL", 35, 43], ["COVID-19", "GENE_OR_GENE_PRODUCT", 35, 43], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 106, 120], ["anti-factor Xa", "PROTEIN", 106, 120], ["COVID", "TEST", 35, 40], ["thromboembolic complications", "PROBLEM", 67, 95], ["anti-factor Xa activation", "TREATMENT", 106, 131], ["may be associated with", "UNCERTAINTY", 44, 66], ["thromboembolic", "OBSERVATION", 67, 81], ["prophylactic range", "OBSERVATION", 148, 166]]], ["This prompts for vigilance as it suggests that it may be difficult to predict the risk of thromboembolic complications using standard tests, and equally hard to safely conclude that a patient has adequate treatment with LMWH.DiscussionStrengths of this study includes data from TEG with and without heparinase, allowing assessment of heparin effects.", [["thromboembolic", "DISEASE", 90, 104], ["LMWH", "CHEMICAL", 220, 224], ["heparin", "CHEMICAL", 334, 341], ["patient", "ORGANISM", 184, 191], ["LMWH", "SIMPLE_CHEMICAL", 220, 224], ["heparinase", "GENE_OR_GENE_PRODUCT", 299, 309], ["heparin", "SIMPLE_CHEMICAL", 334, 341], ["TEG", "PROTEIN", 278, 281], ["patient", "SPECIES", 184, 191], ["thromboembolic complications", "PROBLEM", 90, 118], ["standard tests", "TEST", 125, 139], ["LMWH", "TREATMENT", 220, 224], ["this study", "TEST", 248, 258], ["data from TEG", "TEST", 268, 281], ["heparinase", "TREATMENT", 299, 309], ["heparin effects", "TREATMENT", 334, 349], ["thromboembolic", "OBSERVATION", 90, 104], ["LMWH", "OBSERVATION", 220, 224]]], ["Weaknesses include the relatively low number of patients and events and the fact that a number of patients in the study still receive critical care.ConclusionCOVID-19 patients have hypercoagulability with high maximum amplitude (MA) on TEG, and often show insufficient effect of standard doses of LMWH.", [["hypercoagulability", "DISEASE", 181, 199], ["LMWH", "CHEMICAL", 297, 301], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 167, 175], ["LMWH", "SIMPLE_CHEMICAL", 297, 301], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 167, 175], ["Weaknesses", "PROBLEM", 0, 10], ["the study", "TEST", 110, 119], ["critical care", "TREATMENT", 134, 147], ["ConclusionCOVID", "TEST", 148, 163], ["hypercoagulability", "PROBLEM", 181, 199], ["TEG", "TEST", 236, 239], ["LMWH", "TREATMENT", 297, 301], ["hypercoagulability", "OBSERVATION", 181, 199], ["insufficient", "OBSERVATION", 256, 268], ["LMWH", "OBSERVATION", 297, 301]]], ["Our results suggest that neither anti-factor Xa activity nor TEG can reliably determine the effect of LMWH in patients with COVID-19.", [["LMWH", "CHEMICAL", 102, 106], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 33, 47], ["TEG", "GENE_OR_GENE_PRODUCT", 61, 64], ["LMWH", "SIMPLE_CHEMICAL", 102, 106], ["patients", "ORGANISM", 110, 118], ["anti-factor Xa", "PROTEIN", 33, 47], ["TEG", "PROTEIN", 61, 64], ["patients", "SPECIES", 110, 118], ["neither anti-factor Xa activity", "PROBLEM", 25, 56], ["TEG", "TEST", 61, 64], ["LMWH", "TREATMENT", 102, 106], ["COVID", "TEST", 124, 129], ["LMWH", "OBSERVATION", 102, 106]]], ["Further studies are needed to investigate the optimal dose of LMWH in these patients as well as potential alternative thrombosis prophylaxis.Sources of fundingThe study was funded by 10.13039/501100009252SciLifeLab, the 10.13039/501100004063Knut and Alice Wallenberg Foundation and in part by the 10.13039/501100004359Swedish Research Council (grant no 2014-02569 and 2014-07606).", [["LMWH", "CHEMICAL", 62, 66], ["thrombosis", "DISEASE", 118, 128], ["LMWH", "SIMPLE_CHEMICAL", 62, 66], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Further studies", "TEST", 0, 15], ["LMWH", "TREATMENT", 62, 66], ["potential alternative thrombosis prophylaxis", "TREATMENT", 96, 140], ["The study", "TEST", 159, 168], ["LMWH", "OBSERVATION", 62, 66], ["thrombosis", "OBSERVATION", 118, 128], ["funding", "OBSERVATION", 152, 159]]], ["The funders had no part in study design; data collection, analysis or interpretation; writing of the report or the decision to submit for publication.Declaration of Competing InterestNone.", [["data collection", "TEST", 41, 56], ["analysis", "TEST", 58, 66], ["no part", "UNCERTAINTY", 16, 23]]]], "12c9ab49212adab891025a8c40240a518b9df65c": [], "96f69dc185b80e245b1b237837c65673bf2ee6cf": [["L'identification virale par les outils traditionnels est significativement plus fr\u00e9quente chez les jeunes asthmatiques, ainsi que lors de l'utilisation des outils de biologie mol\u00e9culaire de fa\u00e7on non significative.", [["L'identification virale par les", "TEST", 0, 31], ["est significativement", "TEST", 53, 74]]], ["L'\u00e9pid\u00e9miologie comparative retrouve la pr\u00e9pond\u00e9rance dans les deux groupes d'\u00e2ge du rhinovirus (45 %), puis du virus respiratoire syncytial (28 %) et de l'ent\u00e9rovirus (8,5 % Les premi\u00e8res donn\u00e9es sur l'\u00e9pid\u00e9miologie de l'infection virale et l'asthme ont \u00e9t\u00e9 obtenues dans les ann\u00e9es 1970-1980 par l'isolement viral et la s\u00e9rologie [1] .", [["Les premi\u00e8res donn\u00e9es sur l'\u00e9pid\u00e9miologie de l'infection virale et l'asthme ont \u00e9t\u00e9 obtenues dans les ann\u00e9es 1970-1980 par l'isolement viral et la s\u00e9rologie", "SPECIES", 175, 331], ["L'\u00e9pid\u00e9miologie", "TREATMENT", 0, 15], ["du rhinovirus", "TEST", 82, 95], ["puis du virus respiratoire syncytial", "TEST", 104, 140], ["et de l'ent\u00e9rovirus", "TEST", 148, 167], ["viral et la s\u00e9rologie", "TREATMENT", 310, 331]]], ["L'\u00e9pid\u00e9miologie virale, avec ces techniques virologiques modernes, lors des exacerbations d'asthme est disponible chez l'enfant d'une dizaine d'ann\u00e9e [3] mais pas chez celui \u00e2g\u00e9 de moins de deux ans.PATIENTS ET M\u00c9THODESCette \u00e9tude \u00e9pid\u00e9miologique r\u00e9trospective a collig\u00e9 les enqu\u00eates virologiques \u00e0 partir des s\u00e9cr\u00e9tions obtenues par aspiration nasale chez les enfants hospitalis\u00e9s pour crise d'asthme aigu\u00eb dans un service de p\u00e9diatrie g\u00e9n\u00e9rale.", [["L'\u00e9pid\u00e9miologie virale", "TEST", 0, 22], ["lors des exacerbations", "PROBLEM", 67, 89], ["mais pas chez", "TEST", 154, 167], ["a collig\u00e9 les enqu\u00eates virologiques", "TREATMENT", 261, 296], ["partir des", "TREATMENT", 299, 309]]], ["Les examens paracliniques ont port\u00e9 sur le dosage de la prot\u00e9ine C r\u00e9active, la num\u00e9ration des polynucl\u00e9aires neutrophiles, l'examen cytobact\u00e9riologique des crachats (ECBC) \u00e0 l'admission.", [["Les examens", "TEST", 0, 11], ["paracliniques", "TEST", 12, 25], ["la num\u00e9ration des polynucl\u00e9aires", "TEST", 77, 109], ["neutrophiles", "TEST", 110, 122]]], ["Ces pr\u00e9l\u00e8vements ont \u00e9t\u00e9 transmis imm\u00e9diatement dans un flacon st\u00e9rile au laboratoire de virologie.", [["Ces pr\u00e9l\u00e8vements", "TEST", 0, 16]]], ["Les comparaisons statistiques des donn\u00e9es quantitatives ont \u00e9t\u00e9 effectu\u00e9es \u00e0 l'aide du test non param\u00e9trique de Mann-Whitney.", [["du test", "TEST", 84, 91]]], ["Pour les petits effectifs, les calculs statistiques ont \u00e9t\u00e9 r\u00e9alis\u00e9s par la m\u00e9thode exacte de Fischer.", [["Pour les petits effectifs", "PROBLEM", 0, 25]]], ["L'identification virale par les outils traditionnels du diagnostic virologique est significativement plus fr\u00e9quente chez les jeunes asthmatiques : la positivit\u00e9 de IF/CV correspond \u00e0 un \u00e2ge moyen de 28,4 mois, la n\u00e9gativit\u00e9 de cette recherche correspond \u00e0 un \u00e2ge moyen de 43 mois (p < 0,01).", [["L'identification virale par les", "TEST", 0, 31], ["diagnostic virologique est significativement", "TEST", 56, 100]]], ["Ceci est \u00e9galement retrouv\u00e9 lors de l'utilisation des outils de biologie mol\u00e9culaire, La pr\u00e9sence d'une neutrop\u00e9nie relative est retrouv\u00e9e lors de l'analyse des r\u00e9sultats en fonction des donn\u00e9es de l'IF/CV.", [["Ceci", "TEST", 0, 4], ["CV", "ANATOMY", 203, 205]]], ["Lorsque l'IF/CV est positive, le chiffre moyen des polynucl\u00e9aires neutrophiles est de 5 230/mm 3 (\u00b1 2 470) versus 7 150/mm 3 (\u00b1 4 350).", [["Lorsque", "TEST", 0, 7], ["CV est", "TEST", 13, 19], ["le chiffre", "TEST", 30, 40]]], ["Il n'y a pas diff\u00e9rence significative selon les r\u00e9sultats des techniques mol\u00e9culaires (positivit\u00e9 \u00e0 6 800/mm 3 \u00b1 4 400 versus n\u00e9gativit\u00e9 \u00e0 5 800/mm 3 \u00b1 3 000).DISCUSSIONLa corr\u00e9lation saisonni\u00e8re entre la survenue des infections virales et les pics de crises d'asthme est tout \u00e0 fait perceptible en clinique [6, 7] .", [["infections", "DISEASE", 218, 228], ["a pas", "TEST", 7, 12], ["positivit\u00e9", "TEST", 87, 97], ["n\u00e9gativit\u00e9", "TEST", 126, 136], ["saisonni\u00e8re entre la survenue des infections", "TREATMENT", 184, 228], ["et les pics de crises", "PROBLEM", 237, 258]]], ["Le rhinovirus reste le facteur cl\u00e9 de ces exacerbations, puis le virus respiratoire syncytial.", [["Le rhinovirus", "ORGANISM", 0, 13], ["puis le virus", "ORGANISM", 57, 70], ["rhinovirus", "SPECIES", 3, 13], ["Le rhinovirus reste le facteur cl\u00e9 de ces exacerbations", "PROBLEM", 0, 55], ["puis le virus respiratoire syncytial", "PROBLEM", 57, 93], ["rhinovirus", "OBSERVATION", 3, 13]]], ["La pr\u00e9valence de ces deux agents infectieux ne correspond pas \u00e0 celle retrouv\u00e9e lors des bronchiolites inaugurales [9] .", [["La pr\u00e9valence de ces deux agents", "TREATMENT", 0, 32], ["infectieux", "TEST", 33, 43]]], ["L'IF/CV n\u00e9cessite le maintien de l'int\u00e9grit\u00e9 cellulaire et de la viabilit\u00e9 virale.", [["CV n\u00e9cessite le maintien", "TREATMENT", 5, 29]]], ["La technique PCR peut d\u00e9tecter des particules virales infectieuses et non infectieuses, l'isolement viral ne d\u00e9c\u00e8le pas les particules d\u00e9fectives, il est g\u00ean\u00e9 par les inhibiteurs des virus pr\u00e9sents dans les \u00e9chantillons (mucine, interf\u00e9ron, bact\u00e9ries\u2026).", [["La technique PCR", "TEST", 0, 16], ["peut", "TEST", 17, 21], ["des particules", "TEST", 31, 45], ["virales", "TEST", 46, 53], ["et non infectieuses", "PROBLEM", 67, 86], ["l'isolement", "TEST", 88, 99], ["viral ne d\u00e9c\u00e8le pas les", "TEST", 100, 123], ["d\u00e9fectives", "TEST", 135, 145]]], ["Pr\u00e9sentation paraclinique et \u00e9volution de la cohorte.\u00c2ge < 2 ans (n = 59)\u00c2ge \u2265 2 ans (n = 59) p Prot\u00e9ine C r\u00e9active (mg/L) 8,1 (\u00b1 7,6) 10,7 (\u00b1 12) NS Polynucl\u00e9aires neutrophiles (mm 3 ans, une charge virale plus importante est n\u00e9cessaire pour induire des sifflements, puis plus l'asthme vieilli, moins cette charge est n\u00e9cessaire pour d\u00e9clencher une exacerbation, les facteurs allergiques \u00e9tant parall\u00e8lement pr\u00e9pond\u00e9rants [12] .", [["\u00c2ge", "TEST", 53, 56], ["\u00c2ge", "TEST", 73, 76], ["Prot\u00e9ine C", "TEST", 96, 106], ["r\u00e9active", "TEST", 107, 115], ["mg/L)", "TEST", 117, 122], ["NS", "TEST", 147, 149], ["Polynucl\u00e9aires", "TEST", 150, 164], ["neutrophiles", "TEST", 165, 177], ["une charge virale", "TEST", 189, 206], ["importante", "TEST", 212, 222], ["est", "TEST", 223, 226], ["pour induire des sifflements", "PROBLEM", 238, 266], ["puis", "TEST", 268, 272], ["pour d\u00e9clencher une exacerbation", "PROBLEM", 330, 362]]], ["L'infection latente est habituellement non permissive, sans r\u00e9plication virale, mais elle s'accompagne souvent de l'expression de quelques prot\u00e9ines virales pr\u00e9coces, qui, si elles s'expriment \u00e0 la surface, voire hors de la cellule, peuvent g\u00e9n\u00e9rer des ph\u00e9nom\u00e8nes inflammatoires et immunitaires chroniques ou intermittents.", [["infection", "DISEASE", 2, 11], ["L'infection", "PROBLEM", 0, 11], ["infection", "OBSERVATION", 2, 11]]], ["Avec le virus respiratoire syncytial, l'infection latente ou persistante du poumon n'a pas \u00e9t\u00e9 d\u00e9montr\u00e9e m\u00eame si ses effets au long cours sont bien individualis\u00e9s [13] .", [["Avec le virus respiratoire syncytial", "ORGANISM", 0, 36], ["Avec le virus respiratoire syncytial, l'infection latente ou persistante du poumon n'a pas \u00e9t\u00e9 d\u00e9montr\u00e9e m\u00eame si ses effets au long cours sont bien individualis\u00e9s", "SPECIES", 0, 162]]], ["L'infection persistante ad\u00e9novirale tant chez des enfants asthmatiques non r\u00e9pondeurs aux cortico\u00efdes inhal\u00e9s [14] qu'en p\u00e9riode intercritique [15] [10] .", [["infection", "DISEASE", 2, 11], ["L'infection", "PROBLEM", 0, 11], ["ad\u00e9novirale", "PROBLEM", 24, 35], ["infection", "OBSERVATION", 2, 11]]], ["Cuningham et al. [19] ont \u00e9galement pratiqu\u00e9 leurs investigations chez 65 enfants asymptomatiques, la d\u00e9tection en PCR s'est r\u00e9v\u00e9l\u00e9e similaire (28 %)\u2026 Toujours dans cette \u00e9tude, Mycoplasma pneumoniae a \u00e9t\u00e9 identifi\u00e9 \u00e0 deux reprises dans les deux groupes de patients.", [["patients", "ORGANISM", 257, 265], ["Mycoplasma pneumoniae", "SPECIES", 178, 199], ["patients", "SPECIES", 257, 265], ["leurs investigations", "TEST", 45, 65], ["chez", "TEST", 66, 70], ["asymptomatiques", "TEST", 82, 97], ["la d\u00e9tection", "TEST", 99, 111], ["Mycoplasma pneumoniae", "PROBLEM", 178, 199], ["Mycoplasma pneumoniae", "OBSERVATION", 178, 199]]], ["La corr\u00e9lation entre infection aigu\u00eb ou chronique \u00e0 Chlamydia pneumoniae ou Mycoplasma pneumoniae et asthme aigu ou chronique n'est pas d\u00e9montr\u00e9e \u00e0 l'\u00e9vidence.CONCLUSIONLa grande sensibilit\u00e9 des outils mol\u00e9culaires apporte une modification des r\u00e9sultats \u00e9pid\u00e9miologiques lors du diagnostic des viroses respiratoires communes aux d\u00e9pends probablement de leur sp\u00e9cificit\u00e9.", [["infection", "DISEASE", 21, 30], ["Mycoplasma pneumoniae", "SPECIES", 76, 97], ["La corr\u00e9lation entre infection", "TEST", 0, 30], ["Chlamydia pneumoniae", "PROBLEM", 52, 72], ["Mycoplasma pneumoniae", "PROBLEM", 76, 97], ["l'\u00e9vidence.CONCLUSIONLa grande sensibilit\u00e9 des", "TREATMENT", 148, 194]]], ["Cependant, aucune comparaison entre les \u00e9tudes n'est vraiment satisfaisante en l'absence de standardisation des proc\u00e9dures.", [["Cependant", "TREATMENT", 0, 9]]], ["Actuellement, le gain en efficacit\u00e9 du diagnostic mol\u00e9culaire se heurte au co\u00fbt, \u00e0 la complexit\u00e9 et \u00e0 la dur\u00e9e n\u00e9cessaire pour leur r\u00e9alisation.", [["pour leur", "OBSERVATION", 122, 131]]], ["Le rhinovirus, le virus respiratoire syncytial, puis les ent\u00e9rovirus sont dans notre \u00e9tude les principaux agents identifi\u00e9s lors des exacerbations aigu\u00ebs nettement s\u00e9par\u00e9es des autres agents habituellement retrouv\u00e9s dans les infections aigu\u00ebs de l'arbre respiratoire.", [["infections", "DISEASE", 225, 235], ["Le rhinovirus", "ORGANISM", 0, 13], ["le virus respiratoire syncytial", "ORGANISM", 15, 46], ["rhinovirus", "SPECIES", 3, 13], ["Le rhinovirus", "TEST", 0, 13], ["le virus respiratoire", "TEST", 15, 36], ["lors des exacerbations", "PROBLEM", 124, 146], ["des autres agents", "TREATMENT", 173, 190], ["rhinovirus", "OBSERVATION", 3, 13], ["le virus", "ANATOMY", 15, 23]]], ["Le pleconaril est, par exemple, efficace sur les infections \u00e0 picornavirus (rhinovirus et ent\u00e9rovirus) r\u00e9duisant la symptomatologie clinique.CONCLUSIONLes hypoth\u00e8ses \u00e9tiopathog\u00e9niques sont nombreuses, donc encore \u00e0 d\u00e9finir pour relier l'identification virale et la symptomatologie clinique.", [["infections \u00e0 picornavirus", "DISEASE", 49, 74], ["rhinovirus", "ORGANISM", 76, 86], ["rhinovirus", "SPECIES", 76, 86], ["Le pleconaril est", "TEST", 0, 17], ["efficace sur les infections", "PROBLEM", 32, 59], ["picornavirus", "PROBLEM", 62, 74], ["rhinovirus et ent\u00e9rovirus", "TREATMENT", 76, 101]]], ["L'atteinte des cellules \u00e9pith\u00e9liales, l'intervention de cytokines (IL-6, IL-8, IL-11\u2026) et de m\u00e9diateurs (LTC4, hista-mine\u2026), le recrutement cellulaire (polynucl\u00e9aires \u00e9osinophiles et neutrophiles\u2026), voire la diffusion syst\u00e9mique (lymphocytes, cellules mononucl\u00e9\u00e9es\u2026) ne doivent pas \u00eatre consid\u00e9r\u00e9s isol\u00e9ment de m\u00eame que les interactions entre virus, cellules mastocytaires, basophiles et IgE.", [["LTC4", "CHEMICAL", 105, 109], ["cytokines", "PROTEIN", 56, 65], ["lymphocytes", "CELL_TYPE", 230, 241], ["IgE", "PROTEIN", 388, 391], ["l'intervention", "TREATMENT", 38, 52], ["cytokines", "TEST", 56, 65], ["IL", "TEST", 67, 69], ["IL", "TEST", 73, 75], ["IL", "TEST", 79, 81], ["LTC4", "TEST", 105, 109], ["le recrutement cellulaire", "TEST", 125, 150], ["polynucl\u00e9aires", "TEST", 152, 166], ["et neutrophiles", "TEST", 180, 195], ["la diffusion syst\u00e9mique", "TEST", 205, 228], ["lymphocytes", "TEST", 230, 241], ["cellules", "TEST", 243, 251], ["mononucl\u00e9\u00e9es", "TEST", 252, 264], ["LTC4", "ANATOMY", 105, 109]]], ["Ces diff\u00e9rents mod\u00e8les sugg\u00e8rent les divers objectifs potentiels d'une intervention th\u00e9rapeutique.", [["Ces", "TEST", 0, 3], ["intervention th\u00e9rapeutique", "TREATMENT", 71, 97]]]], "5408b9cea3b1caf9f6cd026140d5414fab4c6e81": [["IntroductionThe 2015 outbreak of Middle East Respiratory Syndrome coronavirus (MERS-CoV) posed a serious public health threat in the Republic of Korea.", [["Middle East Respiratory Syndrome coronavirus", "DISEASE", 33, 77], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 33, 77], ["MERS-CoV", "ORGANISM", 79, 87], ["Middle East Respiratory Syndrome coronavirus", "SPECIES", 33, 77], ["MERS-CoV", "SPECIES", 79, 87], ["Middle East Respiratory Syndrome coronavirus", "PROBLEM", 33, 77], ["Middle", "ANATOMY_MODIFIER", 33, 39], ["Respiratory Syndrome", "OBSERVATION", 45, 65]]], ["It has drawn a lot of attention not only because it was the largest outbreak of MERS-CoV outside the Middle East regions but also because it has been claimed to be a super-spreading event (SSE) similar to the SARS outbreaks in 2003 [2] .", [["SARS", "DISEASE", 209, 213], ["MERS-CoV", "ORGANISM", 80, 88], ["MERS-CoV", "SPECIES", 80, 88], ["largest", "OBSERVATION_MODIFIER", 60, 67], ["outbreak", "OBSERVATION_MODIFIER", 68, 76], ["Middle", "ANATOMY_MODIFIER", 101, 107]]], ["SSE is an outbreak where a small number of infected cases generated a large number of secondary infections [3] ; for example, 20% of infectious individuals are responsible for 80% of newly generated infections.", [["infections", "DISEASE", 96, 106], ["infections", "DISEASE", 199, 209], ["individuals", "ORGANISM", 144, 155], ["infected cases", "PROBLEM", 43, 57], ["secondary infections", "PROBLEM", 86, 106], ["infectious individuals", "PROBLEM", 133, 155], ["newly generated infections", "PROBLEM", 183, 209], ["small", "OBSERVATION_MODIFIER", 27, 32], ["infected", "OBSERVATION_MODIFIER", 43, 51], ["large", "OBSERVATION_MODIFIER", 70, 75], ["number", "OBSERVATION_MODIFIER", 76, 82], ["secondary", "OBSERVATION_MODIFIER", 86, 95], ["infections", "OBSERVATION", 96, 106], ["infectious", "OBSERVATION", 133, 143], ["infections", "OBSERVATION", 199, 209]]], ["Super-spreading events have been observed in the transmission dynamics of many infectious diseases including SARS transmission in Hong Kong and Singapore [4] .", [["infectious diseases", "DISEASE", 79, 98], ["SARS", "DISEASE", 109, 113], ["many infectious diseases", "PROBLEM", 74, 98], ["infectious", "OBSERVATION", 79, 89]]], ["Stein identified the complex interplay among hosts, pathogens and environments for super-spreading events in many infectious diseases [5] .", [["infectious diseases", "DISEASE", 114, 133], ["infectious", "OBSERVATION", 114, 124]]], ["Furthermore, Shen et al. defined SSE as a patient transmitting a disease to at least eight contacts, based on an analysis of the SARS spread data [6] . these five colors represent the cases by each super-spreader (yellow color is unknown due to multiple contacts).", [["SARS", "DISEASE", 129, 133], ["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["a disease", "PROBLEM", 63, 72], ["an analysis", "TEST", 110, 121], ["the SARS spread data", "TEST", 125, 145], ["yellow color", "PROBLEM", 214, 226]]], ["This shows significant heterogeneity in the 2015 MERS-CoV transmission: five super-spreaders (3%) infected 79% (147/186) of the total MERS-CoV cases.IntroductionHaving identified the MERS-CoV outbreak in Korea as an SSE, it is necessary to develop a mathematical model that can capture the heterogeneity of infectivity among patients.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 134, 142], ["MERS-CoV", "ORGANISM", 183, 191], ["patients", "ORGANISM", 325, 333], ["patients", "SPECIES", 325, 333], ["MERS-CoV", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 134, 142], ["MERS-CoV", "SPECIES", 183, 191], ["significant heterogeneity", "PROBLEM", 11, 36], ["the total MERS", "TEST", 124, 138], ["a mathematical model", "TREATMENT", 248, 268], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["heterogeneity", "OBSERVATION", 23, 36], ["infectivity", "OBSERVATION", 307, 318]]], ["There have been various approaches to model the SSE in infectious disease transmission dynamics.", [["infectious disease transmission", "DISEASE", 55, 86], ["infectious", "OBSERVATION", 55, 65]]], ["Firstly, the standard compartmental models have been used.", [["the standard compartmental models", "TREATMENT", 9, 42]]], ["They assumed that superspreaders have a longer infectious period than normal infected individuals.", [["infected", "OBSERVATION_MODIFIER", 77, 85]]], ["While their model was simple and clear, a SIR-type model is inherently limited in capturing the individual heterogeneity of attributes, including contact numbers and infectivity.", [["clear", "OBSERVATION", 33, 38]]], ["Another way of modeling SSE is a branching process model.", [["modeling SSE", "OBSERVATION", 15, 27], ["branching process", "OBSERVATION", 33, 50]]], ["In each discrete time step, an infected individual produces a random number of secondary infections that follows a certain probability distribution.", [["infections", "DISEASE", 89, 99], ["an infected individual", "PROBLEM", 28, 50], ["secondary infections", "PROBLEM", 79, 99], ["discrete", "OBSERVATION_MODIFIER", 8, 16], ["infected", "OBSERVATION", 31, 39], ["secondary", "OBSERVATION_MODIFIER", 79, 88], ["infections", "OBSERVATION", 89, 99]]], ["There are a small number of cases whose value is far from the mean and these are used to model super-spreaders.", [["small", "OBSERVATION_MODIFIER", 12, 17], ["number", "OBSERVATION_MODIFIER", 18, 24]]], ["Lloyd-Smith et al. employed a negative binomial distribution and defined an SSE where any single patient infects more than the nth percentile of the distribution [12] .", [["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104]]], ["Garske and Rhodes suggested a branching process model implemented in continuous time instead of discrete generation [14] .", [["a branching process model", "TREATMENT", 28, 53], ["branching process", "OBSERVATION", 30, 47]]], ["In addition to these methods, agent-based modeling (ABM) can be a useful tool in modeling SSEs.", [["SSEs", "DISEASE", 90, 94], ["SSEs", "CANCER", 90, 94], ["these methods", "TREATMENT", 15, 28], ["agent-based modeling (ABM", "TREATMENT", 30, 55]]], ["Due to the dramatic increase in computing power and its strength in modeling individual heterogeneity, it has been employed in modeling various aspects of infectious disease transmission dynamics especially in modeling SSEs with spatio-temporal factors.", [["spatio-temporal factors", "PROTEIN", 229, 252], ["the dramatic increase", "PROBLEM", 7, 28], ["infectious disease transmission dynamics", "PROBLEM", 155, 195], ["temporal factors", "PROBLEM", 236, 252], ["dramatic", "OBSERVATION_MODIFIER", 11, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["individual", "OBSERVATION_MODIFIER", 77, 87], ["heterogeneity", "OBSERVATION", 88, 101], ["infectious", "OBSERVATION_MODIFIER", 155, 165]]], ["In ABM, SSEs are usually modeled by incorporating a small number of agents (super-spreaders) who can generate a larger number of secondary infections than normal agents.", [["infections", "DISEASE", 139, 149], ["secondary infections", "PROBLEM", 129, 149], ["small", "OBSERVATION_MODIFIER", 52, 57], ["larger", "OBSERVATION_MODIFIER", 112, 118], ["secondary", "OBSERVATION_MODIFIER", 129, 138], ["infections", "OBSERVATION", 139, 149]]], ["Another way is to make the infectious period of super-spreaders longer while the infectivity is same with normal agents [11, 14] .", [["infectious", "OBSERVATION_MODIFIER", 27, 37]]], ["Each of these ways pays attention to different aspects of the super-spreaders and can be useful for capturing and analyzing SSEs.IntroductionIn particular, a group of studies has employed ABM in modeling SSEs from the perspective of the contact network.", [["SSEs", "CANCER", 124, 128], ["contact network", "MULTI-TISSUE_STRUCTURE", 237, 252], ["the super-spreaders", "TREATMENT", 58, 77]]], ["Fujie and Odagaki developed agent-based models on an irregular lattice network and suggested two kinds of models in their work; a strong infectiousness model and a hub model [15] .", [["lattice network", "MULTI-TISSUE_STRUCTURE", 63, 78]]], ["Comparing the results of two models with SARS transmission data in Hong Kong, they concluded that the hub model provides a closer match with the real-world data.", [["SARS", "DISEASE", 41, 45]]], ["Small, Tse and Walker suggested a small-world network model where individuals have local links that connect to immediate neighbors and non-local links that connect to far-away nodes [16] .", [["Walker", "TREATMENT", 15, 21], ["small", "OBSERVATION_MODIFIER", 34, 39]]], ["Bifolchi, Deardon and Feng simulated the epidemic spreads through various contact networks to determine which model best predicts the true probabilities of infection [17] .", [["infection", "DISEASE", 156, 165], ["infection", "PROBLEM", 156, 165], ["infection", "OBSERVATION", 156, 165]]], ["Duan et al. suggested an elaborate agent-based model that incorporates a variety of features of agent behaviors that might generate SSE including heterogeneous levels of infectivity and contacts [18] .IntroductionThe present research aims to develop stochastic agent-based models of the 2015 MERS-CoV transmission dynamics in South Korea.", [["MERS-CoV", "SPECIES", 292, 300], ["an elaborate agent", "TREATMENT", 22, 40], ["agent behaviors", "PROBLEM", 96, 111], ["heterogeneous levels of infectivity", "PROBLEM", 146, 181], ["stochastic agent", "TREATMENT", 250, 266], ["heterogeneous", "OBSERVATION_MODIFIER", 146, 159]]], ["Embracing the power of ABM, heterogeneities among agents are implemented in the models.", [["ABM", "PROBLEM", 23, 26], ["power", "OBSERVATION_MODIFIER", 14, 19]]], ["In particular, regular-spreaders and super-spreaders are set to have different transmission rate functions based on different transmission probabilities and a different number of contacts.", [["super-spreaders", "DNA", 37, 52], ["different transmission rate functions", "PROBLEM", 69, 106], ["different transmission probabilities", "PROBLEM", 116, 152]]], ["Based on these heterogeneities, four models are suggested: no super-spreader model (No-SS), the super-spreaders model with higher infectivity (SSM1), the super-spreaders model with higher contacts (SSM2), and super-spreaders model with both higher infectivity and higher contacts (SSM3).", [["spreader model", "TEST", 68, 82], ["higher infectivity (SSM1)", "PROBLEM", 123, 148], ["both higher infectivity", "PROBLEM", 236, 259], ["higher infectivity", "OBSERVATION", 123, 141], ["higher infectivity", "OBSERVATION", 241, 259]]], ["Monte Carlo simulations are carried out under various epidemic scenarios and the results are compared with the real epidemic data of 2015 MERS-CoV in Korea.", [["MERS-CoV", "SPECIES", 138, 146], ["Monte Carlo simulations", "TEST", 0, 23]]], ["The distributions of the basic reproduction number and epidemic outputs are computed as well as the distribution of secondary cases under different models of super-spreaders.", [["epidemic outputs", "TEST", 55, 71], ["secondary cases", "PROBLEM", 116, 131], ["distributions", "OBSERVATION_MODIFIER", 4, 17]]], ["Furthermore, the effectiveness of isolation intervention strategies and their impact on the MERS-CoV transmission dynamics are investigated.SEIR Stochastic Agent-Based ModelWe develop a stochastic agent-based model by generating a random network on a square domain L \u00d7 L with a total number of agents N (as shown in Figure 3 ).", [["square domain L \u00d7 L", "CELL_LINE", 251, 270], ["isolation intervention strategies", "TREATMENT", 34, 67], ["a stochastic agent", "TREATMENT", 184, 202], ["a square domain L \u00d7 L", "TREATMENT", 249, 270], ["a total number of agents", "TREATMENT", 276, 300]]], ["Each agent can have one of the following four epidemiological statuses: Susceptible (S), Exposed (E), Infected (I), and Recovered (R).", [["Infected", "OBSERVATION", 102, 110]]], ["A susceptible agent becomes exposed with a probability defined by the transmission probability distribution, which will be descried below.", [["A susceptible agent", "TREATMENT", 0, 19]]], ["We assume that a newly infected person becomes infectious (asymptomatic) and remains in the exposed stage for a incubation time drawn from a gamma probability density function (PDF) with a mean of 1/\u03ba days and a standard deviation of \u03c3 \u03ba days.", [["person", "ORGANISM", 32, 38], ["person", "SPECIES", 32, 38], ["infectious", "PROBLEM", 47, 57], ["a incubation time", "TEST", 110, 127], ["newly", "OBSERVATION_MODIFIER", 17, 22], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["infectious", "OBSERVATION_MODIFIER", 47, 57]]], ["After this time, the individual becomes infectious (symptomatic) and remains so for a duration of time drawn from a gamma PDF with a mean of 1/\u03b3 days and a standard deviation of \u03c3 \u03b3 days.", [["gamma PDF", "PROTEIN", 116, 125], ["infectious", "PROBLEM", 40, 50], ["a gamma PDF", "TEST", 114, 125], ["infectious", "OBSERVATION", 40, 50], ["symptomatic", "OBSERVATION_MODIFIER", 52, 63]]], ["Subsequently, an infected agent recovers with immunity.", [["an infected agent", "TREATMENT", 14, 31], ["infected", "OBSERVATION", 17, 25]]], ["For simplicity, a gamma PDF is used for both the incubation and infectious period; these have been estimated from the 186 MERS-CoV confirmed cases provided by KCDC (2016) [1] .Transmission Rate FunctionsEach agent is either a regular agent or a super-spreader, and the proportion of super-spreaders in the total population (N agents) is determined by the parameter \u03bb.", [["gamma PDF", "CHEMICAL", 18, 27], ["gamma PDF", "GENE_OR_GENE_PRODUCT", 18, 27], ["gamma PDF", "PROTEIN", 18, 27], ["MERS-CoV", "SPECIES", 122, 130], ["a gamma PDF", "TREATMENT", 16, 27], ["a super-spreader", "TREATMENT", 243, 259], ["the total population (N agents", "TREATMENT", 302, 332], ["infectious", "OBSERVATION", 64, 74]]], ["Agents in the E or I status can infect other S agents within a distance r 0 with the transmission probability function of \u03b2(r).", [["\u03b2(r)", "PROTEIN", 122, 126]]], ["Here, the distance between two agents located at (x 1 ,Transmission Rate FunctionsWe define two types of transmission rate functions for regular-spreaders and super-spreaders.", [["transmission rate functions", "TREATMENT", 105, 132]]], ["Here, super-spreaders are assumed to have either a higher transmission probability or larger number of contacts than regular spreaders (three different models for super-spreaders will be described below).Transmission Rate FunctionsLet us define transmission rate functions for regular-spreaders and super-spreaders.", [["a higher transmission probability", "PROBLEM", 49, 82], ["transmission rate functions", "TEST", 245, 272], ["larger", "OBSERVATION_MODIFIER", 86, 92]]], ["The transmission rate function is defined as a function of the distance between exposed (or infected) and susceptible individuals.Transmission Rate Functions\u2022 Regular-spreader:Transmission Rate FunctionsHere, \u03b2(r) is a decreasing function of the distance r within an effective contact radius r 0 , and \u03b1 is the exponent of the given function of distance r with \u03b1 > 1.", [["\u03b1", "PROTEIN", 302, 303], ["\u03b1", "PROTEIN", 361, 362], ["The transmission rate function", "TEST", 0, 30], ["susceptible individuals", "PROBLEM", 106, 129], ["decreasing", "OBSERVATION_MODIFIER", 219, 229]]], ["Please note that this model is referred as to the no super-spreader model No-SS when there is no super-spreader agent (\u03bb = 0).\u2022Super-Spreader Model 1:\u2022Our first super-spreader model (SSM1) assumes that super-spreaders have a higher transmission probability (or higher infectivity) than regular spreaders within the effective contact radius r 0 .", [["SSM1", "CELL_LINE", 183, 187], ["super-spreader agent", "TREATMENT", 97, 117], ["a higher transmission probability", "PROBLEM", 223, 256], ["higher infectivity)", "PROBLEM", 261, 280]]], ["Please note that \u03b2 1 (r) is a constant function remaining at a value of \u03b2 0 for 0 \u2264 r \u2264 r 0 .\u2022\u2022 Super-Spreader Model 2:\u2022The second super-spreader model (SSM2) assumes that super-spreaders have more links (or a larger number of contacts) than regular spreaders and is modeled by a longer effective contact radius with r n = \u221a 6r 0 .\u2022\u2022 Super-Spreader Model 3:\u2022Lastly, we propose a hybrid model (SSM3) for super-spreaders by considering a combined transmission probability of SSM1 and SSM2 since super-spreaders have both a higher transmission probability and a larger number of contacts [1] .Simulation ResultsAll susceptible agents (either regular or super-spreaders) are located on an L \u00d7 L space, and their positions are randomly assigned at the beginning and fixed during the entire simulation (see Figure 3 ).", [["\u03b2 1", "GENE_OR_GENE_PRODUCT", 17, 20], ["\u03b2 1 (r)", "PROTEIN", 17, 24], ["SSM2", "CELL_LINE", 153, 157], ["super-spreaders", "PROTEIN", 172, 187], ["SSM1", "PROTEIN", 473, 477], ["SSM2", "PROTEIN", 482, 486], ["The second super-spreader model (SSM2)", "TREATMENT", 120, 158], ["a hybrid model (SSM3)", "TREATMENT", 377, 398], ["SSM1", "PROBLEM", 473, 477], ["All susceptible agents", "TREATMENT", 608, 630], ["an L \u00d7 L space", "TREATMENT", 682, 696]]], ["One infected agent (the index case) is randomly located on the bottom of the simulated space (all other agents are S status).", [["infected", "OBSERVATION", 4, 12], ["bottom", "ANATOMY_MODIFIER", 63, 69]]], ["A Monte Carlo simulation is carried out with 1000 trials using the same set of parameter values.", [["A Monte Carlo simulation", "TEST", 0, 24]]], ["The averaged output of 1000 runs (or distributions) is presented from our numerical simulations.", [["The averaged output", "TEST", 0, 19], ["averaged", "OBSERVATION_MODIFIER", 4, 12], ["output", "OBSERVATION_MODIFIER", 13, 19]]], ["Baseline parameter values are given in Table 1 .The Impact of Super-Spreaders on Epidemic OutputsThe impact of different super-spreading models is investigated in terms of various epidemic outputs, including incidence, peak size, peak time and epidemic duration.", [["Baseline parameter values", "TEST", 0, 25], ["Epidemic Outputs", "PROBLEM", 81, 97], ["different super-spreading models", "TREATMENT", 111, 143], ["peak size", "TEST", 219, 228], ["peak", "OBSERVATION_MODIFIER", 219, 223], ["size", "OBSERVATION_MODIFIER", 224, 228]]], ["First, Figure 4 compares incidence profiles using two values of \u03bb (a super-spreader proportion): left with \u03bb = 4% and right with \u03bb = 10%.", [["\u03bb", "TEST", 107, 108], ["left", "ANATOMY_MODIFIER", 97, 101], ["right", "ANATOMY_MODIFIER", 118, 123]]], ["The average incidence of 1000 simulations is displayed as a solid smooth curve along with one particular incidence (a dashed stochastic curve).", [["a solid smooth curve", "PROBLEM", 58, 78], ["a dashed stochastic curve", "TREATMENT", 116, 141]]], ["Clearly, the effect of super-spreaders makes the disease transmission faster and more severe (see SSM3 in both panels) since super-spreaders in SSM3 have a stronger transmission and longer effective radius than the other models (in order of SSM3 > SSM2 > SSM1 > No-SS).", [["SSM3", "SIMPLE_CHEMICAL", 144, 148], ["SSM3", "PROTEIN", 144, 148], ["SSM2", "PROTEIN", 248, 252], ["SSM1", "PROTEIN", 255, 259], ["the disease transmission faster", "PROBLEM", 45, 76], ["SSM3", "TEST", 241, 245], ["SSM2", "TEST", 248, 252], ["SSM1", "TEST", 255, 259]]], ["This becomes more profound under a higher proportion of super-spreaders in the right panel (\u03bb = 10%).The Impact of Super-Spreaders on Epidemic OutputsNext, the detailed epidemic distributions are illustrated in Figure 5 , which shows the peak size, peak time, and epidemic duration using \u03bb = 10% with the mean represented by the dashed vertical line.", [["dashed vertical line", "CELL_LINE", 329, 349], ["more", "OBSERVATION_MODIFIER", 13, 17], ["profound", "OBSERVATION_MODIFIER", 18, 26], ["right", "ANATOMY_MODIFIER", 79, 84], ["panel", "ANATOMY", 85, 90], ["peak", "OBSERVATION_MODIFIER", 238, 242], ["size", "OBSERVATION_MODIFIER", 243, 247], ["peak", "OBSERVATION_MODIFIER", 249, 253], ["vertical line", "OBSERVATION", 336, 349]]], ["The peak time is earlier and the peak size is larger in SSM3 (again in order of SSM3 > SSM2 > SSM1 > No-SS).", [["SSM2", "PROTEIN", 87, 91], ["SSM1", "PROTEIN", 94, 98], ["the peak size", "TEST", 29, 42], ["SSM3", "TEST", 80, 84], ["SSM2", "TEST", 87, 91], ["SSM1", "TEST", 94, 98], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["peak", "OBSERVATION_MODIFIER", 33, 37], ["size", "OBSERVATION_MODIFIER", 38, 42], ["larger", "OBSERVATION_MODIFIER", 46, 52]]], ["This confirms that the impact of super-spreaders is significant on the MERS-CoV transmission dynamics.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["MERS-CoV", "SPECIES", 71, 79], ["significant", "OBSERVATION_MODIFIER", 52, 63]]], ["Also, the detailed epidemic outputs using two values of \u03bb = 4% and \u03bb = 10% are summarized in Table 2 .", [["two values", "TEST", 42, 52], ["\u03bb", "TEST", 56, 57]]], ["Table 2 illustrates the mean and standard deviation under four models for three epidemic outputs (peak size, peak time, and epidemic duration).The Impact of Super-Spreaders on Epidemic OutputsHigher peak size, faster peak time, and earlier epidemic durations are the common features of SSE, which is consistent with the results under SSM3 as shown in the above epidemic outputs.", [["peak size", "TEST", 98, 107], ["Epidemic Outputs", "TEST", 176, 192], ["size", "OBSERVATION_MODIFIER", 103, 107], ["Higher", "OBSERVATION_MODIFIER", 192, 198], ["peak", "OBSERVATION_MODIFIER", 199, 203], ["size", "OBSERVATION_MODIFIER", 204, 208], ["faster", "OBSERVATION_MODIFIER", 210, 216], ["peak", "OBSERVATION_MODIFIER", 217, 221], ["consistent with", "UNCERTAINTY", 300, 315]]], ["This is due to the larger number of contacts and higher transmission rates resulting in the larger epidemic peak in a shorter period of time.The Impact of Super-Spreaders on the Basic Reproduction NumberThe basic reproduction number is one of the most important quantities in mathematical epidemiology.", [["the larger epidemic peak", "PROBLEM", 88, 112], ["larger", "OBSERVATION_MODIFIER", 19, 25], ["number", "OBSERVATION_MODIFIER", 26, 32], ["larger", "OBSERVATION_MODIFIER", 92, 98], ["epidemic", "OBSERVATION_MODIFIER", 99, 107], ["peak", "OBSERVATION_MODIFIER", 108, 112]]], ["It defines the average number of secondary infections in a completely susceptible population.", [["infections", "DISEASE", 43, 53], ["secondary infections", "PROBLEM", 33, 53], ["a completely susceptible population", "PROBLEM", 57, 92], ["average", "OBSERVATION_MODIFIER", 15, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["secondary", "OBSERVATION_MODIFIER", 33, 42], ["infections", "OBSERVATION", 43, 53], ["susceptible", "OBSERVATION_MODIFIER", 70, 81], ["population", "OBSERVATION", 82, 92]]], ["One can obtain an analytic expression of the basic reproduction number (R 0 ) for some compartment models [19] .", [["some compartment models", "TEST", 82, 105]]], ["However, in general, there is no analytic expressions of R 0 for agent-based models, hence, we employ the method for determining R 0 described in [20] .", [["agent", "TREATMENT", 65, 70], ["no", "UNCERTAINTY", 30, 32]]], ["Figure 6 shows the distributions of R 0 in the absence of super-spreaders (No-SS) and the mean is the dashed vertical line.", [["dashed vertical line", "CELL_LINE", 102, 122], ["Figure", "TEST", 0, 6], ["distributions", "OBSERVATION_MODIFIER", 19, 32], ["vertical line", "OBSERVATION", 109, 122]]], ["Sensitivity analyses of R 0 are conducted by varying baseline transmission rates and an effective radius.", [["Sensitivity analyses", "TEST", 0, 20], ["an effective radius", "PROBLEM", 85, 104], ["effective radius", "OBSERVATION", 88, 104]]], ["In our simulation, the effective radius has the most significant impact and higher transmission rates lead to larger R 0 .", [["most", "OBSERVATION_MODIFIER", 48, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["impact", "OBSERVATION", 65, 71], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["larger", "OBSERVATION_MODIFIER", 110, 116]]], ["It shows the impact of super-spreaders on R 0 using two values of \u03bb (super-spreader proportion): on the top with \u03bb = 4% and the bottom with \u03bb = 10%.", [["\u03bb (super-spreader proportion", "TREATMENT", 66, 94], ["\u03bb", "TEST", 113, 114], ["bottom", "ANATOMY_MODIFIER", 128, 134]]], ["Since the basic reproduction number is computed only the first generation by the index case, the differences for R 0 distributions of four models are smaller when \u03bb = 4%.", [["smaller", "OBSERVATION_MODIFIER", 150, 157]]], ["However, the impact of super-spreaders in SSM3 becomes more significant when \u03bb = 10%, with the maximum mean around 5 of SSM3 (the means are in order of SSM3 > SSM2 > SSM1 > No-SS in the bottom panels).", [["SSM3", "PROTEIN", 42, 46], ["SSM3", "PROTEIN", 152, 156], ["SSM2", "PROTEIN", 159, 163], ["SSM1", "PROTEIN", 166, 170], ["SSM3", "TEST", 152, 156], ["SSM2", "TEST", 159, 163], ["SSM1", "TEST", 166, 170]]], ["Please note that there exists a larger right tail in SSM3 (in order of SSM3 > SSM2 > SSM1 > No-SS).", [["right tail", "ANATOMY", 39, 49], ["SSM3", "PROTEIN", 71, 75], ["SSM2", "PROTEIN", 78, 82], ["SSM1", "PROTEIN", 85, 89], ["a larger right tail in SSM3", "PROBLEM", 30, 57], ["SSM3", "TEST", 71, 75], ["SSM2", "TEST", 78, 82], ["SSM1", "TEST", 85, 89], ["larger", "OBSERVATION_MODIFIER", 32, 38], ["right", "ANATOMY_MODIFIER", 39, 44], ["tail", "ANATOMY_MODIFIER", 45, 49]]], ["Obviously, this implies that there is a higher probability for a larger number of secondary cases to appear under SSM3.Further Sensitivity AnalysisThe impact of three epidemic parameters is determined through incidence curves.", [["SSM3", "PROTEIN", 114, 118], ["secondary cases", "PROBLEM", 82, 97], ["Further Sensitivity Analysis", "TEST", 119, 147], ["larger", "OBSERVATION_MODIFIER", 65, 71]]], ["First, the effect of the baseline transmission rate (\u03b2 0 ) on incidence has been investigated in Figure 8 .", [["the baseline transmission rate", "TEST", 21, 51]]], ["In general, disease transmission becomes faster and stronger as \u03b2 0 increases; the peak time is earlier and the peak height is larger in all four models.", [["\u03b2 0", "PROTEIN", 64, 67], ["the peak time", "TEST", 79, 92], ["the peak height", "TEST", 108, 123], ["disease", "OBSERVATION", 12, 19], ["faster", "OBSERVATION_MODIFIER", 41, 47], ["peak height", "OBSERVATION", 112, 123], ["larger", "OBSERVATION_MODIFIER", 127, 133]]], ["Next, the impact of an effective contact radius (r 0 ) has been explored in Figure 9 .", [["an effective contact radius (r 0", "TREATMENT", 20, 52]]], ["There is no outbreak when r 0 \u2264 2 and outbreaks occur when r 0 > 2.", [["outbreak", "PROBLEM", 12, 20], ["no", "UNCERTAINTY", 9, 11], ["outbreak", "OBSERVATION_MODIFIER", 12, 20]]], ["When r 0 reaches around 2.5, outbreaks take place in SSM2 and SSM3 and they get stronger in size and larger in speed as r 0 gets larger.", [["size", "OBSERVATION_MODIFIER", 92, 96], ["larger", "OBSERVATION_MODIFIER", 101, 107], ["larger", "OBSERVATION_MODIFIER", 129, 135]]], ["It is straightforward that if patients can infect other individuals at a further distance, then disease will be transmitted faster.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["It accelerates the change of proportion of cumulative incidence by the different values of r 0 .", [["change", "OBSERVATION_MODIFIER", 19, 25]]], ["As the proportion of super-spreaders gets larger, the peak size becomes larger and the peak time earlier in SSM2 and SSM3, while it does not have a remarkable impact in SSM1.", [["SSM3", "PROTEIN", 117, 121], ["SSM1", "CELL_LINE", 169, 173], ["the peak size", "TEST", 50, 63], ["SSM2", "TEST", 108, 112], ["SSM3", "TEST", 117, 121], ["larger", "OBSERVATION_MODIFIER", 42, 48], ["peak", "OBSERVATION_MODIFIER", 54, 58], ["size", "OBSERVATION_MODIFIER", 59, 63], ["larger", "OBSERVATION_MODIFIER", 72, 78], ["peak", "OBSERVATION_MODIFIER", 87, 91], ["remarkable", "OBSERVATION_MODIFIER", 148, 158], ["impact", "OBSERVATION", 159, 165]]], ["This suggests that a longer effective radius makes the disease spread easier.", [["a longer effective radius", "PROBLEM", 19, 44], ["the disease spread", "PROBLEM", 51, 69], ["disease", "OBSERVATION", 55, 62]]], ["Lastly, we investigated the effect of the exponent term \u03b1 on the transmission rate for super-spreaders.", [["exponent term \u03b1", "PROTEIN", 42, 57]]], ["We vary the value of \u03b1 (the exponent term in \u03b2(r)) for SSM1, SSM2 and SSM3.", [["SSM1", "GENE_OR_GENE_PRODUCT", 55, 59], ["SSM2", "GENE_OR_GENE_PRODUCT", 61, 65], ["SSM3", "GENE_OR_GENE_PRODUCT", 70, 74], ["\u03b1", "PROTEIN", 21, 22], ["SSM1", "PROTEIN", 55, 59], ["SSM2", "PROTEIN", 61, 65], ["SSM3", "PROTEIN", 70, 74], ["SSM1", "TEST", 55, 59]]], ["The transmission rate function decreases rapidly as \u03b1 increases (results are not shown here).", [["The transmission rate function", "TEST", 0, 30], ["decreases", "OBSERVATION_MODIFIER", 31, 40], ["rapidly", "OBSERVATION_MODIFIER", 41, 48]]], ["This leads to the strength and the speed of disease transmission decreasing as \u03b1 increases.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 79, 80], ["\u03b1", "PROTEIN", 79, 80], ["disease transmission", "PROBLEM", 44, 64], ["disease", "OBSERVATION", 44, 51]]], ["The impact of the effective radius r 0 is shown under four models.", [["the effective radius r 0", "TREATMENT", 14, 38], ["effective", "OBSERVATION_MODIFIER", 18, 27], ["radius", "OBSERVATION_MODIFIER", 28, 34]]], ["In all models, the peak size increases rapidly as r 0 increases.", [["the peak size", "TEST", 15, 28], ["peak", "OBSERVATION_MODIFIER", 19, 23], ["size", "OBSERVATION_MODIFIER", 24, 28], ["increases", "OBSERVATION_MODIFIER", 29, 38], ["rapidly", "OBSERVATION_MODIFIER", 39, 46], ["increases", "OBSERVATION_MODIFIER", 54, 63]]], ["The difference is most significant in SSM 3.", [["most significant", "OBSERVATION_MODIFIER", 18, 34]]], ["The change of proportion of cumulative incidence while varying the different values of r 0 is shown that, in each model, the outbreak probability increases rapidly as r 0 reaches a certain range of values.The Impact of Super-Spreaders on Distributions of Secondary CasesAs observed in many infectious diseases, we explore the distributions of secondary cases under four models.", [["infectious diseases", "DISEASE", 290, 309], ["cumulative incidence", "PROBLEM", 28, 48], ["Secondary CasesAs", "PROBLEM", 255, 272], ["many infectious diseases", "PROBLEM", 285, 309], ["cumulative", "OBSERVATION_MODIFIER", 28, 38], ["increases", "OBSERVATION_MODIFIER", 146, 155], ["rapidly", "OBSERVATION_MODIFIER", 156, 163], ["many", "OBSERVATION_MODIFIER", 285, 289], ["infectious", "OBSERVATION", 290, 300]]], ["Figure 10 illustrates the mean distribution of the number of links under each model.", [["mean distribution", "OBSERVATION_MODIFIER", 26, 43], ["number", "OBSERVATION_MODIFIER", 51, 57]]], ["In the absence of super-spreaders, No-SS shows monotone decreases in the number of links (the most homogeneous in four model outputs with the shortest tail from zero to six) (a).", [["monotone decreases", "PROBLEM", 47, 65], ["monotone", "OBSERVATION_MODIFIER", 47, 55], ["decreases", "OBSERVATION_MODIFIER", 56, 65], ["number", "OBSERVATION_MODIFIER", 73, 79], ["most homogeneous", "OBSERVATION_MODIFIER", 94, 110]]], ["As the transmission rates become stronger and the number of contacts increases, the heterogeneity becomes more severe (in order of SSM3 > SSM2 > SSM1 > No-SS).", [["SSM1", "PROTEIN", 145, 149], ["SSM3", "TEST", 131, 135], ["SSM2", "TEST", 138, 142], ["SSM1", "TEST", 145, 149], ["stronger", "OBSERVATION_MODIFIER", 33, 41], ["more severe", "OBSERVATION_MODIFIER", 106, 117]]], ["As shown in (d), SSM3 exhibits the highest level of heterogeneity in the secondary cases (the highest frequency at zero and also the largest right tail).", [["right tail", "ANATOMY", 141, 151], ["SSM3", "GENE_OR_GENE_PRODUCT", 17, 21], ["tail", "ORGANISM_SUBDIVISION", 147, 151], ["SSM3", "PROTEIN", 17, 21], ["SSM3", "TEST", 17, 21], ["highest", "OBSERVATION_MODIFIER", 35, 42], ["heterogeneity", "OBSERVATION", 52, 65], ["secondary", "OBSERVATION_MODIFIER", 73, 82], ["largest", "OBSERVATION_MODIFIER", 133, 140], ["right", "ANATOMY_MODIFIER", 141, 146], ["tail", "ANATOMY", 147, 151]]], ["This is consistent with the results of the basic reproduction number, as shown in Figure 7 .The Impact of Super-Spreaders on Distributions of Secondary CasesWe have fitted the distribution with a power function (ax b ), where x is the number of secondary cases, and compared the slope of each fitted function to the 2015 MERS-CoV data.", [["Secondary CasesWe", "PROTEIN", 142, 159], ["consistent with", "UNCERTAINTY", 8, 23]]], ["First, the left panel in Figure 11 displays the distributions of secondary cases for the 2015 MERS-CoV (blue bar) and the fitted power law distributions (black circled curve).", [["the left panel", "TEST", 7, 21], ["secondary cases", "PROBLEM", 65, 80], ["CoV (blue bar", "TREATMENT", 99, 112], ["black circled curve", "TEST", 154, 173], ["left", "ANATOMY_MODIFIER", 11, 15], ["distributions", "OBSERVATION_MODIFIER", 48, 61], ["secondary cases", "OBSERVATION", 65, 80], ["power", "OBSERVATION_MODIFIER", 129, 134], ["law distributions", "OBSERVATION", 135, 152]]], ["The right panel compares four fitted power law distributions with the MERS-CoV data.", [["The right panel", "TEST", 0, 15], ["right", "ANATOMY_MODIFIER", 4, 9], ["power", "OBSERVATION_MODIFIER", 37, 42], ["law", "OBSERVATION_MODIFIER", 43, 46], ["distributions", "OBSERVATION_MODIFIER", 47, 60]]], ["Obviously, SSM3 shows the best fit to the distribution of secondary cases for the MERS-CoV data (compare the slopes of the green squared and black circled lines).", [["SSM3", "PROTEIN", 11, 15], ["green squared and black circled lines", "CELL_LINE", 123, 160], ["MERS-CoV", "SPECIES", 82, 90], ["SSM3", "TEST", 11, 15], ["CoV data", "TEST", 87, 95], ["the green squared and black circled lines", "TREATMENT", 119, 160], ["circled lines", "OBSERVATION", 147, 160]]], ["For the least-squares fitting procedure, we used the Levenberg-Marquardt method with line-search implemented in MATLAB (The Mathworks, Inc., Natick, MA, USA) in the built-in routine lsqcurvefit which is part of the optimization toolbox.", [["fitting procedure", "TREATMENT", 22, 39]]], ["The resulting parameter estimates are listed in Table 3 .", [["The resulting parameter estimates", "TEST", 0, 33]]], ["Parameter estimation for the distributions of secondary cases.MERS-CoVNoThe Impact of Isolation Intervention StrategiesLastly, we investigate the impact of isolation interventions on the MERS-CoV dynamics.", [["MERS-CoV", "SPECIES", 187, 195], ["Parameter estimation", "TEST", 0, 20], ["secondary cases", "PROBLEM", 46, 61], ["Isolation Intervention", "TREATMENT", 86, 108], ["isolation interventions", "TREATMENT", 156, 179], ["secondary cases", "OBSERVATION", 46, 61]]], ["Two distinct isolation strategies are implemented: a random and a targeted intervention.", [["a targeted intervention", "TREATMENT", 64, 87], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["isolation", "OBSERVATION", 13, 22]]], ["First, a random intervention isolates individuals (20% randomly chosen; both regular and super-spreaders) from the S and E classes at t = 14 day.", [["a random intervention", "TREATMENT", 7, 28]]], ["Second, a targeted intervention isolates individuals (super-spreaders only starting from t = 14 day until the end of epidemic duration) from the E and I classes.", [["a targeted intervention", "TREATMENT", 8, 31]]], ["Here, a targeted isolation intervention means an individual is isolated and either has effective contact with infected individuals (exposed) or is infected by super-spreaders.", [["a targeted isolation intervention", "TREATMENT", 6, 39]]], ["The results under the three models (SSM1, SSM2 and SSM3) are displayed in Figure 12 .", [["SSM3", "DNA", 51, 55]]], ["In all three models, a random selection reduces the peak size proportionally, resulting in a longer epidemic duration (red incidence curves in (a), (b), (c)).The Impact of Isolation Intervention Strategies(a) SSM1 (b) SSM2 (c) SSM3 Figure 12 .", [["a random selection", "TEST", 21, 39], ["a longer epidemic duration", "PROBLEM", 91, 117], ["red incidence curves", "TEST", 119, 139], ["Isolation Intervention Strategies(a) SSM1 (b) SSM2 (c) SSM3 Figure", "TREATMENT", 172, 238], ["peak", "OBSERVATION_MODIFIER", 52, 56], ["size", "OBSERVATION_MODIFIER", 57, 61], ["proportionally", "OBSERVATION_MODIFIER", 62, 76]]], ["The impacts of two isolation strategies on the average number of MERS-CoV cases are compared without isolation (\u03b2 0 = 0.7 is used).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["MERS-CoV", "SPECIES", 65, 73], ["two isolation strategies", "TREATMENT", 15, 39], ["isolation", "TEST", 101, 110]]], ["Random selection reduces incidence proportionally while targeted isolation reduces the peak size and delay the peak time.The Impact of Isolation Intervention StrategiesPlease note that a targeted isolation reduces the peak size significantly at the beginning which can delay the highest peak and result in more preparation time (green incidence curves in (b), (c)).", [["the peak size", "PROBLEM", 83, 96], ["Isolation Intervention", "TREATMENT", 135, 157], ["a targeted isolation", "TREATMENT", 185, 205], ["green incidence curves", "PROBLEM", 329, 351], ["peak", "OBSERVATION_MODIFIER", 87, 91], ["size", "OBSERVATION_MODIFIER", 92, 96], ["peak", "OBSERVATION_MODIFIER", 218, 222], ["size", "OBSERVATION_MODIFIER", 223, 227]]], ["The implementation of targeted isolation while incapable of eliminating a possible outbreak, still manages to reduce the magnitude of the epidemic peak by distributing both the infection cases and hospitalization over a broader window of time.", [["infection", "DISEASE", 177, 186], ["targeted isolation", "TREATMENT", 22, 40], ["outbreak", "PROBLEM", 83, 91], ["the infection cases", "PROBLEM", 173, 192], ["infection", "OBSERVATION", 177, 186]]], ["Distributing the MERS-CoV case burden over long windows in time is highly desirable when resources are limited.The Impact of Isolation Intervention StrategiesA targeted intervention is more effective in both SSM2 and SSM3, while a random intervention is more effective in SSM1.", [["Isolation Intervention", "TREATMENT", 125, 147], ["A targeted intervention", "TREATMENT", 158, 181], ["a random intervention", "TREATMENT", 229, 250], ["MERS", "OBSERVATION", 17, 21], ["CoV", "OBSERVATION_MODIFIER", 22, 25]]], ["It is worth noting that the effectiveness of interventions depends on the infected-network structures.", [["network structures", "MULTI-TISSUE_STRUCTURE", 83, 101], ["interventions", "TREATMENT", 45, 58], ["infected", "OBSERVATION", 74, 82]]], ["These results suggest that the effectiveness of interventions depends on the characteristics of the MERS-CoV transmission dynamics.", [["MERS-CoV", "SPECIES", 100, 108], ["interventions", "TREATMENT", 48, 61]]], ["Hence, it highlights the roles of super-spreaders in the transmission dynamics of infectious disease and planning future interventions.DiscussionsIn this study, we built a stochastic agent-based model on the 2015 MERS-CoV outbreak in Korea from the perspective of SSE.", [["infectious disease", "DISEASE", 82, 100], ["MERS-CoV", "SPECIES", 213, 221], ["infectious disease", "PROBLEM", 82, 100], ["planning future interventions", "TREATMENT", 105, 134], ["this study", "TEST", 149, 159], ["a stochastic agent", "TREATMENT", 170, 188], ["infectious", "OBSERVATION", 82, 92]]], ["Surprisingly, one super-spreader alone infected 53% of the MERS-CoV cases via other super-spreaders (79/147).", [["MERS-CoV", "ORGANISM", 59, 67], ["MERS-CoV", "SPECIES", 59, 67]]], ["To devise effective intervention strategies and countermeasures for future emerging infectious diseases, it is necessary to clarify the generating mechanism of SSEs.", [["infectious diseases", "DISEASE", 84, 103], ["SSEs", "DISEASE", 160, 164], ["SSEs", "CANCER", 160, 164], ["effective intervention strategies", "TREATMENT", 10, 43], ["countermeasures", "TREATMENT", 48, 63], ["future emerging infectious diseases", "PROBLEM", 68, 103], ["infectious", "OBSERVATION", 84, 94]]], ["In this regard, agent-based modeling is a useful tool for incorporating individual heterogeneity into the epidemic model.", [["epidemic model", "OBSERVATION", 106, 120]]], ["The present research developed and analyzed agent-based models with different assumptions concerning the feature of super-spreaders.DiscussionsOur results indicate that the connectivity of individuals and a higher level of infectivity are the most significant factors for the MERS-CoV transmission dynamics.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 276, 284], ["MERS-CoV", "SPECIES", 276, 284], ["super-spreaders", "PROBLEM", 116, 131], ["a higher level of infectivity", "PROBLEM", 205, 234]]], ["The effect of super-spreaders was not remarkably significant in SSM1, but it was in SSM2 and SSM3.", [["SSM2", "GENE_OR_GENE_PRODUCT", 84, 88], ["SSM3", "GENE_OR_GENE_PRODUCT", 93, 97], ["SSM1", "PROTEIN", 64, 68], ["SSM2", "PROTEIN", 84, 88], ["SSM3", "PROTEIN", 93, 97]]], ["The higher baseline transmission rate and the longer contact range produced a more rapid and severe disease spread in SSM2 and SSM3 than in SSM1.", [["SSM1", "DNA", 140, 144], ["The higher baseline transmission rate", "PROBLEM", 0, 37], ["a more rapid and severe disease spread in SSM2", "PROBLEM", 76, 122], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["disease", "OBSERVATION", 100, 107]]], ["Due to the features of super-spreaders, the real-world data demonstrated the best fit with SSM3 compared to SSM1 or SSM2.", [["SSM3", "GENE_OR_GENE_PRODUCT", 91, 95], ["SSM3", "PROTEIN", 91, 95], ["SSM1", "DNA", 108, 112], ["SSM2", "DNA", 116, 120], ["SSM3", "TREATMENT", 91, 95], ["SSM1", "TEST", 108, 112], ["SSM2", "TEST", 116, 120]]], ["The impact of the effective radius on the basic reproduction number R 0 was the most significant.", [["effective", "OBSERVATION_MODIFIER", 18, 27], ["radius", "OBSERVATION_MODIFIER", 28, 34], ["most significant", "OBSERVATION_MODIFIER", 80, 96]]], ["Also, higher transmission rates led to the larger R 0 .DiscussionsFurthermore, the impact of super-spreaders on the distributions of R 0 under SSM3 became more significant as a proportion of super-spreaders increased (the largest right tails in SSM3), which was consistent with the distributions results of secondary cases.", [["right tails", "ANATOMY", 230, 241], ["R 0", "GENE_OR_GENE_PRODUCT", 133, 136], ["SSM3", "GENE_OR_GENE_PRODUCT", 143, 147], ["R 0", "DNA", 133, 136], ["SSM3", "DNA", 143, 147], ["secondary cases", "PROBLEM", 307, 322], ["higher", "OBSERVATION_MODIFIER", 6, 12], ["largest", "OBSERVATION_MODIFIER", 222, 229], ["right", "ANATOMY_MODIFIER", 230, 235], ["tails", "ANATOMY_MODIFIER", 236, 241], ["consistent with", "UNCERTAINTY", 262, 277]]], ["SSM3 showed the highest level of heterogeneity in the distributions of R 0 and secondary cases while No-SS gave the least heterogeneity.", [["SSM3", "GENE_OR_GENE_PRODUCT", 0, 4], ["SSM3", "PROTEIN", 0, 4], ["highest", "OBSERVATION_MODIFIER", 16, 23], ["heterogeneity", "OBSERVATION", 33, 46], ["least", "OBSERVATION_MODIFIER", 116, 121], ["heterogeneity", "OBSERVATION", 122, 135]]], ["All results above suggest that SSE can be more properly characterized by a small number of infectious individuals who can infect others by means of a larger amount of contact with others combined with higher infectivity.", [["higher infectivity", "PROBLEM", 201, 219], ["small", "OBSERVATION_MODIFIER", 75, 80], ["infectious", "OBSERVATION_MODIFIER", 91, 101]]], ["Having only one feature (either higher infectivity or higher connectivity) is not strong enough to generate such a high level of heterogeneity in secondary cases.DiscussionsThe effectiveness of two isolation strategies was examined: a random isolation reduced incidence proportionally while a targeted isolation reduced the peak size and delayed the peak time.", [["two isolation strategies", "TREATMENT", 194, 218], ["peak", "OBSERVATION_MODIFIER", 324, 328], ["size", "OBSERVATION_MODIFIER", 329, 333]]], ["A targeted isolation was more effective in both SSM2 and SSM3 while a random isolation was more effective in SSM1.", [["SSM1", "CELL_LINE", 109, 113], ["A targeted isolation", "TREATMENT", 0, 20], ["SSM3", "TREATMENT", 57, 61], ["a random isolation", "TREATMENT", 68, 86]]], ["These results suggest that the effectiveness of intervention strategies is dependent on the structure of the infection network.", [["infection", "DISEASE", 109, 118], ["intervention strategies", "TREATMENT", 48, 71], ["the infection network", "PROBLEM", 105, 126], ["infection", "OBSERVATION", 109, 118]]], ["However, super-spreaders can be identified in retrospectively; it is very challenging to predict SSEs or super-spreaders.", [["SSEs", "CANCER", 97, 101]]], ["Thus, a targeted isolation intervention might be idealistic to be implemented.", [["a targeted isolation intervention", "TREATMENT", 6, 39]]], ["Nevertheless, we can investigate the most critical factors for generating SSEs and these factors can provide how to devise effective intervention strategies as discussed in [5, 22] .", [["SSEs", "CANCER", 74, 78], ["effective intervention strategies", "TREATMENT", 123, 156]]], ["For instance, various factors include co-infection with another pathogen, immune suppression, changes in airflow dynamics, delayed hospital admission, misdiagnosis, and inter-hospital transfers.", [["co-infection", "DISEASE", 38, 50], ["immune suppression", "DISEASE", 74, 92], ["co-infection", "PROBLEM", 38, 50], ["another pathogen", "PROBLEM", 56, 72], ["immune suppression", "PROBLEM", 74, 92], ["changes in airflow dynamics", "PROBLEM", 94, 121], ["misdiagnosis", "PROBLEM", 151, 163], ["co-infection", "OBSERVATION", 38, 50]]], ["These factors are worthy of investigation and should be incorporated into targeted intervention strategies.", [["targeted intervention strategies", "TREATMENT", 74, 106]]], ["Our results showed that even when early detection was unsuccessful, it is still effective to find possible candidates for super-spreaders and isolate them to reduce potential risks of severe outbreaks.DiscussionsOne of the limitations of this research lies in the shape of the space where the simulations were executed.", [["super-spreaders", "PROBLEM", 122, 137], ["severe outbreaks", "PROBLEM", 184, 200], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["outbreaks", "OBSERVATION", 191, 200]]], ["Although it is well known that infectious disease transmission dynamics depends on the structure of the infection network, we based our model on a random network in order to focus on the effect of super-spreaders on disease transmission.", [["infection", "DISEASE", 104, 113], ["infectious disease transmission dynamics", "PROBLEM", 31, 71], ["the infection network", "PROBLEM", 100, 121], ["disease transmission", "PROBLEM", 216, 236], ["infectious", "OBSERVATION", 31, 41], ["infection", "OBSERVATION", 104, 113]]], ["Despite this simplification, our results from a simple random network clearly demonstrated the role of super-spreaders on disease transmission and the possible effective intervention scenarios.", [["a simple random network", "TEST", 46, 69], ["disease transmission", "TREATMENT", 122, 142], ["effective intervention scenarios", "TREATMENT", 160, 192], ["possible", "UNCERTAINTY", 151, 159], ["effective", "OBSERVATION_MODIFIER", 160, 169]]], ["Further studies are expected to conduct epidemic models based on other network structures, especially more realistic ones.", [["network structures", "MULTI-TISSUE_STRUCTURE", 71, 89], ["Further studies", "TEST", 0, 15], ["epidemic models", "TEST", 40, 55]]], ["Also, the effectiveness of more various intervention strategies and possible epidemic scenarios can be explored in future research.ConclusionsWe developed an agent-based model that can provide a general mathematical tool for any disease outbreaks with super-spreading events.", [["more various intervention strategies", "TREATMENT", 27, 63], ["epidemic scenarios", "PROBLEM", 77, 95], ["an agent-based model", "TREATMENT", 155, 175], ["any disease outbreaks", "PROBLEM", 225, 246]]], ["Super-spreading events in the transmission dynamics of 2015 MERS-CoV showed a high level of heterogeneity.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["MERS-CoV", "SPECIES", 60, 68], ["the transmission dynamics", "TEST", 26, 51], ["high level", "OBSERVATION_MODIFIER", 78, 88], ["heterogeneity", "OBSERVATION", 92, 105]]], ["Heterogeneity in transmission patterns are one of the most critical factors for infectious disease transmission dynamics.", [["Heterogeneity in transmission patterns", "PROBLEM", 0, 38], ["infectious disease transmission dynamics", "PROBLEM", 80, 120], ["infectious", "OBSERVATION", 80, 90]]], ["Our agent-based model has employed real MERS-CoV epidemic features based on the 2015 MERS-CoV epidemiological data.", [["CoV epidemic features", "PROBLEM", 45, 66]]], ["Our findings highlight the roles of super-spreaders in a high level of heterogeneity, underscoring that the number of contacts combined with a higher level of infectivity are the most critical factors for substantial heterogeneity in generating secondary cases of the 2015 MERS-CoV transmission.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 273, 281], ["MERS-CoV", "SPECIES", 273, 281], ["a higher level of infectivity", "PROBLEM", 141, 170], ["substantial heterogeneity", "PROBLEM", 205, 230], ["high level", "OBSERVATION_MODIFIER", 57, 67], ["heterogeneity", "OBSERVATION", 71, 84], ["substantial", "OBSERVATION_MODIFIER", 205, 216], ["heterogeneity", "OBSERVATION", 217, 230]]]], "5c845e1c32163388c0f994368589bf16a6bd0f28": [["COVID-19 pandemicThe global COVID-19 pandemic, caused by the SARS-CoV-2 virus, 1 has highlighted the importance of personal protective equipment (PPE) for health and social care personnel.COVID-19 pandemicIt is important to acknowledge from the outset that PPE has proved a contentious issue across health and social care generally across the United Kingdom (UK), and beyond, and is one that will need to be resolved practically moving forwards.", [["PPE", "CHEMICAL", 257, 260], ["SARS-CoV-2 virus", "ORGANISM", 61, 77], ["CoV-2 virus", "SPECIES", 66, 77], ["SARS-CoV-2 virus", "SPECIES", 61, 77], ["COVID", "TEST", 0, 5], ["The global COVID", "TEST", 17, 33], ["pandemic", "PROBLEM", 37, 45], ["the SARS", "PROBLEM", 57, 65]]], ["This is of critical importance to dentistry, where we have historically placed great emphasis on infection control and universal precautions, given the nature of care provided.Transmission of SARS-CoV-2 virusBased on evidence to date, the World Health Organisation suggests that transmission of the SARS-CoV-2 virus is mainly via respiratory droplet and contact routes, with transmission being possible through aerosol generating procedures (AGPs).", [["infection", "DISEASE", 97, 106], ["SARS", "DISEASE", 192, 196], ["SARS", "DISEASE", 299, 303], ["SARS-CoV-2", "ORGANISM", 192, 202], ["SARS-CoV-2 virus", "ORGANISM", 299, 315], ["CoV-2 virus", "SPECIES", 304, 315], ["SARS-CoV", "SPECIES", 192, 200], ["SARS-CoV-2 virus", "SPECIES", 299, 315], ["infection control", "TREATMENT", 97, 114], ["universal precautions", "TREATMENT", 119, 140], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["the SARS", "PROBLEM", 295, 303], ["CoV-2 virus", "TREATMENT", 304, 315], ["aerosol generating procedures", "TREATMENT", 411, 440], ["infection", "OBSERVATION", 97, 106], ["respiratory droplet", "OBSERVATION", 330, 349]]], ["2 Droplet transmission occurs when a person is in close contact (within 1 m) with someone who has respiratory symptoms (for example, coughing or sneezing) and is therefore at risk of having his/her mucosae (mouth and nose) or conjunctiva (eyes) exposed to potentially infective respiratory droplets.", [["respiratory", "ANATOMY", 98, 109], ["mucosae", "ANATOMY", 198, 205], ["mouth", "ANATOMY", 207, 212], ["nose", "ANATOMY", 217, 221], ["conjunctiva", "ANATOMY", 226, 237], ["eyes", "ANATOMY", 239, 243], ["respiratory symptoms", "DISEASE", 98, 118], ["coughing", "DISEASE", 133, 141], ["sneezing", "DISEASE", 145, 153], ["mucosae", "ORGAN", 198, 205], ["mouth", "ORGANISM_SUBDIVISION", 207, 212], ["nose", "ORGANISM_SUBDIVISION", 217, 221], ["conjunctiva", "ORGAN", 226, 237], ["eyes", "ORGAN", 239, 243], ["person", "SPECIES", 37, 43], ["respiratory symptoms", "PROBLEM", 98, 118], ["coughing", "PROBLEM", 133, 141], ["sneezing", "PROBLEM", 145, 153], ["his/her mucosae (mouth and nose) or conjunctiva (eyes)", "PROBLEM", 190, 244], ["potentially infective respiratory droplets", "PROBLEM", 256, 298], ["mucosae", "ANATOMY", 198, 205], ["mouth", "ANATOMY", 207, 212], ["nose", "ANATOMY", 217, 221], ["conjunctiva", "ANATOMY", 226, 237], ["eyes", "ANATOMY", 239, 243], ["infective", "OBSERVATION_MODIFIER", 268, 277], ["respiratory droplets", "OBSERVATION", 278, 298]]], ["Person-toperson transmission routes for COVID-19 disease can involve direct and indirect contact, 2 and it is important to recognise that this coronavirus is present in saliva.", [["COVID-19 disease", "DISEASE", 40, 56], ["coronavirus", "DISEASE", 143, 154], ["coronavirus", "ORGANISM", 143, 154], ["saliva", "ORGANISM_SUBSTANCE", 169, 175], ["COVID-19", "SPECIES", 40, 48], ["COVID-19 disease", "PROBLEM", 40, 56], ["this coronavirus", "PROBLEM", 138, 154]]], ["3, 4, 5 SARS-CoV-2 is a novel coronavirus and, because of the nature of their occupation, healthcare workers (HCWs) are often at greater risk of infection than the general population.", [["coronavirus", "DISEASE", 30, 41], ["infection", "DISEASE", 145, 154], ["5", "ORGANISM", 6, 7], ["SARS-CoV-2", "ORGANISM", 8, 18], ["coronavirus", "ORGANISM", 30, 41], ["a novel coronavirus", "PROBLEM", 22, 41], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 145, 154]]], ["Appropriate PPE offers an important way of reducing the risk of infection during the provision of healthcare. highly infectious diseases due to exposure to contaminated body fluids, in healthcare staff ' .", [["body", "ANATOMY", 169, 173], ["infection", "DISEASE", 64, 73], ["infectious diseases", "DISEASE", 117, 136], ["body", "ORGANISM_SUBDIVISION", 169, 173], ["Appropriate PPE", "TREATMENT", 0, 15], ["infection", "PROBLEM", 64, 73], ["highly infectious diseases", "PROBLEM", 110, 136], ["contaminated body fluids", "TREATMENT", 156, 180], ["infection", "OBSERVATION", 64, 73], ["infectious", "OBSERVATION", 117, 127]]], ["8 It reviewed contemporary evidence on 'which type of full-body PPE and which method of donning (putting on) or doffing (removing) PPE have the least risk of contamination or infection for HCW, and which training methods increase compliance with PPE protocols' .", [["infection", "DISEASE", 175, 184], ["full-body PPE", "TREATMENT", 54, 67], ["PPE", "TREATMENT", 131, 134], ["contamination", "PROBLEM", 158, 171], ["infection", "PROBLEM", 175, 184], ["PPE protocols", "TREATMENT", 246, 259], ["contamination", "OBSERVATION", 158, 171], ["infection", "OBSERVATION", 175, 184]]], ["8 The evidence from this review is of great importance where there is a risk of highly infectious diseases, and even though COVID-19 is no longer considered to be a high consequence disease in the UK, 9 its findings remain relevant to the current pandemic 10 and continue to be updated.Transmission of SARS-CoV-2 virusThe objective of this paper is to raise awareness of the findings of the above review of PPE 8 and explore their relevance to dentistry, building on our commentary presented on the Cochrane Oral Health website.", [["infectious diseases", "DISEASE", 87, 106], ["SARS", "DISEASE", 302, 306], ["SARS-CoV-2 virus", "ORGANISM", 302, 318], ["CoV-2 virus", "SPECIES", 307, 318], ["SARS-CoV-2 virus", "SPECIES", 302, 318], ["highly infectious diseases", "PROBLEM", 80, 106], ["COVID", "TEST", 124, 129], ["a high consequence disease", "PROBLEM", 163, 189], ["SARS", "PROBLEM", 302, 306], ["CoV", "TEST", 307, 310], ["highly", "OBSERVATION_MODIFIER", 80, 86], ["infectious", "OBSERVATION", 87, 97], ["no longer", "UNCERTAINTY", 136, 145], ["SARS", "OBSERVATION", 302, 306]]], ["10Cochrane and COVID-19Cochrane synthesises the best available evidence using rigorous methodology to answer specific research questions, thus drawing on the body of evidence available to inform decision-making, 11 using thorough methods.", [["COVID", "TREATMENT", 15, 20]]], ["12 The COVID Cochrane group are prioritising questions related to COVID-19, 13 reviewing the literature and synthesising wide-ranging data in a matter of weeks rather than the usual extended period of at least two years.", [["COVID", "TEST", 66, 71]]], ["It involves rapid peer review of protocols and search strategies, working many extra hours to complete them as quickly as possible without compromising their quality, with final peer review and editing before publication.", [["search strategies", "TREATMENT", 47, 64]]], ["7,8 Current work by Cochrane Oral Health includes rapid reviews of mouthwashes and nasal sprays, and methods to reduce aerosols produced during AGPs, as well as a rapid review of international dental guidelines for return to dental services.", [["nasal", "ANATOMY", 83, 88], ["mouthwashes", "TREATMENT", 67, 78], ["nasal sprays", "TREATMENT", 83, 95], ["methods", "TREATMENT", 101, 108]]], ["15Relevance of Cochrane PPE review to dentistryThe PPE review questions for HCWs are relevant to the practice of dentistry and all dental professionals working in clinical settings, including dentists, dental hygienists, dental nurses, dental therapists, orthodontic therapists, dental technicians and clinical dental technicians, along with reception and cleaning staff and practice managers.", [["HCWs", "PROBLEM", 76, 80]]], ["10 Clinical members of the dental team work in close proximity, usually face-to-face, with patients and often for sustained periods of time.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["Over and above the risk associated with proximity to potentially infected individuals, during routine care, they are exposed to saliva and blood and carry out AGPs (for example, use of high-speed air rotors and ultrasonic scalers).", [["blood", "ANATOMY", 139, 144], ["saliva", "ORGANISM_SUBSTANCE", 128, 134], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["AGPs", "GENE_OR_GENE_PRODUCT", 159, 163], ["AGPs", "PROTEIN", 159, 163], ["potentially infected individuals", "PROBLEM", 53, 85], ["routine care", "TREATMENT", 94, 106], ["saliva and blood and carry out AGPs", "PROBLEM", 128, 163], ["high-speed air rotors", "TREATMENT", 185, 206], ["ultrasonic scalers", "TREATMENT", 211, 229], ["infected", "OBSERVATION", 65, 73]]], ["For COVID-19, personal protection entails preventing droplets from entering their mouth, nose or eyes and preventing them from contaminating the skin elsewhere.", [["mouth", "ANATOMY", 82, 87], ["nose", "ANATOMY", 89, 93], ["eyes", "ANATOMY", 97, 101], ["skin", "ANATOMY", 145, 149], ["mouth", "ORGANISM_SUBDIVISION", 82, 87], ["nose", "ORGANISM_SUBDIVISION", 89, 93], ["eyes", "ORGAN", 97, 101], ["skin", "ORGAN", 145, 149], ["COVID", "TEST", 4, 9], ["personal protection entails", "TREATMENT", 14, 41], ["mouth", "ANATOMY", 82, 87], ["nose", "ANATOMY", 89, 93], ["eyes", "ANATOMY", 97, 101], ["skin", "ANATOMY", 145, 149]]], ["Although there is no evidence to say that dental procedures increase the likelihood of patients coughing, if they do, clinicians are in close proximity.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["dental procedures", "TREATMENT", 42, 59], ["patients coughing", "PROBLEM", 87, 104], ["no evidence to", "UNCERTAINTY", 18, 32], ["coughing", "OBSERVATION", 96, 104]]], ["This further increases the chance of aerosol and droplet generation, as well as infected material settling on environmental surfaces and on PPE.Available evidence: relevance to dentistryWhile the search included a broad range of HCWs, only 24 studies (controlled studies, either randomised or non-randomised) were included, most from simulation exercises and none directly associated with dentistry.", [["aerosol and droplet generation", "TREATMENT", 37, 67], ["infected material", "PROBLEM", 80, 97], ["PPE", "TREATMENT", 140, 143], ["controlled studies", "TEST", 252, 270], ["droplet generation", "OBSERVATION", 49, 67], ["infected", "OBSERVATION_MODIFIER", 80, 88], ["material", "OBSERVATION_MODIFIER", 89, 97], ["settling", "OBSERVATION_MODIFIER", 98, 106]]], ["8 In the midst of an acute situation where the primary evidence is difficult, and probably impossible to generate with enough speed to be useful, a judgement has to be made on how confident we are that the findings of this review can be applied to the dental care setting.", [["acute", "OBSERVATION_MODIFIER", 21, 26]]], ["However, in the absence of direct evidence from studies situated in a dental setting, we have to take note of, and realistically apply, the general evidence.Available evidence: relevance to dentistryIt is important to note that 'the certainty of the evidence presented in the review, 8 across all comparisons, was judged to be low or very low' 10 for a range of reasons.", [["studies", "TEST", 48, 55]]], ["This related to the paucity of research addressing each of the questions, together with the fact that much of the available research involved simulations of exposure rather than research in real-life conditions, small sample sizes, high or unclear risk of bias and insufficient detail on whether the PPE used fitted international standards for protective clothing.", [["small sample sizes", "PROBLEM", 212, 230], ["the PPE", "TREATMENT", 296, 303], ["protective clothing", "TREATMENT", 344, 363], ["small", "OBSERVATION_MODIFIER", 212, 217], ["sizes", "OBSERVATION_MODIFIER", 225, 230]]], ["8, 10 Furthermore, most of the research understandably used harmless microbes or fluorescent markers rather than microbes or viruses of concern.", [["fluorescent markers", "TEST", 81, 100], ["viruses", "OBSERVATION", 125, 132]]], ["8,10 Nonetheless, its key findings, against which the questions were relevant to dentistry, are important given the above caveats (Box 1).Available evidence: relevance to dentistryWhile it is important to acknowledge that 'members of the dental team are very experienced in the use of standard PPE, most work within primary care settings, and may be less familiar with the more extensive forms of PPE' , 10 although this is rapidly changing.Available evidence: relevance to dentistryThe Cochrane review suggests that 'covering more of the body' leads to 'better protection.' 8 This included gowns providing better protection than just an apron.", [["body", "ANATOMY", 539, 543], ["body", "ORGANISM_SUBDIVISION", 539, 543], ["standard PPE", "TREATMENT", 285, 297], ["gowns", "TREATMENT", 591, 596]]], ["8 The evidence suggests that added coverage provided by a coverall (one-piece suit) when compared with a gown comes at a cost in terms of increased 'difficulty in doffing' such PPE.", [["increased 'difficulty", "PROBLEM", 138, 159], ["such PPE", "TREATMENT", 172, 180]]], ["8 While there were initial concerns that challenges with doffing increased the risk of contamination, current evidence suggests that, in 'more recently introduced full-body PPE ensembles, there may be no difference in contamination' .", [["contamination", "PROBLEM", 87, 100], ["full-body PPE ensembles", "TREATMENT", 163, 186], ["may be no", "UNCERTAINTY", 194, 203]]], ["8 The review also suggests that 'PPE made from more breathable material may help increase user satisfaction, with little impact on contamination. ' 10 The head and neck areas of the dental team are particularly at risk for HCWs during clinical dental procedures.", [["head", "ANATOMY", 155, 159], ["neck areas", "ANATOMY", 164, 174], ["head", "ORGANISM_SUBDIVISION", 155, 159], ["neck", "ORGAN", 164, 168], ["more breathable material", "PROBLEM", 47, 71], ["clinical dental procedures", "TREATMENT", 235, 261], ["head", "ANATOMY", 155, 159], ["neck", "ANATOMY", 164, 168], ["dental", "ANATOMY", 182, 188]]], ["10 Thus, ensuring PPE coverage is adequate to protect these areas is an important aspect of its effectiveness; in addition, 'better fitting PPE' in this region, 'sealed gown and glove combinations' to protect wrists, and certain design features such as 'tabs to \"grab\" during doffing and donning' may help to reduce the risk of contamination.", [["wrists", "ANATOMY", 209, 215], ["wrists", "ORGANISM_SUBDIVISION", 209, 215], ["ensuring PPE coverage", "TREATMENT", 9, 30], ["glove combinations", "TREATMENT", 178, 196], ["wrists", "PROBLEM", 209, 215], ["contamination", "PROBLEM", 328, 341], ["wrists", "ANATOMY", 209, 215], ["contamination", "OBSERVATION", 328, 341]]], ["8, 10 Overall, PPE should provide full coverage but not be too cumbersome.Available evidence: relevance to dentistryIt is important not to make the mistake of assuming that just 'having' face masks and other elements of enhanced PPE is 'good enough' .", [["PPE", "TREATMENT", 15, 18], ["full coverage", "TREATMENT", 34, 47], ["' face masks", "TREATMENT", 185, 197]]], ["Dental professionals also need to be aware of the risks of contamination associated with donning and, in particular, doffing PPE.", [["contamination", "PROBLEM", 59, 72]]], ["Space for these processes will need to be considered as part of dental surgery organisation where care is being delivered, as well as the time involved.", [["these processes", "PROBLEM", 10, 25], ["dental surgery organisation", "TREATMENT", 64, 91]]], ["Training in donning and doffing is particularly important for dental teams who may not wear this type of PPE for routine practice or who may need to learn new, safer habits carefully.", [["routine practice", "TREATMENT", 113, 129]]], ["The presence of an observer, in particular for doffing PPE, should be considered.", [["doffing PPE", "TREATMENT", 47, 58]]], ["Teams should consider face-toface training opportunities as they may reduce the likelihood of errors, alongside computer simulation or videos which may also support these skills.", [["face-toface training opportunities", "TREATMENT", 22, 56]]], ["10 We need to consider how we can best do this across the four nations of the UK and connect with our global partners who are also facing the same issues.Dental care centresThere is an opportunity, during this COVID-19 outbreak, to use the natural experimental setting that dental care centres provide to create the evidence we need on health outcomes and personnel involved.", [["dental care centres", "TREATMENT", 274, 293]]], ["10 These opportunities include, but are not limited to, the issues of viral transmission rates, those related directly to the training, education and use of PPE, as well as how this affects patient care.", [["patient", "ORGANISM", 190, 197], ["patient", "SPECIES", 190, 197], ["viral transmission rates", "PROBLEM", 70, 94], ["PPE", "TREATMENT", 157, 160]]], ["8, 10 Trials in dental care settings Safe provision of dental care requires a deep understanding of pathogen transmission and how it relates to the various types of care provided; for example, AGPs and non-AGPs.", [["AGPs", "GENE_OR_GENE_PRODUCT", 193, 197], ["AGPs", "PROTEIN", 193, 197], ["non-AGPs", "PROTEIN", 202, 210], ["dental care settings", "TREATMENT", 16, 36], ["dental care", "TREATMENT", 55, 66], ["non-AGPs", "PROBLEM", 202, 210]]], ["10 Trials using high-quality and standardised methodology considering the spread and settle of demonstration pathogens or surrogate measures in dental settings are key, and these should consider the array of different procedures that are considered to generate aerosols.", [["standardised methodology", "TREATMENT", 33, 57], ["surrogate measures", "TREATMENT", 122, 140], ["different procedures", "TREATMENT", 208, 228]]], ["It is worth noting that fluorescent dyes or harmless bacteria and viruses have been used for much of the higher quality simulated research in the past.", [["fluorescent dyes", "SIMPLE_CHEMICAL", 24, 40], ["fluorescent dyes", "PROBLEM", 24, 40], ["harmless bacteria", "PROBLEM", 44, 61], ["viruses", "PROBLEM", 66, 73]]], ["8 They should include all relevant settings and consider single and multiple surgeries as well as laboratories and domiciliary care.", [["single and multiple surgeries", "TREATMENT", 57, 86], ["domiciliary care", "TREATMENT", 115, 131]]], ["10 Studies should be well-designed and of sufficient sample size, with agreed outcomes.", [["10 Studies", "TEST", 0, 10], ["size", "OBSERVATION_MODIFIER", 60, 64]]], ["8 Crossover studies should be conducted where possible.", [["Crossover studies", "TEST", 2, 19]]], ["Details of education and training, fit testing, equipment used (including standards), dental examination and special investigations and procedure(s), length of appointment, nature of patient(s), technique of dental care, donning and doffing processes, environment and a range of outcomes should be recorded.", [["patient", "ORGANISM", 183, 190], ["patient", "SPECIES", 183, 190], ["fit testing", "TEST", 35, 46], ["dental examination", "TEST", 86, 104], ["special investigations", "TEST", 109, 131], ["dental care", "TREATMENT", 208, 219]]], ["For example, it would be helpful to confirm whether standard PPE is adequate for an oral examination while more elaborate PPE, even with its drawbacks, is necessary for treatments where aerosols are actively generated during the procedure.", [["oral", "ANATOMY", 84, 88], ["oral", "ORGANISM_SUBDIVISION", 84, 88], ["an oral examination", "TEST", 81, 100], ["treatments", "TREATMENT", 169, 179], ["aerosols", "TREATMENT", 186, 194], ["the procedure", "TREATMENT", 225, 238]]], ["Also, are the types of PPE required for dental professionals carrying out routine care during peak phases of the COVID-19 pandemic still required for the post-peak phase?", [["PPE", "TREATMENT", 23, 26], ["dental professionals", "TREATMENT", 40, 60], ["routine care", "TREATMENT", 74, 86], ["the COVID", "TEST", 109, 118], ["the post-peak phase", "TEST", 150, 169]]], ["In addition, there needs to be an understanding of the amount of time that recommended PPE can be worn comfortably.", [["PPE", "TREATMENT", 87, 90]]], ["Simulation exercises involving comparison of different levels of PPE will be particularly helpful to inform standard requirements for different aspects of dental care.", [["Simulation exercises", "TREATMENT", 0, 20], ["different levels of PPE", "TREATMENT", 45, 68], ["dental care", "TREATMENT", 155, 166]]], ["10 This includes the effect of masks, face shields and goggles.", [["masks", "TREATMENT", 31, 36], ["face shields", "TREATMENT", 38, 50], ["goggles", "PROBLEM", 55, 62], ["goggles", "OBSERVATION", 55, 62]]], ["10 Furthermore, we will also need to consider shielded patients and the best way of affording them the necessary protection as well as staff.Standard versus enhanced PPEWhile we have considered the review in a dental context, we currently lack critical knowledge on whether viral load and shedding are similar in asymptomatic individuals 16 and to what extent this presents a risk in dentistry.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["viral load", "PROBLEM", 274, 284], ["shedding", "PROBLEM", 289, 297]]], ["We also need to deepen our understanding of aerosol generation generally, 18 as well as specifically in relation to viruses in dental settings.Future considerationsGiven the burden of oral disease 19 and the evidence that transmission of SARS-CoV-2 by seemingly well individuals (pre-symptomatic and asymptomatic), we need to seriously consider how our patient and population needs are best met for the future.", [["oral", "ANATOMY", 184, 188], ["oral disease", "DISEASE", 184, 196], ["SARS", "DISEASE", 238, 242], ["oral", "ORGANISM_SUBDIVISION", 184, 188], ["SARS-CoV-2", "ORGANISM", 238, 248], ["patient", "ORGANISM", 353, 360], ["patient", "SPECIES", 353, 360], ["SARS-CoV", "SPECIES", 238, 246], ["aerosol generation", "TREATMENT", 44, 62], ["oral disease", "PROBLEM", 184, 196], ["SARS", "PROBLEM", 238, 242], ["asymptomatic", "PROBLEM", 300, 312]]], ["Models indicate that pre-symptomatic individuals alone may account for 30-62% of events (confirmed COVID cases).", [["individuals", "ORGANISM", 37, 48], ["pre-symptomatic individuals", "PROBLEM", 21, 48]]], ["20, 21, 22, 23 It is important to remember that most patients attending for dental care will be COVID-negative.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Important questions are being debated regarding the nature and extent of universal precautions, and whether we should adopt a precautionary principle to protect our dental teams and patients until more is known and these can be confidently relaxed.", [["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["universal precautions", "TREATMENT", 73, 94]]], ["Measures such as self-isolation and testing are now being suggested to reduce risk associated with planned and urgent care in Key findings:Future considerations\u2022 Coverage: there is better protection from covering more parts of the body, but this has to be balanced against the possible increase in risk of contamination associated with difficulty donning or doffing, as well as less user comfort hospital settings.", [["body", "ANATOMY", 231, 235], ["body", "ORGANISM_SUBDIVISION", 231, 235], ["self-isolation", "TREATMENT", 17, 31], ["testing", "TEST", 36, 43], ["contamination", "PROBLEM", 306, 319], ["body", "ANATOMY", 231, 235], ["possible", "UNCERTAINTY", 277, 285], ["increase", "OBSERVATION_MODIFIER", 286, 294], ["contamination", "OBSERVATION", 306, 319]]], ["24 PPE should be considered after risk assessment and as just one issue in a larger preventive approach, including aerosol, droplet and splatter reduction and ventilation.", [["risk assessment", "TEST", 34, 49], ["a larger preventive approach", "TREATMENT", 75, 103], ["aerosol", "TREATMENT", 115, 122], ["droplet", "TREATMENT", 124, 131], ["splatter reduction", "TREATMENT", 136, 154], ["ventilation", "TREATMENT", 159, 170]]], ["Risk reduction must be considered along with other major challenges to our staff 's health and wellbeing, including the nature of care and the complex business of dentistry.", [["Risk reduction", "TREATMENT", 0, 14]]], ["We do not have all the answers about universal precautions for the future, but all dental professionals will need to take action in identifying and managing risk in line with national guidance and learning from our colleagues around the world.", [["universal precautions", "TREATMENT", 37, 58]]], ["We have to be able to justify our actions in managing risk, and collect evidence and be prepared to adapt where necessary.In conclusionHaving PPE is important, but so is wearing it properly and removing it safely; it is important to remember that PPE is just one way of protecting dental professionals and patients, all of which require careful consideration and research to inform our journey back to what may become a 'new normal' .", [["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 306, 314], ["PPE", "OBSERVATION", 142, 145]]]]}